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Abstract 
Biologically active peptides and their receptors are involved in many of life's 
essential processes. They are of enormous medical interest as many diseases and 
illnesses can be treated by agents which block or imitate the function of specific 
peptides and their receptors. 
The research described in this thesis encompasses two distinct approaches 
towards the development of peptidomimetics, analogues which mimic specific 
biologically active peptides. Chapter one gives a general introduction to the role of 
peptides in drug discovery and design and some representative examples. 
Chapters two deals with the rational design of a new cis-hydroxyethylamine 
peptidomimetic isostere and its application to the development ofHIV drugs. Chapter 
three describes the synthesis of 1,5-disubstituted tetrazole dipeptide compounds, based 
on the designed isostere, and their extension in the N and C directions. The HIV -1 
protease inhibition results of a series of tetrazoles are presented in chapter four. 
Compounds based on the designed isostere gave reasonable JlM Ki values, compared 
with the nM values of the most potent known HIV protease inhibitors. The 
hydroxymethylene group was found to be crucial to activity and the QC ligand was 
shown to be favoured at the P3 site over Cbz. The C3 and C6 configurations adjacent 
to the tetrazole ring were also shown to influence the activity of the inhibitors. These 
design principles on which the cis-hydroxyethylamine isostere was based were justified 
and have given a basis for future development of the structure. 
A more traditional approach to drug discovery is the exploitation and 
development of the biological activity of potent natural products. Previous work has 
established the potent activity of the a.-hydroxyamidoacetal C7 -C 10 functionality of 
the sponge metabolites my calami des A and B. Chapter five describes two synthetic 
routes to a general a.-hydroxyamidoacetal structure (see 5.5), and the synthesis of a 
series of mycalamide analogues with varying Rt-~ substituents, for example the 
epimers (1 'S,2S)- and ( 1 'R,2S)-2-hydroxy-N-(1-methoxybenzyl)-3-phenylpropanamide. 
The assignment of configuration and antitumour activity of the series of analogues is 
presented in chapter six. The compounds show modest in vitro antitumour activity. 
5 
The level of activity appears to be more sensitive to changes at Rz than R1 and to 
favour a (1 ~)-configuration. The amino acid based analogues (R1 = NHR) showed 
comparable or improved activity over the R1 = OR analogues, and supported the 
proposal that the series of analogues act as peptidomimetics. 
Chapter seven details the X-ray crystallographic analysis of a crystal of 
(DMAP)5(benzoic acid)3(H20)10, with a unique layered structure in which benzoate 
anions are two-dimensionally clathrated by water molecules. 
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Chapter One 
Introduction 
7 
Peptides are essential to sustaining life in nature. In humans biologically active 
peptides are involved in vital processes such as blood pressure regulation, respiration, 
digestion, metabolism, reproduction, immune defence and sensitivity to pain. These 
processes involve the interactions of specific peptides, hormones, neurotransmitters 
and enzyme substrates, with receptors or enzymes. Thus, peptides are of enormous 
medical interest, being implicated in many diseases and illnesses and having 
applications in the development of therapeutic agents. Medical conditions including 
hypertension, emphysema, gastrointestinal diseases, diabetes, fertility disorders, 
Acquired Immuno Deficiency Syndrome (AIDS), prostate cancer, neuropsychiatric 
disorders, pain and inflammation can be treated with therapeutic agents which block or 
imitate the function of specific biologically active peptides and their receptors or 
enzymes. 
What follows in this introduction is a brief discussion of the structure and 
properties of peptides and some representative examples. Finally, a discussion of the 
role of peptides in the process of drug discovery and design, with a particular emphasis 
on natural product-based systems and peptidomimetics. 
Peptides and Proteins 
Peptides and proteins (there is no clear boundary between these two classes of 
compounds) consist of varying sequences of amino acid building blocks joined by 
amide linkages. Despite an apparent lack of diversity, they serve a variety of purposes 
in living organisms: structurally important proteins such as keratin in skin and collagen 
in tendons; enzymes (large flexible, globular proteins which catalyze many important 
chemical reactions); and smaller peptides such as hormones (from the Greek for "to set 
in motion") and neurotransmitters which can act as chemical messengers. Proteins also 
function in the interconversion of chemical, mechanical and light energy forms. 
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Twenty primary amino acids exist in proteins in nature, with several hundred 
more non-protein amino acids having evolved from the diverse metabolism of species, 
mainly from the plant world and micro-organisms. Humans and all animals must 
obtain the essential primary amino acids in their diets from the plant kingdom. The 
biosynthesis of the primary amino acids in plants starts with ammonia, itself formed by 
the fixation of nitrogen gas from the air or the reduction of nitrate from the soil. In 
contrast to animal metabolism, plants conserve all the available nitrogen that they 
intake. The identification of the primary amino acids from various natural sources 
occurred over a century1 from 1820, when Braconnet characterized glycine and 
leucine, until threonine was isolated in 1925. a-Amino acids contain an amino (NH2) 
group, a carboxylic acid (COOH) and a sidechain group R attached to a central carbon 
(figure 1.1). The common amino acids differ only in the nature of the R sidechain. 
L-a-amino acid 
Figure 1.1: General structure ofthe primary amino acids. 
Of the two possible enantiomers, only that designated as the L-enantiomer is 
found in most peptides and proteins. A variety of sidechains exist with different 
functional groups, structures and properties. Amino acids are linked together by 
condensing the amino group of one with the carboxylate of another to form an amide 
or peptide (CONH) bond. Two or more linked amino acids are called a peptide while 
a larger polypeptide may be termed a protein. An amide bond has partial double bond 
character due to conjugation of the lone pair of nitrogen electrons with the carbonyl 
double bond. Consequently, there is no free rotation in the peptide chain about the 
amide bonds, with two slowly interconverting, cis and trans coplanar forms possible 
(figure 1.2). The trans form is energetically favoured over the cis due to less steric 
hindrance. However, cis amide bonds can be found in peptides containing N-alkylated 
amino acids (such as proline), in cyclic peptides, and in peptide chain folding where 
they are more energetically accessible. The typical charge separation in amide bonds 
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means that the peptide backbone is quite polar and suitable for hydrogen bonding. The 
positively charged hydrogen on nitrogen readily interacts with negatively charged 
carbonyl oxygens (figure 1.2). 
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Figure 1.2: Properties of an amide bond. 
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Peptide chains are folded or coiled in an ordered way to give secondary and 
tertiary structure. Ordered three-dimensional structures such as a-helices and f3-
pleated sheets are exhibited with a high degree of regularity in proteins despite the 
huge number of possible conformations? The biological properties of peptides and 
proteins vary greatly with sequence and ultimately three-dimensional structure. The 
prediction of three-dimensional protein structures from amino acid sequence, and the 
understanding of the relationships to biological function, has been the focus of much 
research.3 
Peptides and proteins with useful biological properties and complex functions 
have evolved in nature by natural selection, and their blueprints encoded in the genetic 
material DNA. Protein synthesis occurs in cells on the ribosomes, under the direction 
of messenger RNA (mRNA) molecules, which transfer the protein codes from the 
DNA in the cell nucleus. The amino acids for protein synthesis are brought to the 
ribosomes by specific transfer RNA (tRNA) molecules. 
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As advances in chemistry, medicine, and molecular biology are made, more 
biologically active peptides and proteins continue to be discovered and characterized, 
and their functions and interactions more clearly understood. 
Free peptides in large concentrations are rare in humans. For peptide 
hormones to carry messages between remote cells it seems that a large amount of 
hormone would need to be produced. This is avoided by the extremely specific 
recognition of the hormone by receptors only at the target site. Other receptors along 
the way do not recognize and bind incompatible ligands. Peptides can also act as 
neurotransmitters. They are released at nerve endings and evoke a response after 
interacting with receptors on a nerve cell. 
Proteases are an important class of enzyme which catalyze the hydrolysis of 
amide bonds in peptides. Their biological activities are closely interrelated with a 
number of peptides. Certain proteases can liberate peptide hormones and 
neuromodulators from inactive precursors, while others repress biological response by 
degrading these peptide messengers. They are strictly regulated by endogenous 
peptide inhibitors. 
Enormous interest has developed in the discovery of naturally occurring 
peptides and the elucidation of their biological activities. What follows is a brief 
discussion of some biologically important peptides. 
Glutathione (GSH) 
1.1 
GSH is a tripeptide first observed as a reducing agent in yeast in 1888 and later 
identified as y-L-glutamyl-L-cysteinyl-glycine. GSH is the most abundant intracellular 
thiol in almost all aerobic biological species due to the relative stability of its y-peptide 
bond to degrading protease enzymes. The biochemical functions of GSH are mostly 
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due to the thiol functional group and include protecting cells against the toxic, radical 
and non-radical products of oxygen. 
An interesting effect of GSH, not related to the thiol group but to the 
recognition of the peptide backbone,4 is observed in hydra (small, freshwater 
hydrozoan polyps). A contraction of the polyps' stinging tentacles to trap its prey is 
biochemically induced by 1 o-6 M GSH. 
Oxytocin and Vasopressin 
I I Cys-Tyr-lle-Gin-Asn-Cys-Pro-Leu-Giy-NH2 1.2 
cts-Tyr-Phe-Gin-Asn-CJs-Pro-Arg-Giy-NH2 1.3 
I I Cys-Tyr-lle-Gin-Asn-Cys-Pro-Arg-Giy-NH2 1.4 
(oxytocin ring) (vasopressin sidechain) 
The peptide hormones5 oxytocin 1.2 and vasopressin 1.3 are released by the 
pituitary gland, an important regulatory gland found at the base of the brain. Oxytocin 
causes rhythmic contractions of the uterus to initiate childbirth and the release of milk 
from the mammary gland, whereas vasopressin raises blood pressure and has an 
antidiuretic effect. The discovery of such hormones at the turn of the century led to 
the realization that physiological responses can be initiated by biochemistry. All 
physiological responses were previously thought to be caused by electrical impulses 
through the nervous system. 
A deficiency of vasopressin causes excessive excretion of water and leads to 
the unpleasant condition diabetes insipidus. Large scale synthesis of vasopressin6 has 
allowed control of the disease in patients. 
Extensive research on the structures of oxytocin and vasopressin led to great 
advances in peptide synthesis and elucidation, and a Nobel Prize for Vincent du 
Vigneau d. 7 Each structure contains an intramolecular disulphide bond and a 
glycinamide at the C-terminal, and only differ to each other by two amino acid 
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residues, despite their differences in activity. A number of receptors are involved in 
their biological activities. A conceivable common evolutionary ancestor of the two 
principle pituitary hormones, vasotocin 1.48 was synthesized and later found in extracts 
of the pituitary glands of birds and reptiles, plus in the pineal gland of mammals. It 
contains the ring of oxytocin and side chain of vasopressin, and exhibits the biological 
activity of both. 
Renin-Angiotensin System 
Asp-Arg-Vai-Tyr-lle-His-Pro-Phe 1.5 
The renin-angiotensin system plays an important role in the regulation of blood 
pressure.9 An increase in cases of cardiovascular diseases in humans, such as 
hypertension and heart failure (responsible for 10% of deaths in western society\ lead 
to enormous interest in this system. 
The system produces angiotensin II 1.5, one of the most potent known 
vasoconstrictors. It starts with the protein angiotensinogen (mass of about 60kDa) 
which is synthesized in the liver and passes into the blood. Angiotensinogen travels to 
the kidneys where it is cleaved by the aspartic protease renin to give angiotensin I. 
Angiotensin I is then cleaved to the biologically active 1.5 by angiotensin converting 
enzyme (ACE), found primarily around the lungs. Release of 1.5 affects blood 
pressure directly by constriction of the blood vessels (after binding to specific 
receptors on the surface of the cells) and indirectly by release of the hormone 
aldosterone from the adrenal gland (inducing sodium ion and water retention). 
Inactivation of 1.5 occurs by enzymatic cleavage of the C-terminal residue to form 
angiotensin III. Successful antihypertensive agents10 are being used in medicine which 
inhibit the action of the ACE enzyme on its peptide substrate angiotensin I. Agents 
which inhibit the action of renin on angiotensinogen have also been extensively studied 
however none have been successful in clinical trials. 10' 11 
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Insulin 12 
II GIVEQCCTSICSL YQLENYCN 
FVNQHLbGSHLVEALYLVbGERGFFYTPKT 
1.6 
Insulin 1.6 is the primary peptide hormone responsible for glucose metabolism. 
It is released by specialized cells in the pancreas and acts on nearby liver cells to 
suppress the breakdown of glycogen to glucose. A deficiency of 1.6 causes the disease 
diabetes mellitus which affects millions of people around the world. Treatment of 
patients is possible through industrial synthesis of human insulin by biogenetic 
engineering. This involves harnessing the protein synthesizing machinery of 
microorganisms with the appropriate DNA sequences incorporated into the cells. 
Insulin has a complex three-dimensional structure consisting of two peptide strands 
joined by disulphide linkages. 
Somatostatin 
Ala-Giy-Cys-Lys-Asn-Phe-Phe-Trp 
\ I HO-Cys-Ser-Thr-Phe-Thr-Lys 
1.7 
Somatostatin13 1.7 is a cyclic peptide formed in the hypothalamus. Its 
biological activity is as a release-inhibiting factor, preventing the release of growth 
hormone (GH) from the pituitary gland. It also acts on the pancreas, preventing the 
release of both insulin and glucagon, leading to a lowering of blood glucose 
concentration and is thus interesting in developing possible treatments for diabetes 
mellitus. In the digestive tract, motility is inhibited by somatostatin, the blood supply 
restricted and secretion of gastric acid and gastrin reduced. These properties have led 
to therapeutic use of somatostatin in the treatment of acute gastrointestinal diseases. 
Receptors for somatostatin have been isolated and biochemically characterized. 
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Enzymes and Receptors14 
Enzymes are proteins which act specifically on peptide or non-peptide 
substrates catalyzing many chemical transformations. Almost every biological bond-
breaking and bond-forming reaction, including the breakdown of food and its 
reconstruction into other biomolecules, is catalyzed by one or more enzymes. 
Enzymes are characterized by the chemical reactions they catalyze and their 
substrate specificity. Proteases are an important class of enzyme which catalyze the 
hydrolysis of amide bonds in peptides and proteins. This class of enzyme is the topic 
of some of the research presented in this thesis. Proteases are divided into types (four 
common types are shown in table 1.1) according to their mechanism of action (an 
example is the aspartic protease mechanism, scheme 1.1 ). 
Table 1.1: Types ofproteases. 
Protease Significant Examples Normal Function 
type Active site 
Aspartic renin blood pressure regulation 
HIV protease HIV replication 
pepsin digestion 
Serine Ser chymotrypsin digestion 
His 
Asp thrombin blood coagulation 
post protein cleaving hormone metabolism 
enzyme 
Metallo zinc ion angiotensin converting blood pressure regulation 
enzyme 
carboxypeptidase digestion 
Cysteine Cys cathepsins B, H, L, protein turnover, bone 
calcium activated neutral resorption 
pro teases 
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Scheme 1.1: Aspartic protease catalyzed hydrolysis of an amide bond. 
15 
All enzymes possess an active site cavity where catalysis takes place. The 
active site is also sensitive to chirality, meaning most reactions are stereospecific. 
Proteases bind very specifically to peptides. Peptide sequence and conformation is 
crucial to favourable enzyme-substrate interactions. A protease active site contains 
pockets, into which sidechain groups of specific amino acid residues can project, and a 
scaffolding of potential binding points (through hydrogen bonding, hydrophobic and 
electrostatic interactions). The active site of a protease to which a peptide substrate 
binds is defined in terms of a series of subsites (figure 1.3).I5 Amino acid residues of 
the substrate are sequentially designated P1, P2, P3 ... Pn and PI', P2', P3' ... Pn' in theN-
terminal and C-terminal directions, respectively, from the amide cleavage site PI-P{ 
These residues of the substrate are located in sub sites of the enzyme designated as S 1, 
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82, 83 ... 8n and 81', 82', 83' ... 8n', respectively. The specificity pockets/subsites of the 
enzyme determine the amino acid residues accepted by the active site and define the 
bioactive conformation. 
peptide substrate 
enzyme binding sites 
Figure 1.3: 8chechter15 notation for protease-substrate binding. 
As the substrate binds in the active site, there is a structural change in the 
overall protease-substrate complex which brings a suitable catalytic group (an example 
is the aspartate residues in scheme 1.1) of the enzyme to bear on the substrate. The 
amide bond is cleaved and the products dissociate from the active site. Enzymes bind 
most tightly to the transition state of the reaction they catalyze, stabilizing it and 
lowering its free energy. This means that the activation energy is lowered relative to 
the equivalent uncatalyzed reaction, and rates of reaction can be greater than 1012 
times faster. 
The stereospecificity of the active site has great possibilities for the use of 
enzyme catalysis in organic synthesis and has recently been reviewed. 16 
Many other receptors exist which do not participate in chemical reactions like 
enzymes, but do participate in the transfer of information and signals between cells, by 
the recognition of active compounds such as hormones and neurotransmitters. These 
receptors are also proteins and structurally similar to enzymes. Receptors are 
characterized by the nature of their ligand. Receptors are usually located on cell 
membranes and the binding of an active compound occurs as for enzyme-substrate 
complexes, where a structural change takes place. As a result of binding, a 
characteristic effect occurs. The function of receptors is to receive and filter signals 
and to transmit the correct information on to another site where, for example, an 
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enzymatic reaction might be affected. The insulin hormone receptor is an integral 
membrane glucoprotein which binds insulin 1.6, migrates and makes the hormone 
available to be metabolized within the cell. 
Drug discovery and design 
There are two basic approaches to drug discovery, rational design and mass 
screening. The expanding knowledge of important peptide-receptor complexes and 
their specific function has lead to a more rational approach in the design of therapeutic 
agents (from this point on, the term drug receptor will be used in a generic sense to 
encompass both enzymes and receptors, as discussed above). Computer assisted 
molecular modelling, X-ray crystallographic analysis and NMR spectroscopic methods 
have been instrumental in the elucidation of important biological processes. The shift 
in philosophy towards rational design should continue until successful drugs are able to 
be designed de novo with predictable biological activity. At present mass screening 
programs for lead ligands is a valuable process to give starting points in drug 
development. 
A major goal in medicinal chemistry is the identification of potent and specific 
ligands to biological receptors. Identification of such ligands is a fundamental step in 
probing ligand-receptor function and developing therapeutic agents. Advances in 
genetic engineering in the 1970s lead to the availability of large quantities of many 
biologically important peptides and proteins. As a result the identification of target 
receptors has accelerated and demands on screening for ligands has greatly increased. 
Random and mass screening of natural products and existing compound databases are 
extremely labour and time intensive. Therefore recently, enormous efforts have gone 
into the synthesis of combinatorial libraries where in excess of 50,000 different 
compounds can be synthesized rapidly and screened for biological activity. 
Combinatorial chemistry has been described as the science of efficient divergent 
synthesis. 17 Compounds based on common building blocks such as peptides and 
oligonucleotides are ideal to form such libraries as a vast number of combinations are 
possible. If tetrapeptides based on combinations of the twenty primary amino acids 
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were synthesized then 160,000 (204) products would be possible. The libraries can be 
based on a random strategy of screening every possible combination of building block, 
or a directed strategy of screening mutations of a lead compound. 
The preparation of such combinatorial libraries18 can be achieved by the split 
synthesis technique on small chemically inert polymer beads. For example, you can 
take 100,000 polymer beads (10 ~m diameter) and attach the same starting molecule 
to each. Then divide the beads into five groups and perform a different chemical 
reaction on each. Mixing of the beads, dividing into five new groups and performing 
another five reactions generates 25 compounds. Repeat this process four more times 
and a staggering 15,625 different compounds are generated, each attached to its own 
bead. An essential step is to tag the molecules as they grow, so that each can be 
identified at the end. Several techniques are available for tagging, including adding 
DNA nucleotides at each stage to a different site on the bead. The DNA sequence can 
then later be identified by using the polymerase chain reaction. A recent development 
is tagging the molecules using microchip memories. Beads containing microchips can 
be sent radio signals at each stage to record details, to be read in an instant when 
synthesis is complete. 
Fast and effective screening of combinatorial libraries for desirable biological 
activity is required to prevent a bottleneck developing, with the enormous numbers of 
different compounds being generated. One potentially powerful technique is the use of 
an appropriate antibody which will bind to desirable ligands. By linking the antibody 
to an enzyme that causes staining when the antibody binds, the desirable molecule in 
the library can be identified. 
Many new building blocks and reactions from organic synthesis are being 
applied to the preparation of more rational small molecule libraries. 19 
Nature provides a wealth of interesting compounds (peptidic and non-peptidic) 
with novel structures and potent biological activities, which provide previously 
undreamt of new ideas and leads in the development of therapeutic drugs. 
Traditionally, a random and mass screening of natural products, followed by 
synthetic manipulation and refinement, has been employed to discover lead compounds 
in drug development. It is not unusual for natural products from one organism to bind 
to receptors in another. 
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Throughout history humans have been interested in naturally occurring 
compounds. Natural products were once the only source of medicines for mankind. 
Healing creams and liniments were produced from plant extracts in practically all 
ancient cultures. Even chimpanzees have been known to chew certain leaves only 
when suffering from gastro-intestinal problems. Natural products have been used in 
medicine since ancient times. In China, the Pen-Tsao was compiled by Shen Nung 
around 2800 BC and describes 365 herbal drugs used in those times. One of the first 
known drugs ephedra, described by Shen Nung and also included in ancient Greek 
medicine, was isolated from the 'horsetail' plant mahuang. It has been used as a 
stimulant to remedy respiratory diseases, to induce fever and perspiration, and to 
depress coughing. In the seventeenth century, the Jesuits brought with them from 
South America some medicinal concoctions developed by the Incan Indians, including 
the bark of the china tree for the treatment of malaria. In 1820 Pelletier and Caventou 
isolated the active component, quinine, from the china tree and sparked a rapidly 
growing interest in isolating medicinal natural products. 
More recently the development of modern chromatographic techniques has 
enabled the separation of complicated mixtures of compounds from natural extracts. 
The process of purification can be guided by bioassays indicating which components of 
the mixtures have useful biological properties. Natural products being screened for 
drug discovery are isolated from many different sources. The National Cancer 
Institute (NCI) organizes enormous screening projects including compounds extracted 
from all three major organism types: plants, animals and microbes. The marine 
environment is a more recent source of potentially useful natural products. The Roche 
Institute among others are involved in major efforts to collect a wide variety of 
organisms from the world's oceans. What follows is a brief discussion of some 
important natural product pharmaceuticals. 
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Paclitaxel 
1.8 
An extensive screening of plant materials, as part of the NCI campaign against 
cancer, lead to the discovery20 of paclitaxel 1.8 from the bark of the Pacific Yew tree. 
It has been hailed as a miracle drug against cancer but is in short supply due to its 
natural scarcity. To obtain one kilogram of paclitaxel, 3000 rare and slow-growing 
trees would have to be sacrificed. Ironically, the yew tree was regarded as the tree of 
death by the Greeks, because of its poisonous extracts which were commonly used in 
suicide and murder attempts. Paclitaxel has a unique mechanism of action, 21 causing 
cancer cell death by stabilization of microtubules (large proteins involved in many 
aspects of cellular biology). The novel molecular architecture of 1.8 was determined 
by X-ray crystallography and has recently been the subject of enormous synthetic 
efforts. The Nicolaou223 and Halton groups22b simultaneously reported the challenging 
first total syntheses of 1.8 after a heated race with thirty or so groups around the 
world, however these syntheses are unsuitable as large scale sources of 1.8 for drug 
purposes. Semisynthetic supplies23 of 1.8 are now available which should meet the 
demands of ongoing clinical trials. 
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Enediynes 
1.9 
A new class of natural products, the enediyne anticancer antibiotics24 (an 
example is dynemicin A 1.9), were discovered from various bacterial sources and 
exhibit potent anticancer activities. They possess novel molecular architecture, potent 
biological activity and fascinating mechanisms of action. Their activity is exerted by 
the enediyne ring which undergoes Bergman cyclization25 (scheme 1.2) to form a 1,4-
benzenoid diradical species. This species is very damaging and leads to cleavage of 
DNA strands. This intriguing cycloaromatization was demonstrated separately in 
1972, however its full biological significance only became apparent after the enediynes 
were revealed by nature. Potentially selective activity of certain enediynes for cancer 
cells can stem from their ingenious triggering and delivery systems, which means 
cycloaromatization of the enediyne does not occur until the molecule has reached its 
target. This class of natural product has sparked the development of a number of 
potent and therapeutically useful analogues. Selected enediynes are in clinical trials . 
. 
-- 0 2H·,.. 0 
enediyne 
Scheme 1.2: Bergman cyclization.25 
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Cyclosporin A and FK506 
1.10 
1.11 
Cyclosporin A 1.1026 and FK506 1.1127 are fungal natural products that inhibit 
the specific signal transduction pathways which lead to T -lymphocyte activation. 
They are employed as immunosuppressive agents to prevent graft rejection after organ 
and bone marrow transplantation, and are responsible for a revolution in clinical 
transplantation. Cyclosporin A binds to a protein receptor called cyclophilin that is 
identical to the enzyme peptidyl-prolyl isomerase28 which catalyses the 
interconversion of cis and trans rotomers of peptidyl-prolyl amide bonds in peptide 
substrates. FK506 binds to a similar receptor FKBP. Research on the biological 
activity of these immunosuppressants is unravelling the complex cascade of events 
leading to T -cell activation?9 
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Peptidomimetics30 
Peptides are a rational starting point in drug design due to their biological 
significance. They can have potentially high specificity and affinity for a target 
receptor, as discussed for substrate-enzyme complexes above. Unfortunately these 
factors are often negated by their poor pharmacological properties of low metabolic 
stability and poor absorption after oral ingestion. Peptides are susceptible to 
hydrolysis by proteases in the gastrointestinal tract, inside cells, and in serum, and are 
rapidly excreted through the liver and kidneys. Due to their relatively high molecular 
mass and lack of specific transport systems, they are not absorbed readily after oral 
ingestion. 
So although a peptide may have potent activity against a target in vitro, it may 
not have high enough concentration at the target site in vivo to be an effective drug. 
Peptides have been employed as drugs in only a few cases: insulin 1.5 and vasopressin 
1.3 are given to patients suffering from the deficiency diseases diabetes mellitus and 
diabetes insipidus, respectively. 
Therefore, a logical step m rational drug design is to convert the three-
dimensional structural information contained in biologically active peptides to small 
non-peptide ligands. Such compounds, called peptidomimetics, are expected to have 
more favourable pharmacological properties and still retain the potency and selectivity 
of parent peptides. 
Peptidomimetics are based on knowledge of the conformational, topochemical 
and electronic properties of a native peptide and its receptor. 
A most important principle in the design of peptidomimetics is the formation of 
conformationally restricted ligands which mimic the bioactive conformation of the 
native peptide. If necessary the required bioactive conformation can be stabilized by 
introducing elements which force rigidity. Structural elements are added to a ligand in 
defined positions which ensures that important hydrogen bonding, electrostatic and 
hydrophobic interactions can still occur with the receptor. Mass screening of natural 
products and combinatorial libraries (discussed above) produce lead compounds which 
are often conformationally restricted analogues of peptides that have the required 
properties to be recognized by the receptor or enzyme. An example is morphine, an 
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extract of the opium poppy, which has been used and misused for its pain-killing and 
euphoria-generating effects. Morphine 1.12 mimics the three-dimensional structure of 
endogenous peptides called enkephalins (figure 1.4), at a common receptor.31 
Enkephalins are rapidly degraded in the body and so are poor pain-killing drugs. 
However, elucidation of their structure-activity relationships has resulted in useful 
synthetic analgesics more potent than morphine. 
Me 
N 
1.12 
NH2 
CO-Giy-Giy-Phe-Met-Thr-Ser-Giu-Lys-Ser-
Gin-Thr-Pro-Leu-Vai-Thr-Phe-Lys-Asn-Aia-
lle-lle-Lys-Asn-Aia-Tyr-Lys-Lys-Giy-Giu 
HO 
Figure 1.4: Morphine 1.12 imitating f3-endorphin 
Several strategies have been established for the design of conformationally 
restricted and metabolically stable analogues of parent peptides of interest, and some 
ofthese are detailed below. 
Chapter One Introduction 25 
Side chain modification of amino acid residues 
~ HO Ph~ H2N OH OH ~ OH H 0 0 0 
1.13 1.14 1.15 1.16 
A well established strategy is the replacement of natural amino acid sidechains 
with unnatural derivatives. Conformational restriction is possible by introducing 
sterically demanding groups or rigid bridging units. Phenylalanine analogues 1.13 and 
1.14 have been employed in potent ligands of the angiotensin II receptor.32 Compound 
1.15 is a phenylalanine analogue where the dihedral angle ca-cP is restricted to a very 
narrow range. It has been incorporated into various opioid antagonists with high 
selectivity for the j.t receptor.33 Another example 1.16, involves modification of the 
tyrosine side chain by introducing methyl groups at the 2', 6' and ~ positions which 
hinders free rotation about the cP -cr bond and can favour the formation of bioactive 
conformations. 34 
Modification of the Peptide Backbone 
Isosteric or isoelectronic replacement of units in the peptide backbone can 
lower the peptide character of the molecule and increase its biological half-life, while 
still retaining favourable properties of the parent peptide. The most general 
replacements are shown in table 1.2. 
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Table 1.2: General modifications of the peptide backbone. 
~ --0-- -@}---
depsi aza thio 
-ill- ~ -----[§]---
reduced 
-(CO~ ~ ~ 
keto methylene bora n= 1, 2 
IP=O(OH)j-
~ 
Another approach is retro-inverso modifications (figure 1.5)35 where natural L-
amino acids are replaced with their D-enantiomers and the direction of the peptide 
chain is reversed. The small number of retro-inverso derivatives36 that show activity 
comparable to their parent peptides indicates the importance of the peptide backbone 
for recognition by the receptor. 
natural peptide 
retro-inverso 
modification 
Figure 1.5: Retro-inverso modifications of a natural peptide 
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Replacement of an amide bond can make the molecule more hydrolytically 
stable to protease enzymes, force bioactive conformations and mimic reaction 
pathways. Various amide bond replacements are discussed below. 
Dipeptide analogues 
A classical approach in the design of enzyme inhibitors is the incorporation of 
hydrolytically stable dipeptide isosteres into peptide sequences. This approach was 
developed after the discovery of a variety of novel enzyme inhibitors from screening 
done on culture filtrates of microorganisms.37 The peptide natural product pepstatin 
1.17 was discovered to be an inhibitor of aspartic proteases (pepsin, renin, cathepsin 
D, zymosin and later HIV protease) and contained a previously unknown y-amino acid 
statine. Statine mimics the tetrahedral intermediate formed by enzyme-catalyzed 
hydrolysis of an amide bond (figure 1.6). A ligand which more closely resembles a 
transition state or intermediate species of a reaction would be expected to bind better 
to the catalyzing enzyme, than one resembling the starting substrate. X-ray 
crystallographic studies of enzyme-inhibitor complexes have confirmed that the (3S)-
hydroxyl group of statine hydrogen bonds to catalytically essential aspartate residues in 
the active site. 38 These clues on reaction mimetics provided by 1.17 lead to the idea of 
transplanting critical features of active natural products into other structural 
frameworks to develop selective and potent inhibitors of different protease enzymes. 
Statine as a y-amino acid is one atom short of being a true dipeptide mimic 
based on the natural substrate, and so a series of related but previously unknown 
structures were designed (figure 1.6). Typically, these dipeptide isosteres incorporate 
a hydroxymethylene transition state mimic and a replacement for the amide bond which 
is cleaved in the substrate. The isosteres also permit the selection of suitable 
sidechains for a target enzyme based on the sequence specificity of the substrate. 
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enzyme 
natural peptide 
tetrahedral transition state 
of enzyme-catalyzed hydrolysis 
Me 
Me~Me H 0 ~Me 
Vai-Vak.~~N0~~0H pepstatin 1.17 
H OH 0 Me H OH 0 
statine 
hydroxyethylene 
dihydroxyethylene 
reduced amide 
hydroxyethylamine 
Figure 1.6: Hydrolytically stable dipeptide isosteres. 
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The hydroxyethylene isostere was the first of such structures used, being 
incorporated into the amino acid sequence of the renin substrate to produce potent 
renin inhibitors. 39 Renin was the subject of much interest due to its implications in 
cardiovascular disease. Molecular modelling studies suggested that the related 
dihydroxyethylene isostere might interact via both hydroxyl groups with the catalytic 
aspartate residues, and so compound 1.18 was prepared40 and found to be a potent 
inhibitor of renin (ICso 0.35 nM). 
o~~J)""'= N 1 h N 
OH~ H 0 
Boc-Phe-His-N 
H 
1.18 
The hydroxyethylamine isostere has been incorporated into effective inhibitors 
of HIV protease41 that mimic the Phe-Pro cleavage site in the viral protein gag-pol. 
JG-365 1.19 was an initial potent inhibitor (IC50 0.24 nM) based on incorporation of 
the hydroxyethylamine isostere into the minimum substrate peptide sequence required 
for activity. Extensive structure-activity relationship studies lead to inhibitor 1.20 (Ro 
31-8959, ICso 0.4 nM) with improved pharmacological properties. X-ray 
crystallographic studies of these HIV protease-inhibitor complexes has facilitated the 
development of new ligands. 
Ph Ac-Ser-Leu-Asn-~~Nx_ 
H OH 
O lle-Vai-OMe 
1.19 
Ph~ H~ 
QC-Asn-~~N 
H OH 
0 
1.20 
HIV protease crystallizes as a C2 symmetric homodimer with each amino acid 
chain contributing one catalytically essential aspartate residue. Pseudo-C2 symmetric 
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isosteres were designed, based on this principle, and incorporated into potent inhibitors 
(figure 1.7).42 Interestingly, the configuration of the COH centre has little effect on the 
activity of these compounds. 
Ph~i ~ :N~ N ... H HO OH 
: 0 
I 
I 
I 
~ 
Ph .,........Ph 
Cbz-Vai,NVN' Val-cbz 
H OH H 
Phe-Pro scissile 
amide bond 
pseudo-C2 symmetric 
inhibitor 
Figure 1.7: Design of a pseudo-C2 symmetric HIV protease inhibitor. 
Conformational Restriction 
Conformational restriction43 is an important principle in peptidomimetics. 
Analogues which assume the bioactive conformation of a target peptide are potentially 
more selective and potent ligands for a receptor. Also, ligands which are 
'preorganized' for receptor-binding have a lower relative entropy cost. Techniques of 
conformational restriction include a variety of short or long-range cyclizations and the 
introduction of other rigid elements which make the molecule less flexible and may 
induce a favourable bioactive conformation. An understanding of the conformational 
implications of such restrained analogues is important to further design and 
development. 
1.21 1.22 1.23 
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Substrate-based cyclization techniques can link two side chains 1.2144, two 
backbone units 1.2245 or a side chain and a backbone unit 1.2346 . Much research has 
been done on the synthetic problems encountered in developing such systems. 
Many potent macrocyclic peptides are found in nature, such as somatostatin 1. 7 
and cyclosporin A 1.10. The structure of cyclosporin A incorporates a number of 
peptidomimetic design techniques. It is cyclic, and possesses seven N-methylated 
amide bonds, several D-amino acids and some unusual C-alkylated substituents, which 
combined with intramolecular hydrogen bonding, all limit conformational freedom. In 
addition to their conformational restriction, macrocyclic peptides frequently possess 
more favourable pharmacological properties than linear peptides. Hydrophobic side 
chains of cyclic peptides provide a hydrophobic exocyclic surface that shelters 
cleavable amide bonds from degrading proteases and facilitates the penetration of cell 
membranes. 
1.24 1.25 
Synthetic macrocyclic peptidomimetics (for a recent review see Fairlie et al. 47) 
have been developed based on X-ray crystal structures of HIV protease-inhibitor 
complexes. Macrocycles were incorporated into inhibitors 1.19 and 1.20, to link the 
P1 and P3 residues which are arranged closely in space in the active site, to give 
compounds 1.24483 and 1.25.48b Molecular modelling of enzyme-bound structures 
superimposed well onto the X-ray crystal structure of bound 1.19. Compounds 1.24, 
1.25 and derivatives are potent inhibitors (1-30 nM) of HIV protease and display 
enhanced metabolic stability. 
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Cis amide bond analogues 
The partial double bond character of the amide bond leads to cis and trans 
isomers. In peptides the more stable trans configuration predominates. Exceptions 
include N-alkylated amino acids, cyclic peptides and turns (discussed below). Many 
cis amide bonds occur in the biologically active conformations of peptides. The 
biological activity of angiotensin II 1.5 is correlated with the isomerization of the His-
Pro amide bond to the cis configuration. 49 The simulation of cis amide bonds which 
could occur in the biologically active conformation of a peptide is an important 
technique in designing peptidomimetics. Compounds 1.26, 50 1.27 and 1.2851 are 
examples of dipeptide analogues mimicking cis amide bonds. Each of these 
compounds incorporates a rigid ring structure as surrogate for the amide bond which 
restricts the relevant torsion angle to a value close to 0°. Incorporation of 1.27 into a 
cyclic hexapeptide analogue of somatostatin gave a compound· with some biological 
activity. 52 
H N-N 
I II ,, 
Cbz-NY'N"N O 
Ph/ Me~~ 
OMe 
1.26 
M~ 
Boc-N 0 
Ph OH 
1.27 1.28 
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Imitation of secondary structure 
0 ~ 0 Me 0 R30~¥ $ 0~ oj: ~ ~ ~s o R ~JYNy ~Pl N---i N--1 H R1 H' 
M H 
f3-turn 1.29 1.30 
Figure 1.8: f3-turn mimietics. 
The retention of peptide secondary structure in mimetics is crucial to retention 
of biological activity. a.-Helix and f3-sheet structures, turns and loops are essential 
components of peptide and protein conformation. The f3-turn (figure 1.8) is a 
structure common to many biologically active cyclic peptides, and has been postulated 
in many cases for the active conformation of linear peptides. In many proteins, f3-turn 
structures are exposed and may be a part of ligand recognition sites. The secondary 
structures of peptides can interchange because of the inherent flexibility of peptides. 
Therefore, conformational restriction of bioactive secondary structures has been of 
great interest. The f3-turn is the most frequently imitated secondary structure. 
Examples of f3-turn mimetics include structures with still recognizable peptide chains 
1.29,53 to those with completely non-peptidic components 1.30. Structure 1.30 has 
been used to produce two antiparallel peptide chains54 or, simply by changing the 
anchor groups, two parallel peptide chains (f3-sheet mimetics). 55 
A mimic of 0.-loop secondary structures 1.31 has also been recently 
described. 56 A 0.-loop is a larger conformationally stabilized curve in a peptide chain, 
involving from six to sixteen residues. Such loops are found in many proteins and 
thought to have an important role in biological recognition. Structure 1.31 mimics the 
peptide sequence of residues 41-48 in interleukin-1 a., an important mediator in 
immunological and inflammatory processes. 57 
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1.31 
In addition, many of the techniques discussed above which restrict the 
conformational flexibility of a backbone and sidechains, can be applied to stabilize 
secondary structures. For example, the incorporation of cis amide surrogates into a 
backbone can stabilize the conformation of a ~-turn. The use of such constrained units 
has been reviewed.43 
Scaffold peptidomimetics 
The support of essential side-chain elements on a completely unnatural 
framework is an interesting technique in designing compounds with favourable 
pharmacological properties. The structural frameworks are based on natural products 
or known drugs whose pharmacological properties are known. The relative 
conformational rigidity of such systems is important in mimicking the active 
conformation of a peptide. Also, the framework prevents hydrophobic collapse of the 
structure to an inactive conformation. Examples of scaffold mimetics and the original 
peptides are shown in figure 1.9. The steroid scaffold is a completely non-peptidic 
framework which is able to bear the appropriate sidechain groups to mimic a ~-turn 
region of the bioactive peptide RGD. 58 ~-D-Glucose is able to serve as the scaffold for 
mimics of a cyclic hexapeptide, which is known to bind to the somatostatin receptor. 59 
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somatostatin analogue 
Figure 1.9: Examples of scaffold mimetics (left) and the original peptides (right). 
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Work Described in this Thesis 
The research described in this thesis is divided into two related projects, which 
represent two distinct approaches towards the development of peptidomimetics as 
discussed above, rational design and the development of leads from natural products. 
Chapters two through four describe the design, synthesis and biological activity of a 
new, generally applicable cis-hydroxyethylamine dipeptide isostere, and its applications 
to the inhibition of HIV protease. The principles on which this rationally designed 
peptidomimetic is based are discussed above. It is hoped that the shift towards rational 
design will continue so that drugs may be designed de novo, based on a knowledge and 
understanding of receptor-ligand interactions. 
Chapters five and six describe the synthesis and biological activity of a series of 
analogues, of a class of natural products with potent antiviral and antitumour activity. 
It is thought that the parent natural products exert their bioactivity through an 
inhibition of protein synthesis, and are therefore acting as peptidomimetics. As a result 
of previous, extensive, structure to activity correlations on the parent compounds 
mycalamides A and B, a minimum essential substructure required for retention of 
biological activity was proposed. The series of analogues described in this thesis was 
based on this substructure. This approach to drug development looks to exploit the 
biological activity of natural products, which can lead to highly selective, more potent 
and less toxic compounds. 
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Chapter Two 
Design of a cis-Hydroxyethylamine Isostere 
Introduction 
A central underlying principle of peptidomimetics is conformational restriction 
(see chapter one for a discussion), where the flexibility of a system is restricted and 
bioactive conformations are promoted. The replacement of components of a target 
peptide with various structural modifications (isosteres) can be a probe of the 
conformational requirements for biological activity, by allowing different degrees of 
rotational freedom along the peptide backbone. Such modifications can also improve 
the pharmacological properties of the analogue by reducing its peptidic character, 
making it more biostable and hence more suitable as a therapeutic agent. The ultimate 
goal being to produce a non-peptidic ligand constrained to the appropriate bioactive 
conformation. 
Cis-trans isomerization of amide bonds occurs as a result of the partial double 
bond character of the CO-NH bond. The configurations of the amide bonds in a 
peptide is of crucial importance to the conformation of the molecule and therefore, to 
its ability to bind to a receptor. In many cases, binding to a receptor will only occur 
with a cis configuration at certain amide bonds. Cis amide bonds can also occur in N-
alkylated amides, secondary structures such as turns, constrained cyclic peptides and 
bioactive conformations. 
In a normal amide bond the trans configuration is energetically favoured over the cis 
by approximately 10 kcal/mol, due to less steric hindrance between adjacent groups. 
In N-alkylated amides however, this energy difference is smaller (approximately 2 
kcal/mol), due to both isomers having similar 1 ,4-steric interactions, and cis-trans 
isomerization can be observed by NMR. N-Alkylated amides are found in a variety of 
biologically important peptides and make the cis-amide isomer more energetically 
accessible for recognition and binding by the receptor. Proline is the only naturally 
occurring primary amino acid that leads to N-alkylated ami des. Over 10% of proline 
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residues in protein X-ray crystal structures have been found with cis amide bonds. The 
NMR studies of morphiceptin (Tyr-Pro-Phe-Pro-NH2) have shown four different 
isomers generated from cis-trans isomerization of the Tyr-Pro and Phe-Pro amide 
bonds. 60 N-Methylated amino acids are commonly found in naturally occurring peptide 
antibiotics. Conformational calculations and NMR studies on Sar-Sar dipeptide 2.1 
(where Saris N-methylglycine) showed that the cis isomer is only 0.6 kcal/mol higher 
in energy than the trans (scheme 2.1).61 
0 
MeHN~~~OH 
Me 0 
trans-2.1 
Scheme 2.1: Cis-trans isomerization of2.1. 
cis-2.1 
There are many examples of the cis amide configuration in biologically active 
peptides and analogues. In a series of angiotensin II 1.5 analogues, trans to cis 
isomerization of the His-Pro bond was observed by NMR,62 when the compound was 
titrated in D20 from acidic to neutral pD. The amount of cis isomer present was 
correlated with biological activity for the angiotensin II receptor in rat uterine. This 
suggested that the cis isomer was the one bound to the receptor and responsible for the 
observed activity. It has also been proposed63 that the cis-trans isomerization of 
proline amide bonds might also play a role in transduction of membrane proteins. The 
isomerization of these membrane-bound proteins, and the resulting redirection of the 
protein chain, is proposed to provide the conformational change necessary for the 
reversible opening and closing of transport channels. Others suggested that cis-trans 
isomerization is also responsible for many of the slow kinetic events observed in 
enzyme kinetics and protein folding. 64 
Asp-Arg-Vai-Tyr-lle-His-Pro-Phe 1.5 
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Cyclosporin A 1.10, an immunosuppressant drug, is a conformationally 
constrained cyclic peptide containing seven N-methylated amide bonds. It is known 
that 1.10 inhibits a rotamase enzyme that catalyzes cis-trans isomerization of peptidyl-
prolyl amide bonds. In non-polar solvents or in the solid state, it was observed that the 
hydrophobic peptide forms a twisted f3-sheet structure with the MeLeu-MeLeu amide 
bond (shown in box) fixed in the cis conformation. In more polar solvents, like 
methanol or water, several conformations were observed with isomerization occurring 
about that amide bond. 
Somatostatin 1. 7 is a large cyclic peptide with an intramolecular disulfide 
bridge between two cysteine sidechains. Structure-activity relationship studies 
indicated that the Phe7-Trp8-Lys9-Thr10 sequence (the numbers indicate the position 
of the residue in the peptide sequence) was important for activity and that a f3-turn 
within this sequence was required for receptor recognition. Based on these studies, 
conformationally restricted analogues with smaller ring structures to stabilize the turn, 
were synthesized, 65 such as 2.2. Conformational analyses of these highly active 
analogues indicated that a cis amide bond between Phe-Pro was important for activity. 
As a result of these and other studies, cis amide bond surrogates have been 
designed to force the cis configuration in peptide analogues, in order to mimic 
bioactive conformations and probe receptor specificity. Replacement of the amide 
bond with surrogates also improves the metabolic stability of potential drugs by 
preventing amide cleavage from degrading protease enzymes. 
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The dipeptide analogue 1.27, containing an ortho-substituted benzene ring as a 
cis amide surrogate, was incorporated into the somatostatin analogue 2.2 as a 
replacement for the Phe-Pro sequence to give 2.3. The analogue 2.3 showed 
substantial bioactivity compared to the parent somatostatin. 52 A cis amide surrogate 
based on 1.27 has also been incorporated into analogues of the RGD peptide, leading 
to an active inhibitor of cell adhesion, 66 and also into inactivators of trypsin-like 
proteases. 67 
1.27 1.28 
The synthesis of a 1,2-disubstituted pyrrole-based dipeptide analogue 1.28 has 
been developed in our laboratories, as a generally applicable cis amide surrogate. 51 
Analogues of the Gly-Gly, Gly-Ala, and Gly-Leu dipeptides were prepared and shown 
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to be easily extended in the C direction. By the correct choice of side chain groups, 
this surrogate can be applied specifically as a peptidomimetic. 
H H 
~ ArH 
trans cis 
Scheme 2.2: Isomerization of an olefin. 
The trans olefinic group68 has been successfully used as a surrogate for a trans 
amide bond. However, the corresponding cis olefin is unsuitable as a cis amide 
surrogate due to the ease of cis to trans olefin isomerization (scheme 2.2). The CO-
NH portion of the urethane bond of common N-terminal protecting groups such as 
Cbz and Boc has a high tendency to assume a cis configuration. 69a A synthetic scheme 
was developed69b where a urethane bond was derived from the sidechain hydroxyl 
group of tyrosine (figure 2.1 ). The incorporation of these urethane linkages into 
backbones promoted cyclization of the compounds and gave rise to a family of 
macrocyclic peptide analogues, with numerous possible applications. 
/,_N 
H 
0 
Figure 2.1: Tyrosine cis-urethane linkage (shown in box). 
Smith, Hirschmann et a!. 70 have developed very successful pyrrolinone-based 
peptidomimetics as mimics of ~-strands. In these compounds 3,5,5-pyrrolin-4-one 
heterocycles are linked as replacements for the amide bonds of a native peptide to give 
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a novel completely non-peptidic scaffolding with attached sidechain groups (figure 
2.2). Such compounds were shown to adopt the favorable pleated backbone 
conformations and antiperiplanar sidechain trajectories observed in some HIV protease 
inhibitors such as 1.19. Pyrrolinone-based compounds also have improved 
pharmacological properties than the corresponding peptide-based peptidomimetics. 
Marshall et a!. 71 first proposed the tetrazole ring system as a cis amide bond 
surrogate to lock a dipeptide analogue in an equivalent configuration. The major 
concern in designing a surrogate is the amount of geometric and steric similarity to the 
cis amide bond. Using a novel procedure50 for assessing conformational mimicry, it 
was shown that approximately 88% of the conformations accessible to the cis isomer 
of the dipeptide 2.4 are also accessible to the tetrazole analogue 2.5. This index of 
conformational mimicry was measured by the ability of 2.5 to orient the backbone and 
sidechains, on either side of the tetrazole ring, in a similar manner to that of 2.4. As 
the receptor-bound conformation of a target peptide is not always known, such 
statistical arguments for the suitability of analogues are useful. During these studies, 
the tetrazole 2.5 was found to have more conformational freedom than 2.4. This 
probably reflects the increased valence angle a.C-C=N of the tetrazole relative to the 
corresponding a.C-C=O angle of the dipeptide. Based on these studies, Smith et al. 72 
concluded that the tetrazole analogue is an excellent conformational mimic of the cis 
amide bond. 
2.4 
N-N 
II '' AcHN~N"N 
Me ~~ = 0 Me'~ NHMe 
2.5 
The tetrazole 1.26 was incorporated73 into the cyclic somatostatin analogue 2.6 
as a replacement for Phe-(N-Me)Ala. The resulting analogue showed nearly equivalent 
activity, indicating that it is the cis configuration of this amide bond that exists in the 
biologically active conformation of 2.6. The tetrazole dipeptide 1.26 has also been 
incorporated into a substrate sequence of HIV protease as a replacement for the Tyr-
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Pro scissile amide bond. 74 Molecular modelling of the tetrazole analogue and the 
substrate showed good correlation between the two conformations. However the 
tetrazole analogue was found not to inhibit the HIV protease. This result may indicate 
that the increased steric bulk of the tetrazole ring in the active site may prevent 
effective binding of the analogue. 
H N-N 
I // '' Cbz-N~N"N 
= L/P 
Ph/ Me~~\ 
OMe 
1.26 
(N-Me)Aia-Tyr-0-Trp 
PLVai-L/. 
2.6 
The tetrazole surrogate has also been incorporated as a replacement for the 
Leu-Gly amide bond of deaminooxytocin75 2. 7 (see oxytocin 1.2 for comparison), to 
give 2.8 as a conformational probe of the importance of the cis configuration to this 
amide bond. Comparison of the bioactivity of 2.8 with that of a corresponding 
analogue incorporating a trans olefin surrogate suggested that a trans configuration 
was important to this amide bond. Replacement of the Pro-Pro and Ser-Pro amide 
bonds of bradykinin with tetrazole surrogates 76 gave analogues with greatly diminished 
activity relative to the parent peptides, suggesting either a cis configuration was not 
required or that the steric bulk of the tetrazole prevented key binding interactions. 
S-------, ~ Tyr-lle-Gin-Asn-C s-Prn-Leu-Giy-NH, 
0 2.7 
s I H N-N 
I '' Tyr-lle-Gin-Asn-Cys-Pro-N0N"N 
o Me = '--f0 Y. NH2 
2.8 
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A classic strategy in the design of protease inhibitors is the incorporation of 
non-hydrolyzable dipeptide isosteres into the natural enzyme substrate at the P1-P 1' 
cleavage site. Isosteric replacement of the scissile amide bond CO-NH (with CH2NH 
in the case of the hydroxyethylamine isostere) increases the metabolic stability of the 
inhibitor. 
A number of dipeptide isosteres have been developed. The application of the 
transition state mimic principle has considerably increased the activity of these 
inhibitors. In such compounds, an sp3 hydroxymethylene group is inserted in the 
centre of the isostere as a mimic of the tetrahedral transition state for hydrolysis of the 
P1-P1' amide bond. Enzymes bind more favourably to ligands resembling the transition 
state of the reaction than to those resembling substrate. The idea of using such 
isosteres was developed from the peptidomimetic natural product pepstatin 1.17, 
which was discovered37 as a potent mechanism-based inhibitor of aspartic proteases. 
Pepstatin contains the dipeptide isostere statine, from which other isosteres have been 
developed (figure 2.2). 
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The hydroxyethylamine isostere was first used to yield potent renin inhibitors, 77 
such as 2.9, by incorporation into the substrate sequence of angiotensinogen as a 
replacement for the scissile P1-P1' residues. However, due to its relatively large size 
and peptidic character, 2.9 possesses poor pharmacological properties and is not 
promising as an oral antihypertensive. 
Me 
Me~ Me Me Boc-Phe-His-';IY~X:IIe-Phe-OMe 
H OH H 0 
2.9 
In comparison with other dipeptide isosteres (figure 2.2), such as statine and 
hydroxyethylene, the hydroxyethylamine isostere retains the favourable interactions of 
the hydroxymethylene function while causing less disturbance to the pattern of 
substrate-like binding. In particular, the amino function more closely mimics the 
position ofthe amide nitrogen ofthe substrate. 
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statine 
hydroxyethylene 
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hydroxyamide 
a-ketoamide 
amino ketone 
Figure 2.2: Non-hydrolyzable dipeptide isosteres. 
The hydroxyethylamine isostere has also been used in inhibitors78 of the metallo 
protease ACE, an important enzyme in the renin-angiotensin system. Incorporation 
into the known substrate N~benzoyl-Phe-Ala-Pro as a replacement for Phe~Ala gave 
potent inhibitor 2.10. A series of compounds based on 2.10 were synthesized to 
investigate the consequences of structural and configurational modifications to activity. 
The configuration of the hydroxymethylene group was found to be important with the 
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(3R)-epimer of 2.10 possessing 400-fold greater activity than the (3S)-epimer. The 
removal of the hydroxyl group altogether resulted in extremely poor activity. The 
secondary amine of the hydroxyethylamine core was also shown to be important for 
activity when replaced by an ether function, resulting in a poorly active analogue. This 
suggested that the amino group acts as an important hydrogen bond acceptor-donor in 
the active site. 
Ph~ ., Me 
PhCO~~~~Pro 
H OH H 0 
2.10 
The hydroxyamide79 and the a-ketoamide80 dipeptide isosteres (figure 2.2) 
have been used successfully in potent HIV protease inhibitors (for a discussion see the 
following section on HIV protease inhibition). The extra amide bonds of these 
structures may make them less hydrolytically stable than the hydroxyethylamine 
structure, however they provide more possible hydrogen bonding interactions with a 
receptor. It was proposed that a-ketoamide based inhibitors of HIV protease are 
hydrated within the active site to form a stabilized hydrate which is a good transition 
state mimic (figure 2.3). 
Ph~ ~ 
QC-Asn-~~N~ 
H <50 
,H' H \ 0 NHiBu , 0 \ 0 , I \ : H A I I 
Asp125 o 6Yo 
Asp25 
Figure 2.3: Proposed hydrated a-ketoamide in the active site. 
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Related to the hydroxyethylamine isostere is the aminoketone structure (figure 
2.2), resulting from conversion of the hydroxyl group of the hydroxyethylamine 
isostere to a ketone. The resulting ACE inhibitor 2.11 was synthesized78 to compare 
with 2.10 and was found to be more potent. The mode of action of 2.11 would be 
similar to an cx-ketoamide (figure 2.3), where nucleophilic attack on the ketone in the 
active site, would lead to a hemi-ketal transition state mimic. The ketomethylene 
(COCH2) component of the aminoketone isostere is found in the naturally occurring 
aminopeptidase inhibitor arphamenine, and has also been incorporated into inhibitors of 
a number of other enzymes, including aminopeptidase81 and renin. 82 
Ph~ M PhCO~'ll~~Pro 
H 0 H 0 
2.11 
Ph~ M PhCO~~~~Pro 
H OH H 0 
2.10 
arphamenine 
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cis-Hydroxyethylamine Isostere 
cis amide bond surrogate 
cis-hydroxyethylamine 
isostere 2.12 
hydroxyethylamine dipeptide 
isostere 
Figure 2.4: Design of our cis-hydroxyethylamine isostere. 
49 
The subject of a significant part of the research undertaken in this thesis is a 
peptidomimetic structure combining the design principles of a cis amide bond 
surrogate and the hydrolytically stable hydroxyethylamine dipeptide isostere. This new 
cis-hydroxyethylamine isostere 2.12 incorporates a tetrazole ring in the centre of the 
dipeptide analogue to conformationally constrain the 1 and 5 substituents in a cis 
configuration (figure 2.4). The isostere 2.12 is generally applicable in the design of 
peptidomimetics by selection of suitable natural or unnatural sidechains at R1 and R2, 
and peptidic or non-peptidic extensions in theN and C directions. 
The isostere 2.12 can also be modified to give an a-ketotetrazole 2.13, where 
the hydroxyl group is converted to a ketone. This modification combines the design 
principles of the a-ketoamide and amino ketone isosteres discussed above. 
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2.13 
One envisaged application for isosteres 2.12 and 2.13 is in the design of HIV 
protease inhibitors, based on the known binding conformation of JG365 1.19 (see 
following for a discussion). 
HIV Protease Inhibition 
The Human Immunodeficiency Virus (HIV) infects almost 20 million people 
worldwide and leads to the deadly disease AIDS. Enormous research is being directed 
toward developing therapeutic drugs to treat HIV. Until recently AIDS has been an 
inevitably fatal, incurable disease. However this year, exciting new clinical results have 
emerged. Powerful combinations of HIV protease and HIV reverse transcriptase 
inhibitors have been shown to reduce viral levels in the blood of infected patients to 
undetectable levels. These combinations of drugs include the more established HIV 
reverse transcriptase inhibitors, such as AZT and 3 TC, and three recently approved 
HIV protease inhibitors, including 1.20. 
A second development is the discovery of chemokines, 83 compounds secreted 
by certain white blood cells that potently inhibit HIV replication. It has been shown 
that a chemokine receptor has a critical role in HIV' s ability to infect cells. Complete 
eradication of the virus from patients is now a possibility. 
The HIV protease84 is a virally encoded enzyme that cleaves viral polypeptides 
transcribed from the gag and pol genes, late in the viral replicative cycle. Although it 
can cleave a number of specific peptide bonds, the HIV protease is unusual in being 
able to cleave the Phe-Pro and Tyr-Pro sequences of its substrate. The amide bonds of 
proline residues are not very susceptible to cleavage by other mammalian 
endopeptidases. The protease is essential for the assembly and maturation of infectious 
virions. Inactivation of HIV protease, by a single mutation of the Asp25 residue in the 
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active site, resulted in non infectious virions and lead to the targeting of HIV protease 
inhibition as a viable strategy for treatment of the virus. The HIV protease belongs to 
the class of aspartic proteases (see chapter one) that includes renin and pepsin and 
which catalyzes the hydrolysis of amide bonds via aspartate residues in the active site. 
An enormous effort has been directed toward developing renin inhibitors as 
antihypertensive drugs, based on the mechanism of action of aspartic proteases. Many 
of the principles established in these efforts have now been applied to the design of 
HIV protease inhibitors. 
The rational design of inhibitors based on isosteres such as those shown in 
figure 2.2, has been greatly facilitated by the availability of three-dimensional X-ray 
crystal structures of HIV protease in its native form85 and in a number of inhibitor 
complexes. 86 The HIV protease (figure 2.5) is a homodimer comprising two 
identically folded ninety-nine amino acid subunits that form a hydrophobic active site 
cavity. This C2 symmetry is a unique feature of retroviral proteases. Two 
conformationally flexible flaps are able to close around the substrate upon binding. 
This is shown in figure 2.5, by a comparison of the conformation of free enzyme with 
that of enzyme bound to an inhibitor. 87 The two catalytic aspartate residues are 
centered in a cylindrical substrate binding groove. One residue acts as a base, initiating 
nucleophilic attack on the scissile amide bond of the substrate by an active site-bound 
water molecule. The other aspartate residue acts as an acid, stabilizing the carbonyl 
oxygen in the tetrahedral intermediate (see scheme 1.1). In order for rational drug 
design to succeed, it has been important to characterize the structures of the enzyme 
and its inhibitor complexes. A superimposition87 of the X-ray crystal structures of 
twelve different HIV protease-bound inhibitors is shown in figure 2.6. Figure 2.6 
demonstrates how a number of different molecules can adopt the same conformation 
and bind to the enzyme. It also defines the S3-S3' pockets of the enzyme and the shape 
and binding properties of the active site. 
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Figure 2.5 : Computer generated images87 of the structure of native IDV protease 
(top) versus inhibitor (MVT 101)-bound IDV protease (bottom) . Note that the flaps 
are opened in the native which close upon the inhibitor. 
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\ 
Figure 2.6: Superimposition of the X-ray crystal structures of 12 enzyme-bound 
inhibitors . 87 
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The hydroxyamide (norstatine) isostere (figure 2.2) was incorporated into 
potent HIV protease inhibitors, 79 such as 2.15, to compare with related 
hydroxyethylamine-based compounds, such as 2.14. The two types of inhibitors differ 
by one function, a carbonyl group in 2.15 which is a methylene group in 2.14. The 
extra amide bond of 2.15 may make it less hydrolytically stable than 2.14, however it 
provides more possible hydrogen bonding interactions in the active site. Compounds 
based on 2.15 were found to be 10-20 times more potent inhibitors of HIV protease 
than compounds based on 2.14. 
Ph~ ~ 
Cbz-~~Nx 
H 0 
O OMe 
2.16 
The a-ketoamide dipeptide isostere80 (figure 2.2) appears to be more potent 
than any other known mechanism-based isostere in HIV protease inhibitors. In 
general, activated ketones have been used in inhibitors of aspartic and serine proteases. 
HIV protease inhibitors such as 2.16 were proposed to form stabilized hydrates within 
the active site (see figure 2.3). 
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Ph 
QC-Asn-N 
H 
2.17 
Other isosteric Pt-Pt' replacements have been employed and exhibit potent 
activity. Benzamide-based inhibitor 2.17 was developed by Kaldor et al. 88 at the Lilly 
laboratories based on enzyme-inhibitor X-ray crystal structures. Molecular modelling 
calculations indicated that the benzamide carbonyl would be able to rotate out of the 
resonance plane of the adjacent benzene ring to enable a crucial hydrogen bonding 
interaction with a highly localized water molecule in the flap region. This prediction 
was later confirmed by the X-ray crystal structure of the IDV protease-2.17 complex. 
A number of benzene-substituted derivatives with varying activities were also 
prepared, to investigate the dimensions of the benzamide binding pocket at S 1'. 
Ph MeO~H~ ~ HO~N - N~OH 
lJHOH OMe 
Ph 
2.18 
In a novel approach, IDV protease inhibitors were designed which mimic the 
approximate C2 symmetry of the enzyme. Kempf et al. 42 imagined placing the C2 
symmetry axis of the enzyme through the proposed tetrahedral intermediate for amide 
hydrolysis and performing the Cz operation on either the P1 or P1' regions of the 
substrate (see figure 1. 7). Such structures may provides advantages over traditional 
substrate-based inhibitors, in terms of potency and selectivity for mv protease over 
other aspartic proteases. An X-ray crystal structure of the mv protease-2.18 complex 
showed an extended binding conformation, spanning the S2 to S2' subsites. 89 Several 
C2 symmetric inhibitors are undergoing clinical trials. 
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A key feature of all the potent peptide-based inhibitor-HIV protease complexes 
is the hydrogen bonding from the two central carbonyls of the inhibitor to a water 
molecule which bridges to the Ile50 and Ile150 residues in the flaps of the enzyme. 
Ph Ac-Ser-Leu-Asn-~~2 
H OH 
O lle-Vai-OMe 
1.19 
Ph~ H,,,. 
QC-Asn-~~N 
H OH 
1.20 
Potent and selective HIV protease inhibition is possible by mimicking the Phe-
Pro cleavage site unique to retroviral proteases. Since this cleavage site is rare in 
mammalian endopeptidases, such inhibitors have a selective advantage for HIV 
protease and are not as easily degraded by other enzymes. Incorporation of the 
hydroxyethylamine dipeptide isostere into the minimum substrate peptide sequence 
required for recognition gave 1.19.41'90 It is a potent inhibitor in vitro but failed to 
inhibit HIV in cell culture, possibly due to its largely peptidic character. Therefore, 
strategies were developed to increase favourable pharmacological properties. Smaller 
inhibitors, occupying two or three chain positions in the active site and having reduced 
or no peptidic character were targeted. Potent hydroxyethylamine-based inhibitor 1.20 
was developed41 by the Roche laboratories as a result of substantial structure-activity 
correlations, and exhibits strong antiviral activity. It was recently approved for 
marketing in the USA under the name Saquinavir, and is one on the drugs involved in 
exciting new clinical results. 
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Figure 2.7 : Superimposition of enzyme-bound 1.19 (JG365, X-ray) and 1.20 (Ro31-
8959, modelled).91 
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Two distinct inhibitor binding modes91 are observed in the X-ray crystal 
structures of the HIV protease-inhibitor complexes of 1.1992 and 1.20 (figure 2.7). In 
1.19 the He-Val (P2'-P3') residues occupy the S2'-S3' enzyme subsites as expected and 
force a favourable (S)-OH configuration on the transition state mimic. However, in 
1.20 the C-terminal tert-butyl amide group fits well into the S2' subsite with the large 
decahydroisoquinoline (Diq) ring structure occupying the entire S1' subsite, with some 
S3' interactions. This binding mode shows a clear preference for the opposite (R)-OH 
configuration at the transition state mimic. Extension of 1.20 to P3' showed a marked 
decrease in activity. Similarly, inhibitors based on 1.19, lacking a P3' ligand and with 
Pro at P1', show moderate potency and a slight preference for (R)-OH, indicating the 
second binding mode. The superimposition of the HIV protease-bound structures of 
1.19 and 1.20 in figure 2.7, clearly shows the two distinct binding modes with differing 
backbone conformations between the hydroxyl groups and the prolyl or Diq rings. The 
backbone of 1.19 adopts a cis geometry about this region while 1.20 has a trans 
arrangement at the equivalent position from the hydroxyl group to the Diq ring. 
It was envisaged that our designed isostere 2.12 would be able to bind by the 
first mode, adopting a bend cis-type conformation similar to that of 1.19. Molecular 
modelling studies of compound 2.19 (figure 2.8), based on our designed isostere 2.12, 
with a (R)-configuration at the C3 center, were done using the Macromodel software. 
A Monte Carlo conformational search of an energy minimized structure in an Amber 
forcefield, followed by further low gradient minimizations and local minima/maxima 
testing, gave a global energy minima. This structure was flexibly superimposed onto 
the enzyme-bound X-ray crystal structure of 1.19, to generate figure 2.9 (front view) 
and figure 2.10 (side view). An identical modelling study was done on the epimer 
2.20, with a (S)-configuration at C3. The superimposition of modelled 2.20 on 1.19 is 
shown in figure 2.11. It should be noted that although the assignments of (38)-1.19 
and (3R)-2.19 are different, they do have they same relative C3 configurations. 
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1.19 
2.19 
Figure 2.8: Relevant torsion angles of 1.19 and modelled 2.19, from the 
superimposition in figures 2.9 and 2.10. 
Figures 2.9 and 2.10 suggest that the modelled conformation of 2.19 compares 
well with the bioactive conformation of inhibitor 1.19. The torsion angle around the 
tetrazole ring ( 1 °) is restricted to a value close to the corresponding near planar torsion 
angle (11 °) adopted by the backbone of enzyme-bound 1.19 (figure 2.8). The side 
view in figure 2.10 shows clearly the cis conformation of the two superimposed 
backbones of 2.19 and 1.19. This particular torsion angle of 1.19 would not be 
constrained in solution and only adopt the planar cis arrangement upon binding to 
HIV protease. It was envisaged that the conformational restriction imposed by the 
tetrazole ring, would be the basis for mimicking the bioactive conformation of 1.19, 
and result in comparable HIV protease inhibition. 
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Figure 2.9: Front view of the superimposition of modelled 2.19 (in red) on the 
enzyme-bound X-ray crystal structure of 1.19 (in blue) (only the P1-P 1' regions are 
shown, for clarity). 
Figure 2.10 also shows that the two central carbonyl groups (pointing out to 
the left) are in a suitable position to form crucial hydrogen bonds with an active site-
bound water molecule (not shown). The P1 phenylalanine side chain groups can also 
be seen projecting into where the S 1 pocket of the enzyme would be. It is evident from 
the modelling studies that the P3-P 1 ligands of 2.19 are able to occupy the same 
enzyme subsites as 1.19. However, the steric bulk of the tetrazole ring may be a 
hindrance to binding if it is unable to project into the S 1' subsite occupied by the prolyl 
and Diq ring structures of 1.19 and 1.20 (figure 2.7). Another important factor in 
enzyme binding is the choice of a P/ ligand which will completely fill the S1' binding 
pocket. The large Diq ring of 1.20 completely fills the S 1' subsite, as observed in the 
X -ray crystal structure of the HIV protease-1.20 complex, and imparts greater activity 
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compared with the smaller prolyl ring of 1.19. On this basis, it may be favourable in 
the future to alter the P 1' methyl side chain of our designed2.19 to a larger group. 
Figure 2.10: Side view of the superimposition of modelled 2.19 (in red) on the 
enzyme-bound X-ray crystal structure of1.19 (in blue). 
The (JS)-epimer of 2.19, compound 2.20 is shown in figure 2.11 superimposed 
on structure 1.19. Figure 2.11 clearly shows the C3-hydroxyl group of modelled 2.20 
projecting in the opposite direction to the corresponding hydroxyl group of 1.19. 
Comparison to figure 2.9 where the hydroxyl groups of modelled 2.19 and 1.19 are 
superimposed, clearly suggests a preference for the (R)-configuration at C3, in order 
for our designed inhibitors, based on 2.12, to assume the known bioactive 
conformation of 1.19. 
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Figure 2.11: Superimposition of modelled 2.20 (in red), with a (S)-configuration at 
C3, on the enzyme-bound X-ray crystal structure of 1.19 (in blue) (only the P,-P/ 
regions are shown, for clarity). 
Traditionally, the activity of dipeptide isosteres has been enhanced by the 
addition of amino acid residues to both the N and C terminals, to improve recognition 
in the active site. Although this approach has been used to develop potent enzyme 
inhibitors, they generally exhibit poor pharmacological properties due to their peptidic 
character. Extensive research93 is being done to develop non-peptidic ligands for the 
traditional P3-P2' positions of potent HIV protease inhibitors, which will show potent 
activity in clinical trials. 
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Table 2.1: HIV protease activity of 1.19 based inhibitors. 
X y C3 IC5o (nM) Ref 
1.19 Ac-Ser-Leu-Asn Ile-Val-OMe s 0.24 41 
2.21 Ac-Ser-Leu-Asn Ile-Val-OMe R 20 41 
2.22 Cbz-Asn OtBu s 300 41 
2.23 Cbz-Asn OtBu R 140 41 
2.14 QC-Asn OtBu R 23 41 
2.24 Cbz-Asn NHtBu R 210 41 
2.25 Cbz OtBu R 6500 41 
2.26 Ac-Leu-Asn Ile-Val-OMe RS Ki21 nM 79 
2.27 Ac-Leu-Asn Ile-OMe RS Ki4520nM 79 
Ph'l H~., 
QC..Asn-~~N 
H OH 
1.20 ICso 0.23 nM 2.17 ICso 1.5 nM 
Ph'l w 
Cbz-~~Nx 
H 0 
O OMe 
2.16 rc50 405 nM 
0 
QC= oc:iY 
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In order to make comparisons to the activity of known potent inhibitors ofHIV 
protease (table 2.1), suitable P3-P3' ligands were chosen for our designed isostere 2.12 
(table 2.2). The phenylalanine side chain at P1 and asparagine residue at P2 are 
favoured in all the inhibitors. The 2-quinolinylcarbonyl (QC) ligand at P3 seems 
favoured over Cbz by comparison of the activities of 2.14 and 2.23 (table 2.1). 
Inhibitors 1.20 and 2.17 also favour QC-Asn at P3-P2. Ideally, to promote the binding 
mode of 1.19 (which our modelled compound 2.19 mimics), ligands extending from P2' 
to P 4', such as Ile-Val-OMe, would be more favourable (as discussed above). A 
comparison of the activities of 2.26 and 2.2 7 (table 2.1 ), shows how extension of the 
inhibitor by one residue in the C-direction, can significantly increase the activity. 
However initially, a simpler, more synthetically accessible inhibitor was targeted with 
OtBu or NHtBu at Pz' (table 2.2), suitable for comparison to 2.22. 
An inhibitor with Cbz at Pz and OMe at Pz' (table 2.2) was also targeted in 
order to compare the intrinsic potency of our designed cis-hydroxyethylamine isostere 
2.12, with the most potent known a-ketoamide core structure of2.13. 
Table 2.2: Possible P3-P3' ligands for isostere 2.12. 
p3 Pz P1-P1' Pz' P3'-P4' 
2.19 QC Asn PhuN NHtBu - ,, 
--~ § ~;0 H OH S' Me~ 
Cbz Asn OtBu 
Cbz Asn lie Val-OMe 
Cbz OMe 
These proposed comparisons enable a further probe of the effectiveness of our 
designed structure 2.12 to the application ofHIV protease inhibition. It was envisaged 
that, from these initial 2.12-based compounds, further structural modifications such as 
suitable extension from Pz' to P4' and reduction of the compound's peptidic character, 
could be made to maximize the activity. 
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Conclusion 
The new, generally applicable peptidomimetic cis-hydroxyethylamine structures 
2.12 and 2.13 were designed based on the design principles of a cis amide surrogate 
and a hydrolytically stable dipeptide isostere. A possible application of this system in 
the inhibition of mv protease was discussed, based on the known binding 
conformation of an existing potent inhibitor. A series of compounds based on 2.12 
were targeted for synthesis with a view to comparing their activities with those of 
known potent inhibitors. 
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Chapter Three 
Synthesis of the cis-Hydroxyethylamine 
Isostere 
1,5-disubstituted tetrazoles were first proposed by Marshall et al. 71 as a cis 
amide bond surrogate (see chapters one and two). A tetrazole is conveniently 
prepared from the corresponding amide by reaction with phosphorus pentachloride 
(PC15) to give the imidoyl chloride, followed by reaction with hydrazoic acid (HN3) 
(scheme 3.1). Zabrocki et a/. 76 have developed this procedure to prepare 1,5-
disubstituted tetrazole dipeptide analogues suitable for incorporation into larger 
peptides. 
0 Cl N-N 
RAN..-R2 PC15 R(J~N .... R2 HN3 )( ,, R N"N 
1 I Jlo Jlo 1 I 
H R2 
amide imidoyl chloride tetrazole 
Scheme 3.1: Formation of a tetrazole. 
Based on these procedures, a retrosynthesis of the target cis-
hydroxyethylamine isostere (see chapter two for a discussion of the design) was 
devised (scheme 3.2). The tetrazole 2.12 would be derived from the corresponding 
protected unnatural dipeptide 3.1 and then extended in the N and C directions as 
required. The unnatural dipeptide precursor would be prepared by a coupling of the 
corresponding N-protected B-amino acid with a suitable carbonyl-protected a-amino 
acid. 
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~-amino acid 
cis-hydroxyethylamine 
isostere 2.12 
dipeptide 3.1 
Scheme 3.2: Retrosynthetic scheme for the target 2.15 (X is OH or H). 
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Unusual ~-amino acids and their a-hydroxy derivatives occur in a diverse range 
of natural products with significant biological activities. The potent anticancer drug 
taxol 1.8 (see discussion in chapter 1) contains the a-hydroxy-~-amino acid 3.2, which 
is essential to its biological activity.94 Bestatin is well known as an immune-response 
modifier and inhibitor of aminopeptidase B. 95 The N-terminal residue of bestatin is 
composed of the a-hydroxy-~-amino acid 3.3. The configurations of both 3.2 and 3.3 
are crucial to the biological activities of their parent molecules. 
Ph 0 
PhCON¥0H 
I ;: 
H OH 
3.2 3.3 
Apart from their intrinsic properties, ~-amino acids are also useful synthetic 
intermediates in preparing ~-lactams,96 piperidines,97 indolizidines,98 and modified 
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peptides. 99 As a result of their undeniable chemical and pharmaceutical potential, 
enormous efforts have gone into the development of enantioselective syntheses of f3-
amino acids100 and their a.-hydroxy derivatives. 101 
Synthesis of a P-Amino Acid 
Arndt-Eistert homologation of a N-protected a.-ammo acid gtves the 
corresponding f3-amino acid via the Wolff rearrangement of an a.-diazoketone 
intermediate. In the 1940s, it was shown that the Wolff rearrangement of a.-
diazoketones, containing chiral centers adjacent to the carbonyl, occurred with 
retention of configuration. This opened up an ideal synthetic route to homologated a.-
amino acids from cheap and enantiomerically pure starting materials. 
Ph Ph Phu Pth-~x Plh-)yCHN2 11 iii Pth-N OH ~ ~ 
0 
. c:: 3.4 X = OH 3.6 3.7 1 3.5 X= Cl 
Ph Ph Phu Cbz·N~X Cbz~~CHN, __!L,.. lll Cbz-N OH ~ 
H o H 0 H 
ivC:: 3.8 X= OH 3.10 3.11 
3.9 X OCO;Et 
Scheme 3.3: i, oxalyl chloride, DMF, benzene, rt, 1 h; ii, CH2N2, ether, 5 °C, 18 h; iii, 
Ag20, Na2C03, Na28203, dioxane, water, reflux or 78-85 °C, 1.5-2 h, then 10% 
HN03; iv, EtOCOCl, Et3N, ether, THF, -20 °C, 15 min. 
N-Phthalyl and N-benzyloxycarbonyl-L-f3-homophenylalanine (Pth-L-f3Phe 3. 7 
and Cbz-L-f3Phe 3.11) were prepared via Wolff rearrangement of the corresponding a.-
diazoketones (step iii, scheme 3.3). A benzene solution ofPth-L-Phe 3.4 was treated 
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with oxalyl chloride and N,N-dimethylformamide (DMF) to generate the acid chloride 
3.5, which was reacted in situ with diazomethane to give crystalline a-diazoketone 3.6 
in 93% yield. 
Chaturvedi et al. 102 described the preparation of N-Cbz a-diazoketone 3.10 
(scheme 3.3), via the acid chloride. However, attempts to prepare acid chloride 3.12 
by reaction of 3.8 with oxalyl chloride or PC15 resulted in large yields of phenylalanine-
N-carboxyanhydride 3.13 (scheme 3 .4). This intramolecular cyclization is well 
known. 103 The treatment of N-Cbz-amino acids with thionyl chloride, if carried out 
above room temperature is a convenient method for the preparation of N-
carboxyanhydrides (Leuch's anhydrides). 
. ..r-- 3.8 X= OH 
1 
or 
11~3.12 X= Cl 
3.13 
Scheme 3.4: i, oxalyl chloride, DMF, benzene, rt, 1 h; ii, PCls, ether, rt, 15 min. 
A superior procedure104 for the preparation of N-Boc and N-Cbz-amino acid a-
diazoketones is via the corresponding mixed anhydrides. The treatment of Cbz-L-Phe 
3.8 with ethyl chloroformate and triethylamine followed by in situ reaction of the 
mixed anhydride intermediate with diazomethane gave the a-diazoketone 3.10 in 93% 
yield (scheme 3.3, steps iv and ii). 
The a-diazoketones 3.6 and 3.10 were dissolved in dioxane-water and heated 
in the presence of silver(!) oxide to give the corresponding N-protected ~-amino acids 
3.7 and 3.11, in 65% and 56% yields, respectively (scheme 3.3, step iii). A Wolff 
rearrangement of a variety of readily accessible a-diazo carbonyl compounds opens up 
many preparative applications which after 90 years has generated enormous theoretical 
and mechanistic interest. The rearrangement of a-diazoketones proceeds via ketene 
intermediates, with elimination of nitrogen and R1 group migration. Thermal initiation 
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of the rearrangement is catalyzed by metal ions such as Ag(I). A concerted mechanism 
has been proposed105 for the ketene formation (scheme 3.5), from the s-(Z) form of the 
a-diazoketone, where the leaving group N2 and migrating group R1 are in an ideal 
antiperiplanar geometry. A competing, non-concerted, carbenic pathway to the ketene 
has also been proposed. The ketene intermediate can then be trapped by a variety of 
weak acids RXH (where RX can be HO, RO, RNH, HONH, R2N or RS) to give a 
homologated acid or derivative. The ketene intermediate can now also be trapped by 
the amine functionality of an amino acid derivative100 to give a dipeptide-based 
product. This eliminates the extra step of coupling to a f3-amino acid. 
s-Z 
RXH 
Jlo 
1l 
ketene intermediate 
Scheme 3.5: Wolff rearrangement of an a-diazoketone. 
Synthesis of an a-Hydroxy-p-amino Acid 
The methyl esters 3.19 and 3.20 were synthesized from 3.8 by a modified 
procedure (scheme 3.6) to that developed by Herranz et a/ .. 106 Using this procedure, 
the aldehyde 3.16 , prepared in two steps from Cbz-L-Phe 3.8, was converted to a 1:1 
mixture of the cyanohydrin diastereoisomers 3.18. Hydrolysis then gave the methyl 
esters 3.19 and 3.20. 
The key aldehyde 3.16 was prepared from Cbz-L-Phe 3.8, via a reduction with 
lithium aluminium hydride of either 3.14 or 3.15. A 
benzotriazolyltris( dimethylamino )phosphonium hexafluorophosphate (BOP)-mediated 
coupling of 3.8 with O,N-dimethylhydroxylamine107 gave 3.14 in 85% yield, while a 
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similar dicyclohexylcarbodiimide (DCC)-mediated coupling of 3.8 with 3,5-
dimethylpyrazole gave 3.15 in 86% yield. Reduction of 3.14 with lithium aluminium 
hydride, at -50 °C, for fifteen minutes gave the aldehyde 3.16 in 77% yield. However, 
a similar reduction of 3.15 gave a mixture of 3.16 and the alcohol 3.17 in 49% and 
29% yields, respectively. The alcohol 3.17 was formed by further reduction of the 
aldehyde3.16 with excess lithium aluminium hydride. The alcohol3.17 was reoxidized 
to 3.16, in 98% yield, using Dess-Martin periodinane. 108 
N Cbz-~ 'OMe iii 
Ph Cbz-~OH 
H 0 
Ph\rMe 
i/ H 0 
/ 3.14 3.16 ~iv 
3.8 
~ Ph Me ~ Ph 
Cbz-N ') ~Me Cbz-N~OH 
Ph 
v I CN 
3.16-----. Cbz-~~ 
H OH 
3.18 
~·Tr I 
H 0 H 
Vl 
3.15 3.17 
Phv 
,_ Cbz-~ OMe 
H OH 
3.19 
Phl ~ 
+ Cbz-~VoMe 
H OH 
3.20 
Scheme 3.6: i, BOP, Et3N, O,N-dimethylhydroxylamine, CH2Ch, rt, 18 h; ii, 3,5-
dimethylpyrazole, DCC, CHCh, -10 °C, 1 h, rt, 2 d; iii, LiA.IIL, THF, -50 °C, 15 min,-
50 to 0 °C, 20 min; iv, Dess-Martin periodinane, CH2Ch, rt, 1 h; v, KCN, EtOAc, 
water, rt, 18 h; vi, MeOH, ether, HCl(g), S °C, 24 h, water, 5 °C, 2 d. 
The addition of a nucleophile to chiral aldehydes, such as 3.16 (example step v, 
scheme 3.6), can occur with 1,2-asymmetric induction to give an excess of one of the 
two possible epimeric products. 109 Two strategies have been developed to exert 
stereochemical control in such reactions (scheme 3.7): 1) The use of a Lewis acid to 
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form an intermediate chelate, which reacts with a bulky nucleophile, from the least-
hindered face (chelation control); 2) The stereoselective attack of a bulky nucleophile 
according to electronic and steric factors in the presence of non-chelating reagents 
(non-chelation control according to Cram's rule110). Generally the two methods lead 
to the opposite diastereoisomer product. 
Ph PN~H 
\ 0 \ , ,.,, .. 
MXn 
Nu 
Chelation controlled attack 
on the least hindered (back) face 
0 
Ph~H 
PNH~·· Nu 
Non-chelation controlled attack 
(Newman projection of Cram model) 
Scheme 3. 7: Stereoselective control of nucleophilic addition to chiral aldehydes. 
Herranz et al. 106 investigated the chelation and non-chelation controlled attack 
of trimethylsilylcyanide (TMSCN) on Cbz-D-phenylalaninal (the enantiomer of 3.16). 
As expected, they found that under a chelation controlled attack, the threo 
diastereoisomer product (the enantiomer of 3.20) was almost exclusively formed. 
However, under conditions known to favour non-chelation control, an equal mixture 
of the threo and erythro (the enantiomer of 3.19) diastereoisomer products was 
obtained. The steric bulk of the amine protecting group is important in affecting non-
chelation control. lll The bulkier N,N-dibenzylamino aldehydes do form, almost 
exclusively, non-chelation controlled adducts. 112 
With this in mind it was anticipated that a chelation controlled addition of 
TMSCN to 3.16 would give a (2R,3S)-cyanohydrin adduct with the required 
configuration found in the target cis-hydroxyethylamine isostere 2.12. However, 
possibly due to the method of in situ preparation of the TMSCN reagent used, equal 
mixtures of non-silylated cyanohydrin adducts 3.18 were produced. Therefore, in a 
modified procedure, the aldehyde 3.16 was reacted directly with potassium cyanide in 
ethyl acetate-water to give a 1: 1 mixture (by 1H NMR) of the cyanohydrin epimers 
3.18 in 76% combined yield. 
Chapter Three Synthesis of the cis~Hydroxyethylamine Isostere 73 
The reaction of 3.18 in a solution of methanol-ether, saturated with dry 
gaseous hydrogen chloride, gave imidate hydrochloride intermediates which were 
hydrolyzed in situ to give a mixture of 3.19 and 3.20 in 59% combined yield (scheme 
3.6, step vi). Purification of the mixture by flash chromatography gave pure samples 
of 3.19 and 3.20. In an alternative procedure, 113 the cyanohydrin mixture 3.18 was 
hydrolyzed under harsher conditions (refluxing in aqueous 6M HCl) to give an 
epimeric mixture of (2RS,3S)-3-amino-2-hydroxy-4-phenylbutanoic acid (N and C 
deprotected 3.19 and 3.20). This procedure was not pursued further due to the low 
yield of product and the fact that amine deprotection was not desired. 
The methyl esters 3.19 and 3.20 were identified by comparison of 1H NMR, mp 
and optical rotation data with that of the enantiomeric literature compounds106 derived 
from Cbz-D-Phe. 
Ph)-! PhM PhM 
11 
Cbz-~ OMe ,... Cbz-~ OH ,... Cbz-~ OH 
H OH H OH H OAc 
3.19 3.21 3.22 
Phl ~ Ph') ~ 
Cbz-N~OMe _ ____,,.....,. Cbz-N~OH 
Phl. ~ 
_ ____,..,..,. Cbz-N~OH 11 
H OH H OH I = H OAc 
3.20 3.23 3.24 
Scheme 3.8: i, 1.4 equiv NaOH, MeOH, water, rt, 2 h; ii, Ac20, pyridine, rt, 18 h. 
Hydrolysis of 3.19 (scheme 3.8), with 1.4 equivalents of sodium hydroxide 
(step i) in methanol-water, for 2 hours, gave the acid 3.21 in 88% yield. The hydroxyl 
group of 3.21 was then protected, by reaction with acetic anhydride in pyridine (step 
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ii), to give the acetate 3.22 in quantitative yield. A similar sequence using 3.20 gave 
the acid 3.23 (88%) and then the acetate 3.24 (quantitative). 
Ph~ ~ 
Cbz-~~OMe 
H OH 
3.19 
Scheme 3.9: i, 2 equiv K2C03, MeOH, water, rt, 18 h. 
3.25 
Hydrolysis of 3.19 with 2 equivalents of potassium carbonate (scheme 3.9) in 
methanol-water for 18 hours gave the cyclic cis-5-oxazolidinecarboxylic acid 3.25. 
The formation of cis-3.25 confirmed the (2S,3S)-configuration of3.19. 
The coupling of the ~-amino acids 3.7, 3.11, 3.21/3.23, 3.22, 3.24 and 3.25 
with L-alanine benzyl ester (schemes 3 .12, 3 .13, 3. 15 and 3 .16) using the standard 
peptide coupling reagents DCC/1-hydroxybenzotriazole (HOBT)114 or BOP, 115 gave 
the corresponding amides 3.32, 3.34, 3.36/3.37, 3.39, 3.41, and 3.43 in 44% to 61% 
yield, ready for conversion to the corresponding tetrazoles. 
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Conversion of a Dipeptide to a Tetrazole 
Phl ~ Me 
P-N~~~OBzl 
R H 0 
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Phu-N ,, 
3 N 
P-N - N" + 
= ~0 R ~ Me~ 
OBzl 
3.30 
R 
3.27 
,, Ph)-/NN-
3 N 
P-N R ~~"s 0 
Me~ 
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3.31 
Cl Me 
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R H HCI 
-HCll 
Cl Me 
~~3.28 
R H cte 
l-HCl 
Me 
J.. 3 &>l. . ~)=·=N' 6'-f 3.29 
R 8 
HCI 
Scheme 3.10: Acid-catalyzed epimerization during tetrazole formation. 
The conversion of a protected dipeptide 3.26 into a tetrazole 3.30, with 
retention of configuration (scheme 3.11), requires special experimental conditions. 
The use ofPCls to convert the amide bond to the imidoyl chloride 3.27 leads to acid-
catalyzed epimerization at C3 by the proposed mechanism shown in scheme 3.10. A 
reversible elimination of the 3-H of 3.28 to form the dipeptide ketene imine.HCl 3.29, 
leads to a scrambling of the configuration. Proton 3-H is more acidic in the 
hydrochloride 3.28 than in 3.27, and therefore the simple addition of an organic base, 
such as quinoline, to the reaction with PCls when generating 3.27, is effective in 
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preventing most of the acid-catalyzed epimerization (scheme 3. 11). Quinoline is more 
readily protonated than the intermediate 3.27. 
Phl 9 Me i P~ls . Cl Me 
P-NY~Ayoszl qumoh~ 0~ _i_iHN_-l3liJo .... 
R H 0 R 
3.26 3.27 
PhuN - ,, 
P-N - N"'N 
R )-- /p Me~··\ 
OBzl 
3.30 
Scheme 3.11: Tetrazole formation with retention of configuration. 
The resulting tetrazole 3.30 is quite sensitive to base with both the C3 and C6 
centers epimerizing under mildly basic conditions. Therefore, the choice of acidolytic 
protecting groups is crucial to maintaining chiral integrity. Zabrocki et al. 76 preferred 
the use of Cbz for N-terminal amino protection and benzyl ester for C-terminal 
carboxyl protection, with the preferential removal of Cbz, by reaction with HBr in 
acetic acid, providing a synthetic route to a wide variety of chain-extended tetrazole 
isosteres. Studies by Yu and Johnson, 116 on the conversion of normal dipeptides to 
tetrazoles, suggested that the yield of the tetrazole-forming reaction is dependent on 
the choice of protecting groups and also the amino acid sequence. Dipeptides with 
bulky amino acid sidechains gave low yields of tetrazole, very probably due to 
unfavourable cis-1, 4 steric interactions in the transition state leading to the tetrazole. 
Cbz and Pth N-terminal protecting groups were preferred. Boteju and Hruby117 used a 
modified procedure to prepare tetrazoles containing bulky tryptophan sidechains, 
involving longer reaction times in both steps i and ii (scheme 3 .11) and the addition of 
an extra portion of PCls in the formation of the imidoyl chloride (step i). Longer 
reaction times were reported to obtain good yields, while shorter reaction times 
resulted in the recovery of higher percentages of the starting dipeptide. They also 
observed that the C-terminal protecting group had a considerable effect on the overall 
yield of tetrazole. The use of methyl ester over benzyl ester at the C-terminal gave 
drastic reductions in yield, perhaps surprisingly considering that OMe is smaller than 
OBzl. 
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The dipeptide 3.32 was stirred with PCls ( 1 equivalent) in benzene (scheme 
3.12). After 45 minutes, an additional amount ofPCls (0.2 equivalents) was added to 
the reaction mixture. A total reaction time of 1. 5 hours was allowed for complete 
conversion to the imidoyl chloride intermediate. A benzene solution of hydrazoic acid 
was then added and stirring was continued for 48 hours to give a mixture of the 
tetrazole 3.33 (51%) and the unreacted dipeptide 3.32 (30%). A similar procedure 
using the dipeptide 3.34 gave a mixture of the tetrazole 3.35 (47%) and unreacted 3.32 
(34%) (scheme 3.12). 
PhU PhU Me 
i 3 OBzl ii Pth-N OH ----ill- Pth-N N~ ----ill-8 ° 8 
PhuN -
\\ 
3 N 
Pth-N N" 0 
3.7 3.32 
* Me~ 
3.33 OBzl 
Phu Phu Me Phu-~, 
i 3 ~OBzl ii 3 ;N Cbz-N OH ----ill- Cbz-N N s ----ill- Cbz-N N 0 I I I I ~H H H 0 H # Me'\; 
3.11 3.34 3.35 OBzl 
Scheme 3.12: i, L-Ala-OBzl.HCl, DCC, HOBT, EtJN, CH2Ch, rt, 18 h; ii, PCls, 
benzene, 1.5 h, HN3, benzene, rt, 2 d. 
Since the C3 centers of 3.32 and 3.34 were unsubstituted the addition of 
quinoline was not required. No epimerization was observed, under these conditions, at 
the C6 stereocenters of the products 3.33 and 3.35. 
A general procedure for tetrazole formation, modified from above, was 
followed to convert the dipeptides with a stereocenter at C3. The dipeptide 
(3.36/3.37, 3.39, 3.41 or 3.43, schemes 3.13, 3.15 or 3.16) was added slowly to a 
stirred chloroform solution ofPCls (1 equivalent) and quinoline (2 equivalents). After 
1 hour, an additional amount of PCls (0.2 equivalents) was added to the reaction 
mixture. A total reaction time of 3. 5 hours was allowed for complete conversion to 
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the imidoyl chloride intermediate. A benzene solution of hydrazoic acid was then 
added, as above, and stirring continued for 48 hours to give 3.40, 3.42 and 3.44 
(schemes 3.15 and 3.16) 
S~heme 3.13: i, L-Ala-OBzLHCl, DCC, HOBT, Et3N, CH2Ch, rt, 18 h; ii, PC15, 
quinoline, CHCh, rt, 3.5 h, HN3, benzene, 2 d. 
In an initial investigation of the effect of the C3-hydroxyl group on tetrazole formation, 
a partially separated mixture of 3.36 and 3.37 ( 4:1 by 1H NMR) was reacted according 
to the general procedure above. Two products were observed by 1H NMR. The 
major product (85% by 1H NMR) was a mixture of epimers (7:3 by 1H NMR), thought 
to be the amide 3.38 (scheme 3.14). High resolution mass spectroscopy indicated the 
product had a formula Cz1H22NzOs (M+ 382.1529), identical to that of the cyclic 
dipeptide 3.39 (scheme 3.15). However, the 1H NMR data showed differences with 
3.39. The chemical shifts of the signals, 6-H (4.34 ppm) and 3-H (4.67 ppm) in 3.38, 
compared with those of3.39 (4.70 ppm and 5.10 ppm, respectively), us suggested that 
cyclization had occurred from the C3-hydroxyl group to the C8-carbonyl. This is 
consistent with the mass spectroscopy. A small yield (15% by 1H NMR) of an 
unidentified tetrazole compound was observed by the appearance of a characteristic 
resonance for the 7-H3 protons at 1.79 ppm, compared to 1.27 ppm for the dipeptide 
3.36 (see chapter four for a discussion of characteristic NMR data). 
Chapter Three Synthesis of the cis-Hydroxyethylamine Isostere 
Ph~ ~ ~ 
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H OH H 0 
Cbz-N~NH 
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3.36/3.37 
7 
3.38 ° 
Scheme 3.14: i, PC15, quinoline, CHCh, rt, 3.5 h, HN3, benzene, 2 d. 
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To investigate further the role of the C3-hydroxyl group, the dipeptide 3.39 
(where the hydroxyl group is protected within the oxazolidine ring) was reacted 
according to the general procedure for tetrazole formation above, to give a mixture 
(5:3 by 1H NMR) of the tetrazole 3.40 and the unreacted amide 3.39 (scheme 3.15). 
Ph K-M 
.}-o 
0 
3.25 
1 
___.,.. 
Phf - ~ Me 
H-~~~~OBzl ~ 
.}-o H o 
0 
3.39 
Ph)y(-N ,, 
H-N N'N 0 
.}-o ,.l- /; 
0 Me'~,·\ 
OBzl 
3.40 
Scheme 3.15: i, L-Ala-OBzl.HCl, DCC, HOBT, Et3N, CH2Clz, rt, 18 h; ii, PCls, 
quinoline, CHCh, rt, 3. 5 h, HN3, benzene, 2 d. 
Therefore, it was proposed that a suitable protecting group for the C3-hydroxyl 
function was needed during tetrazole formation. Similarly, in the studies ofBoteju and 
Hruby, 117 protection of the indole nitrogen of the tryptophan side chain was required to 
prevent low yields ( < 5-10%) of tetrazoles. The hydroxyl protecting group should be 
small and able to be added and removed in high yield. A bulky protecting group may 
lead to unfavorable steric interactions in the transition state leading to the tetrazole. 
The tetrazole ring forces a cis configuration which increases steric interactions 
between the C3 and C6 centers and their substituents. In addition, the protecting 
group should be able to be removed under non-basic conditions due to the base 
sensitive nature of the tetrazole to epimerization. In separate reactions, the hydroxyl 
functions of 3.21 and 3.23 were quantitatively protected as the acetates 3.22 and 3.24 
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(scheme 3.8, step ii), by reaction with acetic anhydride in pyridine, and used to prepare 
the dipeptides 3.41 and 3.43, respectively (scheme 3.16). The acetate group is not an 
ideal hydroxyl-protecting group for this system however, as it is traditionally removed 
under mildly basic conditions, which leads to some epimerization of the tetrazoles. 
The dipeptide 3.41 was reacted according to the general procedure for 
tetrazoleformation above, to give a mixture of the tetrazoles 3.42 and 3.44 (63%, 17:3 
by 1H NMR) and unreacted 3.41 (14%) (scheme 3.16). A similar procedure using 3.43 
gave a mixture of the tetrazoles 3.44 and 3.42 (63%, 4:1 by 1H NMR) and unreacted 
3.43 (32%) (scheme 3.16). The tetrazoles 3.42 and 3.44 were purified by 
recrystallization or flash chromatography. 
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I I~ ll I ~Q H OAc H 0 H OAc ~ 
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Phl ~ Me Phl ~-N 
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H OAc H 0 H OAc ).._ /~ Me'"~·\ 
OBzl 
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Scheme 3.16: i, L-Ala-OBzl.HCl, BOP, EhN, CH2Ch; ii, PCls, quinoline, CHCh, rt, 
3.5 h, HN3, benzene, 2 d. 
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Extension in the Nand C Directions 
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Scheme 3.17: i, 50% HBr-acetic acid, rt, 20 min; ii, Cbz-L-Asn, DCC, HOBT, EhN, 
CH2Ch, rt, 18 h; iii, KOH, MeOH, water, rt, 18 h; iv tBuNH2, BOP, EhN, CH2Ch, rt, 
18 h. 
Preferential removal of the Cbz N-terminal protecting group in the presence of 
the benzyl ester C-terminal protecting group with HBr in acetic acid, enabled extension 
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of the tetrazole isosteres by coupling to the free N-terminals. Hydrogenation of the 
benzyl ester in the presence of palladium on carbon catalyst enabled subsequent 
coupling to the free C-terminal. 
The tetrazole 3.35 was treated with 50% HBr in acetic acid for twenty minutes 
to give the amine hydrobromide 3.45 in 84% yield, which was then coupled with N-
benzyloxycarbonyl-L-asparagine (Cbz-L-Asn) using DCC/HOBT to give 3.46 in 76% 
yield (scheme 3.17). Hydrolysis of the benzyl ester 3.46 with 1 equivalent of 
potassium hydroxide in methanol-water for 18 hours gave an epimeric mixture of3.47 
and 3.48 (17:3 by 1HNMR), where epimerization had occurred at the C6 stereocenter. 
These mildly basic conditions appeared to catalyze epimerization slowly over time, 
therefore the more suitable hydrogenation procedure for removal of benzyl ester was 
used in subsequent deprotections. The reaction of 3.47 and 3.48 with two equivalents 
of tert-butylamine, two equivalents of triethylamine and BOP for 18 hours gave an 
epimeric mixture of the tert-butyl amides 3.49 and 3.50 (3:2 by 1H NMR) in 16% yield 
(scheme 3 .17). The coupling procedure caused further epimerization at the C6 
stereocenter, probably due to the presence of two organic bases and the long reaction 
time. Reverse phase analytical HPLC confirmed the presence of two epimers (figure 
3.1). The C6 configurations of3.49 and 3.50 were assigned on the basis of their NMR 
data (for a discussion see chapter four). 
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Figure 3.1: HPLC trace of a mixture of3.49 and 3.50. 
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Scheme 3.18: i, QC-L-Asn, BOP, Et3N, CH2Cl2, DMF, rt, 2 d; ii, Hz, 10% Pd/C, 
acetic acid, EtOH, rt, 18 h; iii, tBuNHz, BOP, EhN, CHzCh, rt, 18 h. 
Further amine hydrobromide 3.45 was coupled with N-(2-quinolinylcarbonyl)-
L-asparagine (QC-L-Asn) using BOP to give 3.51 in 60% yield (scheme 3.18). QC-L-
Asn was prepared119 by a coupling of £-asparagine tert-butyl ester with quinaldic acid 
using BOP to give QC-L-Asn-OtBu, which was then converted to the free acid by 
reaction with trifluoroacetic acid. A hydrogenation of the benzyl ester 3.51 with a 
catalytic amount of 10% Pd/C gave the acid 3.52 in 79% yield. This was then coupled 
with tert-butylamine using BOP, to give an epimeric mixture of the tert-butyl amides 
3.53 and 3.54 (1:1 by 1H NMR) in 25% combined yield (scheme 3.18). The epimers 
3.53 and 3.54 were separated by reverse phase HPLC (figure 3.2). Coupling to the C-
terminal had caused epimerization at C6, as observed above. In an attempt to prevent 
epimerization, coupling procedures using only 1 equivalent of the organic bases tert-
butylamine and triethylamine, over shorter reaction times, were tried. However, these 
procedures gave back unreacted free acid and negligible yields of tert-butyl amide. 
The C6 configurations of 3.53 and 3.54 were assigned on the basis of their NMR data 
(for a discussion see chapter four). 
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Figure 3.2: HPLC trace of a mixture of3.53 (1st peak) and 3.54 (2nd peak). 
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The tetrazole 3.42 was deprotected by reaction with 50% HBr in acetic acid to 
give the amine hydrobromide 3.55 in 84% yield. A similar procedure using 3.44 gave 
the amine hydrobromide 3.56 in 89% yield (scheme 3 .19). 
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Scheme 3.19: i, HBr, acetic acid, rt, 20 min. 
A mixture of 3.55 and 3.56 (3 :2 by 1H NMR) was coupled with QC-L-Asn 
using BOP to give a mixture of 3.57 and 3.58, which was used without further 
purification (scheme 3.20). Hydrogenation of the mixture gave the free acids 3.59 and 
3.60 which were then coupled with 5 equivalents of tert-butylamine using BOP, to give 
a diastereoisomeric mixture of the tert-butyl amides 3.61-3.64 (7% yield from 
3.42/3.44). Reverse phase HPLC showed four peaks (figure 3 .3), corresponding to 
the four diastereoisomers resulting from epimerization at the C3 and C6 stereocenters 
adjacent to the tetrazole ring (scheme 3.20). The C3 and C6 configurations of 3.57-
3.64 were assigned on the basis of their NMR data (for a discussion see chapter four). 
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Scheme 3.20: i, QC-L-Asn, BOP, Et3N, CH2Ch, DMF, rt, 2 d~ ii, H2, 10% Pd/C, 
EtOH, rt, 18 h; iii, tBuNH2, BOP, EtJN, DMF, rt, 18 h. 
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Figure 3.3: HPLC trace of a mixture of3.61-3.64. 
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Experiments investigating the removal of the acetate protecting group were 
performed on the tetrazoles 3.42 and 3.44 (scheme 3 .21). The reaction of a mixture of 
3.44 and 3.42 (4:1 by 1H NMR) with 0.2 equivalents of potassium carbonate in 
methanol-water for 30 minutes gave a mixture of the methyl esters 3.66 and 3.65 
(40%, 7:3 by 1HNMR) and the acids 3.68 and 3.67 (29%, 3:1 by 1H NMR); products 
where both the acetate and benzyl ester protecting groups had been removed. Some 
epimerization was observed (by 1H NMR) at the C3 stereocenters during the 
hydrolysis, seen in the distribution of the four products, with an increase in the 
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amounts of the (3S)-epimers 3.65 and 3.67 relative to their corresponding (3R)-
epimers 3.66 and 3.68, respectively. Despite epimerization the (3R)-compounds 3.66 
· and 3.68 were still the dominant components, as compared to the starting (3R)-epimer 
3.44. Also, no significant epimerization was observed at the C6 center, adjacent to the 
C-terminal. Yu and Johnson116 however, observed significant epimerization adjacent 
to the C-terminal of the dipeptide derived tetrazole Cbz-L-Pro-\jf[CN4]-L-Leu-0Me 
after a similar hydrolysis of the methyl ester under the harsher basic conditions of 1 
equivalent of sodium hydroxide in methanol-water for 1.5 hours. 
A similar reaction on a mixture of 3.42 and 3.44 (17:3 by 1H NMR) gave 
corresponding mixtures of3.65-3.68 were the (3S)-compounds 3.65 and 3.67 were the 
dominant components. The configurations of 3.65-3.68 were assigned on the basis of 
the product distributions of the two reactions described, and the known configurations 
of 3.42 and 3.44. The methyl esters 3.65 and 3.66 were separated from the acids 3.67 
and 3.68 by flash chromatography. The epimers 3.65 and 3.66 were separated from 
each other by reverse phase HPLC (figure 3.4), and tested for IDV protease inhibition. 
The 1H NMR spectrum of 3.66 is shown in figure 3. 5. 
,, 
3 N 
Ph~NN-
Cbz-~ N" 
6 0 H OAc ,$<\! /; Me~··\ OBzl 
3.42 
+ 
PhuN - ,, 
Cbz-~ ~ N"N O 
H OAc J- /; Me~··\ 
OBzl 
3.44 
N- ,, 
3 N 
Ph~
Cbz-~ N" 
6 0 + H OH J- /; Me'" .. \ 
OMe 
3.65 
Ph~-N ,, 
3 N 
Cbz-~ N" 6 O + H OH ~ /; Me'"~·\ 
OH 
3.67 
Scheme 3.21: i, K2C03, MeOH-water, rt, 30 min. 
PhuN - ,, 
3 .. N Cbz-N 2 _ N 
I :; ~Q H OH ~ Me~ 
7 OMe 
3.66 
PhuN - ,, 
.,N 
Cbz-N - N 
H OH ~" 1 = hro Me~ OH 
3.68 
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Figure 3.4: HPLC trace of a mixture of3.66 (1st peak) and 3.65 (2nd peak). 
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Figure 3.5: 1H NMR spectrum (solvent CDCh) of3.66. 
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Slee et al. 80 described the oxidation of the hydroxyl group of hydroxyamide 
dipeptide isosteres as a general preparative route to the potent a-keto amide isostere 
(see figure 2.2). An investigation of the potential expansion of our tetrazole isostere 
2.12 to encompass the design principle of the a-keto amide core (compound 2.13, see 
chapter 2 for discussion) was carried out on the tetrazoles 3.65 and 3.66. The reaction 
of a mixture of 3.65 and 3.66 (1: 1 by 1H NMR) with 5 equivalents of Dess-Martin 
periodinane 3.69 for 18 hours gave the a-keto tetrazole 3.70 (quant) (scheme 3.22). 
Dess-Martin periodinane108 is a mild and selective oxidizing agent, widely used for the 
conversion ofprimary and secondary alcohols to aldehydes and ketones, respectively, 
in high yield. 
,, Ph)0N -
,.N 
Cbz-~ N 0 H OH J- /~ 
3.65 
+ 
Me~'\ 
OMe 
PhuN - ,, 
,N 
Cbz-~ ~ N O 
H OH ~L /; Me~·-\ 
OMe 
3.66 
~r 
yooAc 
0 
3.69 
1 
Scheme 3.22: i, 3.69, CH2Ch, rt, 18 h. 
Ph;_; N N-
' \ 
,N 
Cbz-~ N O 
H 0 J_ /~ Me~'\ 
OMe 
3.70 
A hydrolysis of the diastereoisomeric mixture of acetates 3.61-3.64 ( 4 mg) with 
two equivalents of potassium carbonate in methanol-water for 18 hours (scheme 3.23) 
gave a diastereoisomeric mixture of the alcohols 2.19, 2.20, 3.71 and 3.72 (quant), 
which were separated by reverse phase HPLC (figure 3.7), and tested for HIV 
protease inhibition. The C3 and C6 configurations of 2.19, 2.20, 3. 71 and 3. 72 were 
assigned on the basis of their NMR data (for a discussion see chapter four). The 1H 
NMR spectrum of2.19 is shown in figure 3.6. 
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Scheme 3.23: i, K2C03, MeOH-water, rt, 18 h. 
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Figure 3.6: 1H NMR spectrum (solvent CDCh, CD30D) of2.19. 
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Figure 3.7: HPLC trace of a mixture of 2.20 (1st peak), 3.71 (2nd), 2.19 (3rd), and 
3.72 (4th). 
Conclusion 
The procedure for the conversion of a dipeptide to a tetrazole was developed 
and applied successfully to a range of unusual dipeptides, based on the f3-amino acids 
3.7, 3.11, 3.19, 3.20 and 3.25. These f3-amino acids were themselves prepared from 
the corresponding a.-amino acids. General procedures for the extension of the series 
of tetrazole dipeptide isosteres in the N and C directions were developed, and a series 
of potential HIV protease inhibitors based on the target 2.12 was synthesized. The 
activity of this series of compounds is discussed in chapter four. Structure 2.12 was 
also shown to be easily converted to the second target isostere, a.-keto tetrazole 2.13. 
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Chapter Four 
NMR Spectroscopic Analysis and HIV-1 
Protease Inhibition Studies of the cis-
Hydroxyethylamine Isostere 
NMR Spectroscopic Studies 
The 1H and Be NMR data of the synthesized tetrazole derivatives, with general 
structure 2.12, show some characteristic trends. 
cis-hydroxyethylamine 
isostere 2.12 
A series of tetrazole derivatives, including 3.33, 3.35, 3.40, 3.42 and 3.44, was 
synthesized from the corresponding amides 3.32, 3.34, 3.39, 3.41 and 3.43, as 
described in chapter three (see scheme 4.1 for a summary). 
Typically, the tetrazoles are less polar (eluting faster on silica) by comparison 
to the corresponding starting amides, and display some distinctive differences in their 
1H and 13e NMR data. The formation of the tetrazole ring was evidenced, in these 
reactions, by the disappearance of the amide carbonyl carbon resonance at around 170 
ppm and the appearance of a new signal for the tetrazole e4 carbon (non-systematic 
numbering, see scheme 4.1) in the range 151.22 to 152.76 ppm. It was also observed 
in the Be NMR spectra of the tetrazole products, that the resonance for e6 was 
shifted downfield in the order of 6-8 ppm, to around 56 ppm, compared with that in 
the corresponding amide. In addition, the resonance for e3 was shifted upfield 8 to 13 
ppm. An example is given in figure 4.1, where part of the 13e NMR spectra of the 
dipeptide 3.43 and the corresponding tetrazole 3.44 are shown for comparison. Similar 
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differences in chemical shifts were reported by Yu and Johnson116 in the conversion of 
normal dipeptides to the corresponding tetrazole derivatives. 
Phl li Me ~N' ";( ,~')-OBzl 
. 2 
3.32 R1 = Pth, R2 H 
3.34 R1 = CbzH, R2 = H 
(.S)-3.41 R1 CbzH, R2 OAc 
(R)-3.43 R1 = CbzH, R2 OAc 
Ph~ ~ Me 
H-~Y'N!nOBzl 
~0 H 0 
0 
3.39 
3.33Rt Pth, R2 = H 
3.35 R1 CbzH, R2 = H 
(S)-3.42 Rt = CbzH, R2 = OAc 
(R)-3.44 R1 CbzH, R2 = OAc 
PhM-N 
'N H-N N" 
\ 0 5~0 or Me'~~ 
7 Bzl 
3.40 
Scheme 4.1: Preparation of the series oftetrazole derivatives. 
BzlCHz CbzCHz C6 
CDCb 
C3 C2 Cl Ac 
90 70 GO 50 40 30 20 
C6 
C7 
Figure 4.1: Partial 13C NMR spectra (solvent CDCh) of the dipeptide 3.43 (top) and 
the corresponding tetrazole 3.44 (bottom), with characteristic resonance shifts shown. 
ppm 
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These resonance shifts are presumably associated with differences in the 
electron density, and steric effects, of an amide and a tetrazole. The lone pair of the 
tetrazole NS nitrogen (non systematic numbering, see scheme 4.1) is delocalized 
throughout the tetrazole ring, thus it is relatively more electron deficient than the 
nitrogen of the amide bond. On the other hand, the C4 carbon of the tetrazole is more 
electron rich than the carbonyl carbon of the amide because of the mesomeric effect of 
the tetrazole ring. 
The 6-H and 7-H3 proton resonances of the tetrazole derivatives were shifted 
downfield 0.4-1.0 ppm and 0.47-0.61 ppm, respectively, compared with those of the 
corresponding amides. Likewise, the 3-H resonances were shifted downfield 0.5-1.05 
ppm, for both the C3-substituted and non-substituted derivatives. The 2-H resonances 
of the tetrazoles were also shifted downfield, relatively, however only by 0.15 ppm or 
less. An example of these shifts is shown in figure 4.2, which shows the 1H NMR 
spectra ofthe dipeptide 3.43 and the corresponding tetrazole 3.44. 
BzlCHz 
CHzPh 
3 
Ac 
7-HJ 
.. 
7-HJ 
7 5 3 2 ppm 
Figure 4.2: 1H NMR spectra (solvent CDCh) of the dipeptide 3.43 (top) and the 
corresponding tetrazole 3.44 (bottom) (contains <10% 3.42). 
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The tetrazole 3.35 was prepared with a known configuration at C2 and C6. 
Deprotection and chain extension then gave and derivatives 3.46 and 3.51, with 
retention of configuration (scheme 4.2). However, during the preparations of 
3.49/3.50 and 3.53/3.54, epimerization occurred at C6, therefore requiring an 
assignment of the C6 configurations of these compounds. 
PhuN - ~N 
Cbz-N 2 N 
I ~0 H .f-Me~ 
OBzl 
3.35 
PhuN - ,, 
,.N 
,.. R-L-Asn-~ N~O + 
H .f-Me'~7 H!Bu 
3.49 R Cbz 
3.53 R QC 
PhuN - ,, 
R-L-Asn-N N",N 
fi ~~s o Me~ 
Bzl 
3.46 R=Cbz 
3.51 R= QC 
PhuN - ,, 
... N 
R-L-Asn-N N H )..:qo 
Me .. 7 NH!Bu 
3.50 R= Cbz 
3.54 R= QC 
Scheme 4.2: Epimerization at the C6 stereocenter during the preparation of 3.49/3.50 
and 3.53/3.54. 
An analysis of the 1H NMR data revealed a trend in the chemical shifts of the 7-
H3 resonances, from which the configurations at the adjacent C6 stereocenters were 
able to be assigned. This trend was observed throughout the entire series of tetrazole 
derivatives. Tetrazoles with a ( 6S)-configuration gave 7-H3 resonances in a 
characteristic downfield position (1.86 to 1.92 ppm) relative to the corresponding 
(6R)-epimers (1.74 to 1.80 ppm). On this basis, 3.50 and 3.54 were assigned a (6R)-
configuration with 7-H3 resonances in upfield positions by 0.09 and 0.18 ppm, 
respectively, compared to those of3.49 and 3.53 (table 4.1). 
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Table 4.1: Characteristic 1H NMR 7-H3 resonances of the tetrazole derivatives 
(solvent CDCh unless specified). 
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3.x R1 R2 R3 C3 C6 8 7-H3 (ppm) 
3.33 PthN H OBzl s 1.86 
3.35 Cbz-HN H OBzl s 1.88 
3.46 Cbz-L-Asn-HN H OBzl s 1.89a 
3.49 Cbz-L-Asn-HN H NHtBu s 1.87a 
3.50 Cbz-L-Asn-HN H NHtBu R 1.78a 
3.51 QC-L-Asn-HN H OBzl s 1.88 
3.53 QC-L-Asn-HN H NHtBu s 1.92b 
3.54 QC-L-Asn-HN H NHtBu R 1.74b 
3.65 Cbz-HN OH OMe s s 1.92 
3.66 Cbz-HN OH OMe R s 1.88 
a CDCh, 1 drop 
b CDCh, 2 drops CD30D 
Scheme 4.2 outlines the preparation of the tetrazoles 2.19, 2.20, 3.71 and 3.72 
from the f3-amino acids 3.19 and 3.20. Compounds in the sequence up to 3.55 and 
3.56, were prepared separately from the reference compounds 3.19 and 3.20, with 
known configurations at C2, C3 and C6. However in the final steps of the reaction 
sequence, epimerization occurred during the preparation of the derivatives 3.57/3.58, 
3.61-3.64 and 2.19, 2.20, 3.71, 3.72, so that the C3 and C6 configurations of these 
compounds needed to be assigned. Some characteristic 1H NMR data for the tetrazole 
derivatives in the reaction sequence (scheme 4.2) is shown in table 4.2, from which the 
unknown configurations at C3 and C6 were assigned. 
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Phl .. ~ 
Cbz-~~OMe 
H OH 
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,, 
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Cbz-N 2 N"' 
I ~0 H OAc ~ 
Me~ OBzl 
(3S)-3.42 (JR)-3.44 
l l 
(3S)-3.55 (JR)-3.56 
Ph)yl( N N- ,, 
3 ,N 
HBr.H2N N 6 0 
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3.61 3.63 3.62 3.64 
Phv.N N- ,, 
3 ,N 
QC-L-Asn-N N 
6 
O 
H AcN 
Me'7 NHtBu 
Phl ~ 
Cbz-N~OMe 
H OH 
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... 3.20 
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H OH N 
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Scheme 4.2: Epirnerization during the preparation of the epirners 2.19, 2.20, 3.71 and 
3.72. 
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Table 4.2: Characteristic 1H NMR data for tetrazole derivatives leading to 2.19, 2.20, 
3.71 and 3.72 (solvent CDCh unless specified). 
3.x R1 R2 R3 C3 C6 8 2-H 83-H 8 6-H 8 7-H3 
3.42 Cbz Ac OBzl s s 4.58 6.09 5.17 1.84 
3.44 Cbz Ac OBzl R s 4.42 5.92 5.36 1.93 
HBr.H Ac OBzl s s 4.30 6.28 5.65 1.89 
3.56a HBr.H Ac OBzl R s 4.08 5.89 5.71 1.93 
3.57 QC-Asn Ac OBzl s s 4.6 6.36 5.8 1.92 
3.58 QC-Asn Ac OBzl R s * 6.12 * 1.98 
3.61 QC-Asn Ac NH1Bu s s 4.57-4.68 6.32 5.42 1.97 
3.62 QC-Asn Ac NH1Bu R s * 6.24 5.58 2.06 
3.63 QC-Asn Ac NH1Bu s R * 6.22 5.27 1.82 
3.64 QC-Asn Ac NH1Bu R R * 6.18 5.34 1.85 
2.20b QC-Asn H NH1Bu s s 4.65 5.12 5.52 1.93 
2.19b QC-Asn H NH1Bu R s 4.62 5.09 5.55 1.95 
3.7lb QC-Asn H NH1Bu s R 4.61 5.04 5.42 1.80 
3.72b QC-Asn H NH1Bu R R 4.58 5.00 5.49 1.79 
a CD30D 
b CDCh, 2 drops CD30D 
The correlations made above in table 4.1, between the 7-H3 resonances and C6 
configurations of the tetrazole derivatives, were also applied to the series shown in 
table 4.2. On this basis, the two acetates 3.63 and 3.64, with upfield 7-H3 resonances 
at 1.82 and 1.85 ppm, respectively, were assigned a (6R)-configuration. The 
corresponding (6S)-epimers 3.61 and 3.62, gave 7-H3 resonances in relatively 
downfield positions, typically by 0.15 to 0.21 ppm. Similarly, the hydroxyl derivatives 
3.71 and 3.72, with 7-H3 signals at 1.80 and 1.79 ppm, respectively, were assigned the 
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(6R)-configuration. By comparison, the downfield 7-H3 resonances of the (6S)-
epimers 2.20 and 2.19 occurred at 1.93 and 1.95 ppm, respectively. 
The assignment of the C3 configurations of compounds 3.57/3.58, 3.61-3.64 
and 2.19, 2.20, 3. 71, 3. 72 was made by comparison of the chemical shifts of the 2-H, 
3-H, 6-H and 7-H3 resonances, of the entire series of tetrazole derivatives (table 4.2). 
Typically, compounds with a (38)-configuration gave 2-H and 3-H resonances in a 
downfield position, relative to their (3R)-epimers. Similarly, compounds with a (3S)-
configuration gave 6-H and 7-H3 resonances in an upfield position relative to those of 
their (3R)-epimers. The only exception is seen for 3. 71, which had a 7-H3 resonance 
0.01 ppm downfield relative to (JR)-3.72. These trends were observed for 
diastereoisomers at C3, regardless of the configuration at C6. On this basis, the C3 
configurations of3.57, 3.61, 3.63, 2.20 and 3.71 were assigned asS, while those of the 
corresponding (3)-epimers 3.58, 3.62, 3.64, 2.19 and 3.72 were assigned as R (table 
4.2). 
The 3-H resonances of 3.61-3.64 (* table 4.2) were part of a multiplet at 4.57 
to 4.68 ppm and were unable to be distinguished from each other (these epimers were 
not separated). Similarly, the 2-H and 6-H resonances of 3.57 and 3.58 were 
indistinguishable. Consequently, these resonances were unable to be included in the 
correlations between chemical shift and configuration. 
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HIV-1 Protease Inhibition 
The tetrazole-based inhibitors shown in table 4.3, were tested for in vitro IDV-
1 protease inhibition. The compounds were tested at the Centre for Drug Design and 
Development, University of Queensland through the generous support of Dr. David 
Fairlie. The inhibitors show reasonable activity, with ICso values in the micromolar 
(JJM) range. 
An aim of the preliminary results presented in this thesis was to make some 
meaningful conclusions about the biological activity of compounds based on our 
designed cis-hydroxyethylamine isostere, such as 2.19. Some comparisons of HIV 
protease inhibition can be made between the series of tetrazoles and existing potent 
inhibitors. 
H OH H OH 
Ph Ac-Ser-Leu-Asn-~lyy_ 
O lle-Vai-OMe 
Cbz-A.:.~:y_X 
OIBu 0 
1.19 ICso 6 nM* 
PhuN -
' I 
,.N 
QC-Asn-N - N 
I = L bo 
2.22 IC50 0.3 )lM 
H OH ~\ Me~ NH!Bu 
2.19 ICso 60 JiM 
The most potent known IDV protease inhibitors are significantly more potent, 
with ICso values in the low nanomolar (nM) range. Compound 1.19, upon which the 
design of our HIV protease inhibitors was based, exhibits an ICso of 6 nM (* obtained 
under the same assay conditions~ note that the ICso values of most of the existing 
inhibitors were obtained under different assay conditions). However, 1.19 has an 
extended structure spanning from P4-P3', giving it greater potency. A more suitable 
comparison is between the tetrazoles 2.19, 2.20, 3. 71 and 3. 72, and the 
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hydroxyethylamine-based inhibitor 2.22, which all have similar ligands spanning P3-P2'. 
The tetrazoles lack the extended sequence (from P2') known to favour a cis-type 
geometry at P1-P1' (see chapter two, HIV protease inhibition). The tetrazoles 2.19, 
3.71 and 3.72 are approximately 160 fold less active by comparison to 2.22. It may be 
that the steric bulk of the tetrazole ring is preventing close proximity in the active site, 
and therefore hindering stronger binding interactions.§ 
Ph~ ~ 
Cbz-~~2 
H 0 
0 OMe 
2.16 IC50 0.4 J.!M 
Ph~~N N- N 
Cbz-~ N' 0 H OH ~l_ /; Me~··\ 
OMe 
3.65 IC50 460 J.tM 
~~Yy 
H OH 
0 otBu 
2.25 IC50 6.5 J.!M 
N- 1 I Ph)ylN
,N 
Cbz-~ N O 
H 0 ~L h Me~··\ 
OMe 
3.70 
A companson of the potency of our tetrazole core structure with the existing 
hydroxyethylamine and a.-ketoamide core structures, can be made by comparing the 
activities of 3.65/3.66 with the known inhibitors 2.25 and 2.16. All of these 
compounds have the ligand Cbz at P2 and either OtBu or OMe at P2', as Nand C 
terminals. The tetrazole 3.65 shows reasonable activity by comparison to 2.25, being 
70 fold less potent. However, the a.-ketoamide 2.16 is 1100 fold more potent. A 
more useful comparison to a.-ketoamide 2.16 would be the corresponding a.-
ketotetrazole 3. 70. This compound was synthesized, however its biological activity 
will be investigated in future studies. 
§ Preliminary modelling studies by Dr. Fairlie at the 3D Centre for Drug Design, University of 
Queensland suggests a steric problem exists in the active site. 
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CIF\~N~ ~F ~H 0~ 
4.1 
Our inhibitors do show 60 fold more potent activity than the known inhibitor 
haloperidol 4.1, which has an ICso of 3 mM under the same assay conditions. 
Haloperidol was identified 120 by a structure-based computer search of the Cambridge 
Crystallographic Database, for compounds which fit in the active site, and is one of the 
few reported non-peptide based inhibitors ofHIV protease. 
Table 4.3: HIV-1 protease inhibition activity of the tetrazole derivatives. 
3.49/3.50 Cbz-Asn 
3.53 QC-Asn 
3.54 QC-Asn 
3.65 Cbz 
3.66 Cbz 
2.20 QC-Asn 
2.19 QC-Asn 
3.71 QC-Asn 
3.72 QC-Asn 
H NH'Bu 
OH OMe 
OH OMe 
OH NH1Bu 
OH NH1Bu 
OH NH1Bu 
OH NH1Bu 
C3 
s 
R 
s 
R 
s 
R 
C6 
SR 
R 
s 
s 
s 
s 
R 
R 
ICso (J.tM) 
700 (±200) 
170 (±20) 
300 (±100) 
460 (±80) 
720 (±60) 
200 (±80) 
60 (±10) 
43 (±9) 
51 (±3) 
Ki (J.tM) 
200 (±100) 
50 (±20) 
80 (±60) 
140 (±60) 
210 (±70) 
60 (±40) 
17 (±7) 
13 (±6) 
15 (±4) 
An analysis of the activity data also leads to some conclusions about structure-
activity relationships within our series of inhibitors. A comparison of the activities of 
3.49/3.50, 3.53 and 3.54 shows that a clear preference exists for the 2-
quinolinylcarbonyl (QC) ligand at P3 instead of Cbz, as seen previously in comparing 
the inhibitors 2.14 and 2.23, based on 1.19 (see table 2.1). The two fold difference in 
activity between 3.53 and 3.54 suggests that a (S)-configuration at C6 is preferred, as 
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predicted by the modelling studies on our tetrazole system (see chapter two figures 
2.9-2.11). 
Compounds 3.65 and 3.66, with only Cbz at P2, show less activity than 2.19, 
2.20, 3. 71 and 3. 72, which have the favoured QC-Asn ligand at P3-P2 for greater 
recognition. A small difference in activity is also observed between 3.65 and 3.66, 
dependent on the configuration of the C3 center. However, it appears that the (3S)-
configuration of 3.65 is slightly favoured, contrary to the predictions of the modelling 
studies. It may be that extension of the central tetrazole isostere with suitable ligands 
at P2' -P 4' is required to force the targeted bioactive conformation with a (R)-
configuration at C3, discussed in chapter two. 
The most potent of the inhibitors tested were compounds 2.19, 2.20, 3.71 and 
3. 72, containing both the C3-hydroxyl transition state mimic and more favourable 
ligands at P3-P2 and P2' (see chapter two). Compounds 2.19, 3.71 and 3.72 are 
significantly more active than the corresponding compounds, 3.53 and 3.54, which lack 
a C3-hydroxyl group. This is consistent with the C3-hydroxyl group forming crucial 
hydrogen bonding interactions with the aspartate residues in the active site, as 
predicted, and acting as a mimic of the transition state of amide bond hydrolysis. A 
three fold difference in activity is also observed between 2.20 and 2.19, which both 
have (S)-configurations at C6, but differ in their C3 configurations. It appears here 
that the (3R)-configuration of2.19 is preferred. However, compounds 3.71 and 3.72, 
despite having different configurations at C3 and the previously established, 
unfavoured (6R)-configuration, display equal activity to each other and also to 2.19. It 
may be that extension of the inhibitor to P3' and P 4' is required, to force the binding 
mode of 1.19 (see discussion in chapter two), before any clear preferences are 
observed for the (R)-configuration at C3. Another factor to consider is the possible 
steric effects of the bulky tetrazole ring in the active site, which has been suggested 
above as a cause of the generally less potent activity of the tetrazole series. If the 
tetrazole ring is preventing close contact in the active site, the binding interactions to 
the adjacent C3-hydroxyl group may be weakened, causing less significant differences 
in activity between tetrazoles with different C3 configurations. 
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A series of HIV protease inhibitors were synthesized, based on the cis-
hydroxyethylamine peptidomimetic 2.12. The compounds showed reasonable in vitro 
activity, with ICso values in the micromolar range. Some comparisons were able to be 
made with existing potent inhibitors of HIV protease. Our designed dipeptide isostere 
2.12 showed less potent activity against HIV-1 protease than the a-ketoamide and 
hydroxyethylamine core structures. It was proposed that the steric bulk of the 
tetrazole ring was not projecting into the crucial 81' binding pocket of the active site 
effectively and was preventing close proximity. 
Comparison of the activity within the series of tetrazoles allowed some 
structure-activity correlations to be made. QC-Asn at P3-P2 is better than Cbz-Asn and 
also Cbz at P2, as predicted. A ( 6S)-configuration is preferred over 6R for compounds 
3.53 and 3.54, and between compounds 2.19 and 2.20 a (3R)-configuration is 
preferred over 3S, as expected. However, compounds 3.65, 3.66, 3. 71 and 3. 72 show 
no clear trends. It was proposed that extension of structure 2.12 to P3' -P 4' is required, 
in order to favour the targeted bend-type binding conformation of known inhibitor 
1.19. Future studies may include lengthening the backbone of 2.12 between the 
tetrazole ring and the crucial C3-hydroxyl group, to enable the tetrazole ring to bind in 
81' and the hydroxyl group to also still interact with the catalytic aspartate residues. A 
larger more suitable P1' ligand, instead of the methyl group of the existing series, may 
also help to fill the large 81' pocket ofHIV protease. Extension of 2.12 to include P31 
and Pi ligands is proposed to significantly increase the potency of the structure. 
A generally applicable peptidomimetic structure 2.12 has been designed and 
applied to the inhibition of HIV protease. A general synthesis for 2.12 and its 
extension in the N and C directions was developed and a series of compounds with 
reasonable activity were synthesized. 
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Chapter Five 
Synthesis of the Mycalamide Analogues 
Introduction 
The natural products mycalamides A 5.1121 and B 5.2122 were discovered, as 
part of a screening project of New Zealand marine invertebrates, as metabolites from a 
sponge of the genus Mycale, found in Otago Harbour. Bioactivity-directed 
purification of a large scale, organically soluble extract (409g from 12.8kg of sponge) 
gave 5.1 (65 mg, ICso 3.0 ng/mL) and 5.2 (20 mg, ICso 0.7 ng/mL), with potent in vivo 
antiviral and antitumour activity. 
5.1 R=H 
5.2R=Me 
5.3 
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5.4 
Compounds 5.1 and 5.2 belong to a class of natural product, including pederin 
5.3, 123 the onnamides124 (A, 5.4) and theopederins, 125 which is characterized by the 
presence of the 01~Cl0 pederic acid subunit (see structures 5.1-5.4 for numbering) 
and differs principally in the C 15 sidechain. The onnamides and theopederins are also 
isolated from marine sponges while pederin, a potent insect toxin, is isolated from a 
beetle (Paederus juscipes sp.). Mechanism of action studies126 on this class of 
compound indicate that their ability to inhibit protein synthesis is correlated to their 
antitumour activity. The bioactivity results of a series of mycalamide derivatives, 
prepared in this laboratory, also showed that a strong correlation existed between their 
in vitro antiviral and P388 anti-leukaemia activity, 127 supporting the idea of protein 
synthesis inhibition as a common mechanism of action. It is therefore proposed that 
5.1-5.4, and derivatives, are able to act as peptidomimetics. 
An extensive series of microscale structure-activity studies128a-c on 5.1 and 5.2 
was undertaken with a view to understanding the requirements for biological activity. 
More than 110 derivatives were tested. Some of the more important structure to 
activity correlations from this study are summarized in the following. Acylation or 
alkylation of the 7-0H group caused 10-102 fold drops in activity as compared to 5.1. 
All derivatives containing an oxazolidinone ring between 7-0H and C10 were at least 
102 fold less active. Methylation of both the amide nitrogen and 7-0H resulted in a 
103 fold less active derivative. Cleavage of the C8-N9 amide bond resulted in total 
loss of activity. The product of deoxygenation at C 10 was 40 times less active than 
5.1, suggesting the crucial importance of the CIO configuration to the activity. 
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Kocienski129 has also reported that the C10 epimer of mycalamide B (5.2) is some 
three orders of magnitude less active than the parent compound. Further support for 
the critical importance of the C 10 oxygen came from studying the biological activity of 
the various onnamide and theopederin derivatives that have been isolated by the 
Fusetani group from Theonella sp. sponges. 130a-b Most notable was the reported 
inactivity of an onnamide derivative lacking oxygenation at C 1 0. 130a By comparison, 
the removal of C 18-0H by oxidative decarbonylation resulted in a slightly more active 
derivative. These experiments demonstrated that the a-hydroxyamidoacetal C7 -C 10 
functionality of5.1 and 5.2 is essential to their in vitro P388 anti-leukaemia activity. 
The aim of the research undertaken in this thesis was to synthesize and test , in 
vitro against the P3 88 leukaemia cell line, simple analogues of the C7 -C 10 function of 
the parent compounds 5.1-5.4. On this basis, compounds of the general structure 5.5 
were targeted, where R1 to ~ could be variously alkyl, aryl or H and with defined 
stereochemistry at each of the two stereogenic centers. 
5.5 
Synthesis of the My calami de Analogues 
Due to the natural scarcity, challenging structure and potent bioactivity of this 
class of natural products 5.1-5.4, significant efforts have been directed towards their 
total synthesis. Total syntheses of pederin, ma, mb and more recently the mycalamides 
and onnamide A132 have been reported. 
We have developed two general synthetic routes to analogues based on 
structure 5.5. The selection ofR1 to~ was based initially on synthetic utility, then on 
aspects pertaining to the actual structure of the mycalamides, and finally on aspects 
such as solubility. 
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General Method A 
General method A (scheme 5.3) was based on procedures developed during the 
first total synthesis of pederin. Matsumoto 133 reported the first total synthesis of 
pederin 5.3 via a coupling of the two halves of the molecule to form the C8-N9 amide 
bond. The procedure involved the coupling of an acid 5.6 with a methyl imidate 5. 7 to 
give the methyl N-acylimidate 5.8. This was reduced with sodium borohydride to give 
a mixture of the target compound 5.9 and its (1 ')-epimer 5.10 (scheme 5. 1). During 
the development of this procedure a number of model systems [based on acid 5.6 = 
(2S)-mandelic acid or (2RS)-lactic acid] were investigated, which were pertinent to our 
target structure 5.5, having simple R1-~ groups. 
H 
I 
R1YNYR2 
5.9 
R2 
0 0
'Me 
R1YOH R1yN=< 1ll + .. 
11 0-Me 0 0 H 
R2 I 
5.6 H~OMe 5.8 R1YNYR2 5.10 0 0
'Me 5.7 
Scheme 5.1: i, SOCh, pyridine, CH2Cb, rt; ii, 5.7, EhN; iii, NaBJ4, EtOH or MeOH, 
0 °C. 
Previously in our laboratories, (S)-lactic acid acetate 5.11 was reacted with 
methyl benzimidate 5.12 according to this procedure to give an epimeric mixture of 
5.13 and 5.14 (scheme 5.2). However, the mixture was inactive against P388 murine 
leukaemia cells, and so compounds based on the readily available (S)-3-phenyllactic 
acid 5.15, with a different~ group of the substructure 5.5, were targeted. This choice 
of~ was adopted throughout the series ofmycalamide analogues (figure 5.1). 
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OAc 
Me~OH 
0 
5.11 
Ph 
H~OMe 
5.12 
i, ii, iii 
+ 
111 
5.13 
5.14 
Scheme 5.2: i, SOCh, pyridine, CH2Ch, rt, 20 min; ii, 5.12, EhN, rt, 80 min; iii, 
NaB~, EtOH, 0 °C, 4 h. 
Figure 5.1: Choice of~. 
The procedure of Matsuda133, and the similar methodology of Kocienski, 131b 
was modified to include a DCC/HOBT mediated coupling of an acid 5.6 and a methyl 
imidate 5.7, to give the intermediate 5.8. Initially, (S)-3-phenyllactic acid acetate 5.16 
was coupled with methyl benzimidate 5.12 using DCC/HOBT, to give the methyl N-
acylimidate 5.17. Reaction of 5.17, with a large excess of sodium borohydride in 
isopropyl alcohol (IPA), gave a (1')-epimeric mixture of 5.18 and 5.19 (1:1 by 1H 
NMR) in 33% yield (scheme 5.3). The epimers were separated by silica-based radial 
chromatography. Perhaps surprisingly, reduction of 5.17 also resulted in removal of 
the acetate group. Acetate 5.16 was prepared by reaction of acid 5.15 with acetic 
anhydride in pyridine. Compound 5.12 was prepared by reaction of benzonitrile with 
methanol and dry hydrogen chloride gas. 134 
Chapter Five Synthesis of the Mycalamide Analogues 
i15.15R=H 
Y...5.16R=Ac 
5.12 
OAc Ph 
11 
,. Ph~N=< 
. II 0-Me 
0 
5.17 
111 
.. 
112 
OH H 
Ph~NYPh 
5.18 
0 o .... Me 
+ 
OH H 
Ph~NYPh 
o o .... Me 
5.19 
Scheme 5.3: Preparation of 5.18/5.19 by general method A; i, Ac20, pyridine, rt, 3 h; 
ii, 5.12, DCC, HOBT, EhN, CH2Ch, rt, 18 h; iii, NaB~, IPA, rt, 18 h. 
OMc 
Arll 
Nil l'-11 2-II ClhPh 
r"---.,----r---11-r-t-r··......- 1--,--,.~1~r-r-r·~-,.····r·~ 1-~r-,~-~-t-T~T-t~l-.--~-...-,--r-r---t-r-r ,-,-,--r·--1--'~ 
7. 0 6. 5 6, 0 5, 5 S. 0 4. 5 4. 0 3 • 3. 0 PP" 
1.0 5 .s 
Figure 5.2: 1H NMR spectra (solvent CDCh) of5.18 (top) and 5.19 (bottom). 
Compounds 5.18 and 5.19 were identified by NMR Their 1H NMR spectra, 
shown in figure 5 .1, are characteristic of the entire series of mycalamide analogues that 
were subsequently prepared. The distinctive methoxyl resonances at 3.37 and 3.47 
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ppm, and 2-H resonances at 6.10 and 6. 12 ppm indicated successful coupling and 
reduction. 
A similar procedure, using commercially available methyl acetimidate 5.20, 
gave a (!')-epimeric mixture of 5.21 and 5.22 (1: 1 by 1H NMR) in 42% yield (scheme 
5.4). The epimers were partially separated by silica-based radial chromatography. 
This reaction gave analogues with a alternative R2 group, based on structure 5.5. 
OAc 
Ph~OH 
0 
5.16 
Me 
H~OMe 
5.20 
ii 
OH H 
Ph § N 1 Me ~y 5.21 
o o .... Me 
+ 
OH H 
Ph ; N 1 Me ~y 5.22 
() 0 'Me 
Scheme 5.4: i, 5.20, DCC, HOBT, Et3N, CH2Cb, rt 18 h; ii, NaBI!t, IPA, rt, 18 h. 
amino acid-based system 
RHN--. ,-
---... R1~ H 
~NYR2 
0 6~ 
5.5 
Figure 5.3: Extension to amino acid based systems. 
After the development of general method A using the acid 5.15-based system, 
an investigation of its application to amino acid-based systems was carried out (figure 
5.3). A similar procedure, using Cbz-L-Phe 5.23 and imidate 5.12, gave a (!')-
epimeric mixture of 5.24 and 5.25 (1: 1 by 1H NMR) in 42% yield (scheme 5.5). The 
epimers were separated by silica-based radial chromatography. 
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Phi~H I 1' Cbz-~ NYPh 5.24 
Ph~OH 5.12 H o o'Me Ph Cbz-~NH, Cbz-N ... + _____ ,.... 
t4 o 11 H 0 
5.23 Ph~H 5.26 I 1' Cbz-~ NYPh 5.25 
H o o,Me 
Scheme 5.5: i, 5.12, DCC, HOBT, Et3N, CH2Cb, rt 18 h~ ii, NaBH4, IPA, rt, 18 h. 
N-Cbz-L-phenylalaninamide146 5.26 was isolated in 37% yield during the 
purification and separation of 5.24 and 5.25. Amide 5.26 was proposed to be formed 
by an acid-catalyzed decomposition of the amidoacetal function on silica. This 
characteristic decomposition was investigated by monitoring the reaction of 5.18 in 
slightly acidic CDCh, by 1H NMR, over 14 days (scheme 5.6). After 24 hours the 
appearances of a singlet at 3 .49 ppm corresponding to methanol, and a singlet at 10.04 
ppm, corresponding to the benzaldehyde proton, were observed. Over 14 days, the 
signals for 5.18 completely receded and signals corresponding to (S)-3-
phenyllactamide 5.27 appeared and increased with time. The signals for methanol and 
benzaldehyde increased over time in conjunction with the appearance of 5.27. The 
instability of the amidoacetal function was also observed during the development of the 
total syntheses of the parent compounds 5.1-5.4. 135 
5.18 5.27 
H'VPh 
+ II + 
0 
Scheme 5.6: Acid-catalyzed decomposition of amidoacetal functionality. 
MeOH 
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In an extension of the peptide-based system, Cbz-L-Ala-L-Phe 5.28 and the 
imidate 5.12 were reacted according to the general method A to give a (1')-epimeric 
mixture of5.29 and 5.30 (1:1 by 1H NMR) in 54% yield (scheme 5.7). The epimers 
were separated by silica-based radial chromatography. 
Ph\OH 
Cbz-L-Aia-N 
H 
5.12 
11 
5.28 
N 1 Ph Ph\H Cbz-L-Aia-~ '( 
H o'Me 
+ 
Ph~H N f Ph 
Cbz-L-Aia-N
1 
Y 
H 0 O,Me 
5.29 
5.30 
Scheme 5.7: i, 5.12, DCC, HOBT, Et3N, CH2Ch, rt 18 h; ii NaBH4, IPA, rt, 18 h. 
General Method B 
An alternative synthesis, to general method A, of the target structure 5.5, was 
investigated in an effort to develop a higher yielding and cleaner coupling reaction. 
Some useful discussions with Professor Sir John Cornforth at this time, lead to ideas 
for a new synthetic route. 
General method B involved the reaction of a dichloromethane solution of the 
primary amide 5.31 with an a-chloro ether 5.32, in the presence of triethylamine, to 
give directly a (1')-epimeric mixture of5.9 and 5.10 (scheme 5.8). 
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CI~R2 H 
I f 
Me R1YNYR2 
5.9 
5.32 0 O'Me 
R1YNH2 
+ 
0 
H 
5.31 I f R1'(NYR2 5.10 
0
'Me 
Scheme 5.8: General Method B; i, 5.32, Et3N, CH2Ch, 0 °C. · 
In order to compare the two general methods, the primary amide 5.33 was 
reacted with the a-chloro ether 5.34, using this procedure, to give a (1 ')-epimeric 
mixture of 5.35 and 5.36 in 83% combined yield (scheme 5.9). The epimers were 
separated by a combination of silica-based radial chromatography and recrystallization. 
Hydrolysis of the acetates 5.35 and 5.36 with 0.2 equivalents of potassium carbonate 
in methanol-water gave the corresponding hydroxyl compounds 5.18 and 5.19 in 95% 
and 90% yields, respectively. 
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CIYPh 
OH OAc OMe 
Phg= R iii Ph~NH2 5.34 ---.~ 0 II ------~~ lV 
... 1 5.15R=OH 1
'
11 Y...5.27 R=NH2 
v 5.35 __ ,....,. 
5.36 _v_,...,. 
5.33 
5.18 
OH H 
Ph § ~ Ph ~y 
o o,Me 
5.19 
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5.35 
+ 
5.36 
Scheme 5.9: i, acetone, H2S04, -10 oc; ii, NH3, rt, 18 h; iii, Ac20, pyridine, rt, 3 h; iv, 
The acetate 5.33 was prepared by reaction of amide 5.27 with acetic anhydride 
in pyridine. The amide itself was prepared136 by condensation of acid 5.15 with 
acetone followed by reaction with ammonia (scheme 5.9, steps i and ii). A mixture of 
the racemic a.-chloro ether 5.34 and benzaldehyde (17:3 by 1H NMR) was prepared137 
(scheme 5.10), by reaction of benzaldehyde with methanol and dry hydrogen chloride 
gas in ethyl chloride at -60 °C, and was used in the coupling reaction without further 
purification (scheme 5.9, step iv). Mixtures of the racemic a.-chloro ethers 5.37-5.39 
and the corresponding aldehydes (17:3 to 9:1 by 1H NMR) were prepared by a similar 
procedure involving reaction of the aldehyde with methanol and dry hydrogen chloride 
gas at -30 °C. These mixtures were used in subsequent coupling reactions without 
further purification. 
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i R=Ph ClyR 
ii R =Et, Me, iPr 6Me 
5.34 R=Ph 
5.37R=Et 
5.38R=Me 
5.39 R=iPr 
Scheme 5.10: i, MeOH, HCI(g), EtCI, -60 °C, 1 h; ii, MeOH, HCl(gh -30 oc. 
vary the C2 and 
C 1' configurations 
\ I 
\ I 
\ I 
\ R, H t 
JdyN~2 
0 ORa 
5.5 
4 possible epimers 
5.18 
5.19 
5.45 
5.46 
Figure 5.4: Configurational expansion of the series of analogues. 
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In order to investigate fully the effects of the C2 and C 1' configurations of the 
analogues (figure 5.4) on bioactivity, the (2R)-epimers of 5.18 and 5.19 were targeted 
for synthesis. The acetate 5.42 (the enantiomer of 5.33) was reacted with 5.34 
according to general method B to give a (1')-epimeric mixture of5.43 and 5.44 (1:1 by 
1H NMR) in 41% yield (scheme 5.11). The epimers were separated by a combination 
of silica-based radial chromatography and recrystallization. Hydrolysis of the acetates 
5.43 and 5.44 with potassium carbonate (as for 5.35/5.36 above) gave 5.45 and 5.46 
( enantiomers of 5.18 and 5.19) in 60% and 84% yields, respectively. This meant that 
all four possible epimers of the system, 5.18/5.19/5.45/5.46, were able to be tested for 
bioactivity (for a discussion see chapter six). The acetate 5.42 was prepared from (R)-
3-phenyllactic acid 5.40 via amide 5.41, by a similar procedure136 to the preparation of 
5.33 above. 
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... r5.40R=OH 
1
'
114-5.41 R=NH2 
v 
5.43 --lliii>JIIo 
v 5.44--lliii>JIIo 
5.42 
5.45 
5.46 
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5.43 
5.44 
Scheme 5.11: i, acetone, H2S04, -10 oc; ii, NH3, rt, 18 h; iii, Ac20, pyridine, rt, 3 h; 
iv, 5.34, Et3N, CH2Ch, 0 °C, 18 h; v, K2C03, MeOH, H20, rt 2 h. 
5.5 
Figure 5.5: Expansion ofthe series of analogues by altering R2. 
The amide 5.33 and a.-chloro ether 5.37 were reacted according to general 
method B to give a (!')-epimeric mixture of 5.47 and 5.48 in 70% yield, to provide an 
expansion of the series of analogues at R2 (figure 5.5),. The mixture was hydrolyzed 
with 0.2 equivalents of potassium carbonate in methanol-water to give a mixture of the 
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corresponding hydroxyl compounds 5.49 and 5.50 in 92% yield (scheme 5.12). The 
epimers were separated by silica-based radial chromatography. 
OAc 
Ph~NH2 
0 
5.33 
ii 5.47 + 5.48 __ ,..,... 
CI&Et 
Me 
5.37 
+ 
OAc H 
- I 1 Ph = N Et 
"/rXM. 5.47 
+ 
OAc H 
- I 1 Ph :: N Et 
"/rXM. 5.48 
5.49 
5.50 
As in the development of general method A above, an investigation of the 
application of general method B to amino acid-based systems was carried out. Cbz-L-
Phe-NH2 5.26 and a-chloro ether 5.38 were reacted according to general method B to 
give a (!')-epimeric mixture of 5.51 and 5.52 in 52% yield (scheme 5.13). The 
epimers were separated by silica-based radial chromatography. 
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CIYMe Ph:\H N 1 Me OMe Cbz-~ '( 5.51 
Ph 5.38 H o'Me Cbz-~NH, + 
H 0 
5.26 p\rH I 1 cbz-~ N1Me 5.52 
H 0 'Me 
During the development of general method B, the reactions of a-
hydroxyamides 5.27 and 5.41 directly with a-chloro ethers 5.37 and 5.34, respectively, 
in the presence of triethylamine, were investigated. Reaction of a dichloromethane 
solution of 5.27 with 3 equivalents of 5.37 and triethylamine gave 5.49 and 5.50 in 
43% combined yield and a (1', 1")-epimeric mixture of four compounds, identified by 
1H NMR as 5.53 (24% yield) (scheme 5.14). Some amide 5.27 (22%) was reisolated 
after purification on silica, as a result of acid-catalyzed decomposition of 5.49/5.50 
(discussed above). The mixture of products obtained in this reaction suggests that 
coupling of the a-chloro ether with the primary amide is preferred over the alternative 
C2-hydroxyl group coupling. 
OH H 
;: I 
Ph~NYEt 
5.49 
0 1" Et 0
'Me OH Me ..... b H Ph~NH, 5.37 
... + : I Ph~tEt 
OH H 0 
'Me 5.27 ;: I Ph~NYEt 
5.50 5.53 
0 0
'Me 
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The reaction of a dichloromethane solution of amide 5.41 with a larger excess 
of5.34 (>15 equiv) and triethylamine gave a (1',1")-epimeric mixture of5.54-5.57 in 
79% combined yield (scheme 5.15). These adducts are formed by coupling of both the 
amide NH2 and C2-hydroxyl groups with the a-chloro ether, as above. Compounds 
5.54-5.57 were identified by characteristic 1H and 13C NMR signals. By comparison of 
the 1H NMR spectra of 5.54~5.57 with derivatives 5.45 and 5.46, extra resonances 
were observed at 2.93-3.22 ppm for the (1")-methoxyl singlet and at 5.02-5.44 ppm 
for the 1"-H singlet (see figure 5.6). In the 13C NMR spectra, the distinctive 
resonances ofC1" were observed at 103.21-104.76 ppm. The epimers 5.54-5.57 were 
partially separated by silica-based radial chromatography. After the observation of 
these adduct products, coupling by general method B was carried out on hydroxyl-
protected amides, to prevent the possibility of coupling at the C2-hydroxyl group. 
OH 
Ph~NH, 
CI~Ph 5.34 
Me 
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1'-0Me 1"-0Me 
i\rll 
l" -ll 
1'-H 2-H 
CH2Ph 
Figure 5.6: 1H NMR spectrum (solvent CDCh) of one of the epimers 5.54-5.57 
(unassigned). 
OH H 
Ph~NYPh 
0 O,Me 
5.46 
OBn H 
----~·~ Ph~NYPh 
0 O,Me 
5.58 
Scheme 5.16: i, PhCOCI, 4-DMAP, Et3N, CHzCh, rt, 2 d. 
In addition to expanding the series of analogues for structure activity studies, 
attempts were made to prepare compounds suitable for X-ray crystallographic analysis. 
On this basis, ester derivatives of the 2-hydroxyl function were prepared. Compound 
5.46 was benzoylated by reaction with benzoyl chloride,· in the presence of 4-
dimethylaminopyridine and triethylamine, to give 5.58 (scheme 5.16). During attempts 
at recrystallization of the product, some interesting crystals of ( 4-
dimethylaminopyridine)s(benzoic acid)3(H20)10 were obtained which were suitable for 
X-ray crystallography, and which sparked further investigation138 (see chapter seven). 
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Br 
2 CIY1Pr O' ... COPhBr - H Ph~!\JyiPr OMe 5.60 5.39 0 O'Me 0 0 
., Ph~NH2 11 5.27 + 
0 ,...COPhBr 5.59 - H Ph~!\JyiPr 
5.61 
0 0
'Me 
Scheme 5.17: i, 4-BrPhCOCI, 4-DMAP, Et3N, CHzCh, rt, 3 h; ii, 5.39, Et3N, CHzCh, 
rt, 3 h. 
In a further attempt to obtain a suitable crystalline derivative, amide 5.27 was 
reacted with 4-bromobenzoyl chloride, 4-dimethylaminopyridine and triethylamine to 
give the ester 5.59. The ester was reacted with a-chloro ether 5.39 according to 
general method B to give a crude mixture of 5.60 and 5.61 (1: 1 by 1H NMR) (scheme 
5 .17). The ( 1 ')-epimers were purified and partially separated by silica-based radial 
chromatography, giving a 12% combined yield (lowered due to some acid-catalyzed 
decomposition). 
In a similar procedure, the amide 5.27 was reacted with (JS,4R)-camphanic 
chloride, 4-dimethylaminopyridine and diisopropylamine in dichloromethane to give the 
camphanate 5.62. This was reacted with a-chloro ether 5.34 according to general 
method B to give a (1 ')-epimeric mixture of 5.63 and 5.64 (1: 1 by 1H NMR) in 51% 
yield (scheme 5.18). The epimers were partially separated by silica-based radial 
chromatography. Compound 5.63 was crystallized from an epimeric mixture to give 
crystals suitable for X-ray crystallography (see figure 6. 7). A mixture of 5.64 and 5.63 
(9:1 by 1H NMR) was also prepared from a mixture of5.19 and 5.18 (9:1 by 1H NMR) 
using (JS,4R)-camphanic chloride as described for the preparation of 5.62. This 
conversion provided a correlation between the configurations of 5.18/5.19 and 
5.63/5.64, respectively, from which followed the configurations of the entire series of 
analogues (for a discussion see chapter six). 
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Scheme 5.18: i, (JS,4R)-camphanic chloride, 4-DMAP, iPrzNEt, CH2Cb, rt, 18 h; ii, 
5.34, Et3N, CH2Ch, -78 °C, 18 h. 
A comparison of general methods A and B shows that method B proved 
superior to method A, for the preparation of derivatives based on 5.5. In particular, 
coupling of the amide 5.26, 5.33, 5.42 or 5.62 with the a.-chloro ether 5.34, 5.37, 5.38 
or 5.39, to form analogues of general structure 5.5, gave typical yields ranging from 
83% (for 5.35/5.36) to 51% (for 5.63/5.64). The corresponding two step procedure 
of general method A, coupling 5.16, 5.23 or 5.28 with 5.12 or 5.20, proved less 
satisfactory and gave typical yields ranging from 54% (for 5.29/5.30) to 33% (for 
5.18/5.19). Both general methods required the separation of mixtures of (1 ')-epimeric 
products by silica-based chromatography, which resulted in a reduction in yield, due to 
acid-catalyzed degradation of the amidoacetal functionality (discussed above). 
However, sufficient material was able to be obtained for biological testing, so 
alternative separation methods were not investigated. 
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Conformationally Restrained Analogues 
Conformational restriction is an important aspect of peptidomimetics 
(discussed earlier in chapters one and two}, which has been applied in the development 
of ligands, as probes of the bioactive conformation required for receptor binding. A 
series of conformationally constrained cyclic oxazolidinones, based on the target 
structure 5.5, were prepared on this basis (figure 5.7}. In these compounds the amide 
bond is forced to adopt a cis configuration. The configuration of the amide bond is 
essential to the bioactivity of peptides and peptidomimetics, as discussed in chapter 
one. A related technique of cis conformational restriction is discussed in chapters two 
through four. 
constrain 
5.5 oxazolidinone 
Figure 5. 7: Conformational restriction of structure 5.5. 
A dichloromethane solution of the amide 5.27 was reacted with the a.-chloro 
ether 5.37 in the absence of triethylamine to give a mixture of trans-5.66 and cis-5.65 
oxazolidinones (13:7 by 1H NMR} (scheme 5.19}. Separation of the isomers by silica-
based radial chromatography gave a 17% combined yield of 5.65 and 5.66. A 
literature139 synthesis of 2,5-substituted-oxazolidin-4-ones involves the condensation of 
a.-hydroxyamides or cyanohydrins with carbonyl compounds in the presence of an acid 
catalyst. 
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5.27 
Scheme 5.19: i, 5.37, CH2Ch, rt, 18 h. 
Et 
0 ~ Ph~H 
0 
5.65 
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5.66 
A similar procedure using 5.34 gave a mixture of trans-5.68 and cis-5.67 (2: 1 
by 1H NMR) (scheme 5.20). Separation of the isomers by silica-based radial 
chromatography gave a 53% combined yield of 5.67 and 5.68. 
5.27 
ClyPh 
OMe 
5.34 
Scheme 5.20: i, 5.34, CH2Ch, rt, 18 h. 
Ph 
0 ~ Ph~H + 
5.67 
Ph 
p-( 
Ph~NH 
0 
5.68 
The enantiomers of 5.68 and 5.67 were prepared by a similar procedure using 
the amide 5.41 and the a.-chloro ether 5.34 to give a mixture of trans-5.70 and cis-
5.69 (3:2 by 1H NMR) (scheme 5.21). Separation of the isomers by silica-based radial 
chromatography gave a 46% combined yield. 
Ph Ph 
OH 5.34 Ph~H 0 :S' Ph~NH2 .. + Ph~ 
0 0 0 
5.41 5.69 5.70 
Scheme 5.21: i, 5.34, CH2Ch, rt, 18 h. 
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Glucosyl-based Analogues 
The glucosyl derivatives 5.76 and 5.77 (scheme 5.22) were synthesized as 
compounds possessing the previously established, biologically active ( 1 ~)­
configuration (see chapter six for a discussion of bioactivity). As well as modelling 
more closely the structural requirements of the mycalamide skeleton cf 5.1, it was also 
considered that the sugar moiety might impart improved water solubility, which would 
be of assistance in the in vitro cytotoxicity assay. A glucose-derived amino acid 
(Gum) has also been developed as a peptidomimetic and incorporated into cyclic 
somatostatin analogues, with potent activity. 140 
Analogue 5.76 was prepared (scheme 5.22) by the coupling of acid 5.15 with 
glucosylamine 5.75 using DCC/HOBT (59% yield). Hydrolysis of the acetates with 
potassium carbonate gave the hydroxyl derivative 5. 77 in 96% yield. Removal of the 
acetate groups did improve the water solubility of the analogue, as expected. The 
precursor 2,3,4,6-tetra-0-acetyl-~-D-glucopyranosylamine 5.75 was prepared from D-
glucose 5. 71 in four steps. Reaction of 5. 71 with acetic anhydride and concentrated 
sulphuric acid gave the pentaacetate 5. 72 which was reacted immediately with 
hydrogen bromide in acetic acid to give the glucopyranosyl bromide 5. 73 in 94% 
yield. 141 This was converted to the azide 5. 7 4 (72% yield) by reaction with sodium 
azide in formamide. 142 Catalytic hydrogenation of the azide gave the required amine 
5. 75 in 85% yield. 143 
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Scheme 5.22: i, Ac20, H2S04, 100 °C, 2 h; ii, HBr~AcOH, 0 octo rt, 3 h; iii, NaN3, 
HCONH2, 80 °C, 3 h; iv, H2, Pt02, EtOAc, rt, 3.5 h; v, 5.15, DCC, HOBT, CH2Ch, rt, 
5 d; vi, K2C03, MeOH, H20, rt, 30 min. 
Conclusion 
5.5 
Two general methods were developed in the synthesis of a series of analogues 
of general structure 5.5. These methods gave (1')-epimeric mixtures of analogues, 
which were separated by rapid silica-based chromatography, despite undergoing 
characteristic acid~catalyzed decomposition. Sufficient material was obtained for 
testing of in vitro activity against P388 murine leukaemia cells. A discussion of the 
biological activity and assignment of configuration of the epimeric analogues follows in 
chapter six. 
Chapter Six 
Biological Activity and Assignment of 
Configuration of the My calami de 
Analogues 
Molecular Modelling 
130 
Molecular modelling studies were carried out on the reference compounds 5.18 
and 5.19 in the Macromodel modelling program, with a view to assigning the unknown 
Cl' configurations of the series of analogues based on 5.5 (see chapter five). 
Structures 5.18 and 5.19 were energy minimized in the Amber forcefield with CHCh 
solvation. Monte Carlo conformational searching, with a 3 kcal/mol energy window 
and 8 variable torsion angles (shown in figure 6.1 ), gave a series of conformers for 
both structures 5.18 and 5.19. 
5.18 5.19 
OH H 
Ph 3§ 4 N 8 Ph ~5~ ;t 0 
I 'M ~ e 
Figure 6.1: Variable torsion angles (1-8) during the conformational search on 
structures 5.18 and 5.19. 
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Further refmements of the modelled conformers were made, such as a more 
accurate energy mininllzation of each structure to a lower gradient, and a mathematical 
test to exclude those structures not in a local minima of the potential energy surface. 
As a result, a Boltzman distribution of modelled conformers of 5.18 and 5.19 was 
calculated, based on the relative energies of the conformers within each series. The 
lowest energy conformers of modelled 5.18 and 5.19 are shown in figures 6.2 and 6.3, 
respectively. 
Figure 6.2: Lowest calculated energy conformer of modelled5.18. 
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Figure 6.3: Lowest calculated energy conformer of modelled5.19. 
It was hoped that some correlations could be made between the observed NMR 
data and the modelled structures, which would enable an assignment of the ( !')-
configurations of 5.18 and 5.19. Some differences in conformation do exist between 
the modelled epimeric structures, particularly in the torsion angles centered on the C2-
Cl and C2-0H bonds (see torsion angles 4 and 3, figure 6.1). Intramolecular 
distances between relevant protons in the modelled structures of 5.18 and 5.19 are 
shown in table 6.1 (the distances given are characteristic of the most significant 
conformers). The molecular modelling studies suggest that some differences in 
observable nOe effects may exist between the two epimers. Most significantly, it was 
proposed that a positive nOe existed between 2-H and NH in 5.18 which would not be 
observed in 5.19, and that one existed between OH and NH in 5.19 which would not 
be observed in 5.18 (figure 6.4). 
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5.18 5.19 
Figure 6.4: Proposed intramolecular hydrogen bonding (dashed lines) and nOe (solid 
arrows) interactions in the modelled structures 5.18 and 5.19. 
However, comparison to the NMR data of 5.18 and 5.19 showed no significant 
correlations. Positive nOe effects were observed for both 5.18 and 5.19 between 2-H 
and NH, and also between OH and NH. One difference between the NMR data of 
5.18 and 5.19 that was observed was a small positive nOe between 2-H and 1'-H for 
5.18, which was not observed for 5.19 (figure 6.5). However, this observation could 
not be correlated to the modelled structures, where the intramolecular distance 
between 2-H and 1'-H, in both 5.18 and 5.19, is comparable (table 6.1). 
(J'S)-5.18 
(J'R)-5.19 
Table 6.1: Molecular modelling studies of5.18 and 5.19. 
Intramolecular distances in Observed nOe effects 
modelled structures (A) inNMR.data 
5.18 5.19 5.18 5.19 
2-Hto NH 2.5 3.4 + + 
OHtoNH 4.1 2.1 + + 
2-H to 1'-H 4.4 4.6 + 
OHtoCO 1.9 3.6 
OHtoNH 3.9 2.2 
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1'-H 2-H 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 
Epimer 5.18 
1'-H 2-H 
7 •• 7.0 6.5 6. 0 5.5 5. 0 4.5 4. 0 3.5 
Epimer 5.19 
Figure 6.5: Observable positive nOe for 5.18 between 2-H and 1'-H, not seen for 
5.19. 
Different intramolecular hydrogen bonding arrangements are seen in the 
modelled structures of 5.18 and 5.19 (figure 6.4 and table 6.1). Structure 5.18 has a 
hydrogen bond between the OH and carbonyl CO, while 5.19 has hydrogen bonding 
between OH and NH, and OH and OMe (weaker at 4.0 angstroms). The effect of 
hydrogen bonding on the absorption bands of different functional groups can be 
observed by infrared spectroscopy. The position of the carbonyl stretching absorption 
ppm 
ppm 
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band is determined by a number of factors, including intermolecular and intramolecular 
hydrogen bonding, and electronic and mass effects of neighboring substituents. 
Likewise, the distinctive OH stretching and NH bending absorption bands might be 
expected to be shifted, relatively, if differences in intramolecular hydrogen bonding 
exist between epimers. However, compounds 5.18 and 5.19 gave identical infrared 
data for the OH stretching (3406 cm-1), CO stretching (1684 cm"1) and NH bending 
(1504 cm"1) bands. 
Assignment of Configuration 
5.5 
The series of analogues based on structure 5.5 were assigned absolute 
configurations at C2 and Cl', by correlations (figure 6.6) to the absolute configuration 
of camphanate derivative 5.63. The relative configuration of 5.63 was determined 
unambiguously by single crystal X-ray analysis (figure 6. 7). The absolute 
configuration of 5.63, and hence its (1 ')-epimer 5.64, followed from the known 
absolute configurations of 5.27 and (JS,4R)-camphanyl chloride, which were used to 
prepare 5.63 and 5.64 (scheme 5.18). The absolute configuration of 5.19, and hence 
its (1')-epimer 5.18, was assigned on the basis that 5.19 was converted into 5.64. 
Compounds 5.45 and 5.46 gave identical NMR data, but opposite optical rotations, to 
their enantiomers 5.18 and 5.19. The acetates 5.35, 5.36, 5.43 and 5.44 were assigned 
on the basis of their direct conversion, by hydrolysis, to the reference compounds 5.18, 
5.19, 5.45 and 5.46. 
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Configuration determined by 
X-ray crystallography ..,.._ (1 'S)-5.63 
OH H correlated by 
Ph~~YPh identical data (1 'S)-5.18 
o o ... Me 
r 
(1 'S)-5.46 
(1 'R)-5.47 
(1'S)-
5.21 
5.24 
5.29 
5.49 
5.51 
5.60 
(1 ')-epimers 
,....(camphanyl) Q H 
Ph :: Kl 1 Ph 
&XM. (1'R)-5.64 
direct 
conversion 
( 1 ')-epimers 
OH H 
Ph~~YPh (l'R)-5.19 
o o ... Me 
l correlated by lH NMR 
(1'R)-
R H 5.22 
= 1 I 5.25 Ph~NYR2 5.30 
o o .... Me 5.50 
5.52 
5.61 
Figure 6.6: Schematic representation of the correlations of the configurations of the 
series of analogues to the absolute configuration of 5.63. 
The configurations of the other analogues, given in table 6.2, followed by a 
comparison of their 1H NMR data with that of the reference compounds 5.18 and 5.19. 
The methoxyl resonance of the (1 'R,2S)-derivatives 5.19, 5.22, 5.25, 5.50, 5.52 and 
5.61 was in a characteristic downfield position (0.06 to 0.12 ppm) relative to the 
corresponding (1 S,2S)-epimers 5.18, 5.21, 5.24, 5.49, 5.51 and 5.60. The 2-H 
resonance of the (1 'R,2S)-derivatives 5.19, 5.22, 5.50 and 5.61, where R1 = OH or 
OCOPhBr, and R2 =Ph, Et or Me, was also consistently 0.05-0.13 ppm downfield 
relative to 5.18, 5.21, 5.49 and 5.60. A further trend was observed in the relative 
polarity of the epimers on silica. (1 'R,2S)-Derivatives 5.19, 5.22, 5.50 and 5.61 
consistently eluted after their (1')-epimers 5.18, 5.21, 5.49 and 5.60. 
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In the amino acid based compounds 5.25, 5.30 and 5.52, where R1 = NHCbz 
and R2 =Ph or Me, an opposite trend to above was observed with the 2-H resonance 
occurring 0.07 to 0.08 ppm upfield relative to their (1 ~-epimers 5.24, 5.29 and 5.51. 
The methoxyl resonances of epimers 5.29 and 5.30 were too similar to include in the 
correlations. 
05 
C45 
Figure 6.7: X-ray crystal structure of3.63. 
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Table 6.2: Assignment of configuration based on 1H NMR spectroscopic data (solvent 
CDC h). 
Compound R1 R2 1' 2 SOMe o2-H Elution 
5.18 OH Ph s s 3.37 4.32 1 
5.19 OH Ph R s 3.47 4.45 2 
5.21 OH Me s s 3.24 4.36 1 
5.22 OH Me R s 3.30 4.41 2 
5.24 NH-Cbz Ph s s 3.32 4.60 1 
5.25 NH-Cbz Ph R s 3.40 4.53 2 
5.29 NH-Ala-Cbz Ph s s 3.31 4.83 2 
5.30 NH-Ala-Cbz Ph R s 3.30 4.76 1 
5.45 OH Ph R R 3.37 4.32 1 
5.46 OH Ph s R 3.47 4.45 2 
5.49 OH Et s s 3.22 4.38 1 
5.50 OH Et R s 3.31 4.46 2 
5.51 Me s s 3.12 4.55 2 
5.52 NH-Cbz Me R s 3.24 4.47 1 
5.60 OCOPhBr 1Pr s s 3.16 5.60 1 
5.61 OCOPhBr 1Pr R s 3.22 5.64 2 
The relative configurations of the cyclic oxazolidinone derivatives were 
assigned on the basis of an observed positive nOe between the ring protons labelled 1'-
H and 2-H (non-systematic numbering) of cis-isomers 5.65, 5.67 and 5.69, but not 
trans-isomers 5.66, 5.68 and 5.70. The absolute configurations followed from the 
known configurations of the amides 5.27 and 5.41, used to prepare these derivatives 
(scheme 6.1). Compounds 5.69 and 5. 70 gave identical NMR data to their 
enantiomers 5.67 and 5.68. 
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rH R 
OH H O-\\\~R H 9--\\\\H 
Ph~NH2 
... Ph~NH + Ph~NH 
0 
5.27 5.65 R=Et 5.66 R=Et 
5.67 R=Ph 5.68 R=Ph 
rt) ~hH 
OH H o-ffh HO-t Ph~NH2 .... Ph~NH + Ph~H 
0 0 0 
5.41 5.69 5.70 
Scheme 6.1: Observed nOes and assignment of configurations of5.65-5.70. 
The configurations of the glucosyl analogues 5.76 and 5.77 followed from the 
known absolute configurations of the acid 5.16 and amine 5.75 used to prepare these 
compounds. 
OAc OAc 
Ph § OH + AcO~OAc & H2N--t,....O~OAc 
5.16 5.75 5.76R=Ac 
5.77 R=H 
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Biological Activity 
The analogues shown in table 6.3 were each tested for in vitro cytotoxicity 
against P388, a murine leukaemia cell line. IC50 values for each sample were 
determined after incubation for 72 hours with P3 88 cells. The concentration of sample 
required to reduce the P388 cell growth by 50% (comparative to control cells) was 
determined using the absorbance values obtained when the yellow dye MTT 
tetrazolium is reduced by healthy cells to the purple colour ofMTT formazan. 144 
5.5 
All of the analogues exhibited far less activity (ICso 8-400 J..lg/mL) when 
compared to the parent natural products 5.1 and 5.2 (ICso 3.0 and 0.7 ng/mL, 
respectively), however the results were still encouraging. In general, compounds 
based on structure 5.5 with a (1 R,2S)-configuration (5.19, 5.25, 5.30 and 5.36) 
showed significantly greater in vitro cytotoxicity than the corresponding (1 'S,2S)-
derivatives (5.18, 5.24, 5.29 and 5.35), such that a (1 R)-configuration would appear 
to be favourable towards activity (table 6.3). A notable exception was 5.49 and 5.50 
(see below for discussion). An analysis of the data for 5.45 and 5.46, which possess 
the alternative (2R)-configuration, also suggests that the (J R)-configuration of 5.45 is 
favoured over the (1 'S)-configuration of 5.46 for cytotoxic activity. The (1 R)-
compounds 5.19 and 5.46 show similar in vitro antitumour activity such that there 
seems that there is no marked preference for either a (R)- or (S)-configuration at C2. 
The natural products 5.1-5.4, which are the basis for this model system, possess a (S)-
configuration at the equivalent C7 centre. It should also be noted that 5.19 and its 
enantiomer 5.46 have similar activity. 
A preference for a (1 R)-configuration over a (1 'S)-configuration (non-
systematic numbering) does not seem to be evident within the cyclic oxazolidinone 
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series 5.65-5. 70, based on the analysis that the cis compounds 5.65, 5.67 and 5.69 all 
possess similar activity to their trans isomers 5.66, 5.68 and 5. 70. The (2R)-
compounds 5.69 and 5. 70 show greater in vitro antitumour activity than their (2S)-
enantiomers 5.65 and 5.66, suggesting a preference for a (2R)-configuration. In 
general, the conformationally restrained cyclic analogues 5.65-5.70 showed 
comparable or better activity to the acyclic derivatives. If these analogues are all 
interacting with the same receptor(s), then the cyclic derivatives could be explored as 
useful probes of favourable ligand conformations and functions. 
A variety ofR1 groups appear to be accommodated for the induction of in vitro 
cytotoxicity. For example, the corresponding acetates of 5.18 and 5.19, compounds 
5.35 and 5.36, show comparable activity. The camphanyl and 4-bromobenzoyl ester 
derivatives 5.64/5.63 and 5.61/5.60 also show comparable activity to reference 
compound 5.19. However, the (1 ~)-derivatives 5.64 and 5.61 do not show 
significantly greater in vitro antitumour activity over their (1 S)-epimers 5.63 and 5.60, 
as discussed above. 
R1 H 
Ph~NYR2 
o o .... Me 
Compounds numbered 
between 17 and 63 
5.65-5.70 
5.76/5.77 
Figure 6. 7: General structures of the my calami de analogues shown in table 6. 3. 
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Table 6.3: ICso values ofmycalamide analogues against P388 cells. 
Compound R1 R2 1' 2 ICso (J.tg/cm3) 
5.18 OH Ph s s >340 
5.19 OH Ph R s 52 
5.21 OH Me s s >188a 
5.22 OH Me R s >125 
5.24 NH-Cbz Ph s s >1886 
5.25 NH-Cbz Ph R s 14 
5.29 NH-Ala-Cbz Ph s s >125 
5.30 NH-Ala-Cbz Ph R s 36 
5.35 OAc Ph s s >313 
5.36 OAc Ph R s 101 
5.45 OH Ph R R 27 
5.46 OH Ph s R 102 
5.49 OH Et s s 43 
5.50 OH Et R s 176 
5.51 NH-Cbz Me s s >375 
5.52 NH-Cbz Me R s >375 
5.60 OCOPhBr iPr s s 105 
5.61 OCOPhBr iPr R s lOSe 
5.63 Ocamphanyl Ph s s 78d 
5.64 Ocamphanyl Ph R s 42d 
5.65 Et R s 57 
5.66 Et s s 47 
5.67 Ph R s 57 
5.68 Ph s s 37 
5.69 Ph s R 12 
5.70 Ph R R 8 
5.76 Ac R s 267 
5.77 H R s >375 
a activity obtained on a 1 : 1 mixture of epimers 
b activity obtained on a 3: 1 mixture of epimers 
c activity obtained on a 17:3 mixture of epimers 
d activity obtained on a 9: 1 mixture of epimers 
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The amino acid based (!')-epimeric pairs 5.24/5.25, 5.29/5.30 and 5.51/5.52 
(R1 = NHR), were designed to give analogues with more peptidic character. This was 
done since the natural products 5.1-5.4, upon which the series of analogues was 
modelled, exert their biological activity by an inhibition of protein synthesis. Therefore 
analogues which act as peptidomimetics may be able to exploit the activity of the 
parent compounds. The most bioactive compounds in this series (R1 NHR) 5.25 and 
5.30 show activities comparable to, or better than 5.19, where R1 = OH. The 
introduction of an amino group at R1, instead of an alcohol group, also enables 
extension of the analogue as a peptide chain. No significant loss of activity was 
observed in going from the dipeptide analogue 5.25 to the tripeptide analogue 5.30. 
Again a clear preference for the (1 ~)-configuration of 5.25 and 5.30 is observed over 
the (1 ~-configuration of epimers 5.24 and 5.29, in an analysis of the activity data. 
A change from R2 = Ph to Et appears to be tolerated for compounds 5.19 and 
5.49, although in this case, contrary to other compounds given in table 6.3, a (1 ~­
configuration seems to give the most potent in vitro bioactivity (compare epimers 5.49 
and 5.50). It should be noted that the C2 and Cl' centers of 5.49 possess the same 
relative configurations of the corresponding C7 and C 10 centers of the parent natural 
products 5.1-5.4. The oxazolidinone derivatives 5.65 and 5.66, where R2 = Et, also 
show comparable activities to the analogues 5.67 and 5.68, where R2 = Ph. 
The glucosyl derivatives 5.76 and 5.77 show less activity than the 
corresponding R2 Ph and Et analogues. It was hoped that the sugar moiety would 
closely resemble the C10-Cl2 ring of the parent natural products 5.1 and 5.2, and that 
this would lead to relatively favourable activity. Furthermore, that the improved water 
solubility of the sugar might be of assistance in the in vitro cytotoxicity assay. 
However, hydrolysis of the tetraacetate 5.76 to give 5.77, which did have improved 
water solubility, resulted in a less active derivative. This may reflect a need to 
penetrate a hydrophobic cell membrane in the in vitro assay. 
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The four diastereoisomers 5.54-5.57 where R1 = OCH(OMe)Ph all show 
comparable or better activity (table 6.4) to 5.19 where R1 OH (table 6.3). In an 
analysis of the activity of these compounds there appears to be no preference for the 
configuration of any one of the four diastereoisomers. However, two of the 
diastereoisomers were tested as minor components of mixtures and so their activity 
results are less meaningful for comparison. 
0 1" Ph 
Me,... y 
0 H 
Ph... )_.._ ).J 1' Ph 
'-'211 y 
o o .... Me 
5.54 
Me,...06PhH 
Ph~~YPh 
0 O,Me 
5.56 
Me .... o,,,,(Ph 
0 H 
Ph~~YPh 
o o ... Me 
5.57 
Table 6.4: IC50 values ofunassigned adducts 5.54-5.57 
5.x I' I" 2 isomera ICso (~-tg/cm3) 
5.54 R R R A 52 
5.55 R s R BlAb 39 
5.56 s R R C/Db 24 
5.57 s s R D 28 
a The four diastereoisomers A-D, corresponding to 5.54-5.57, but are unassigned 
b activity obtained on a 1 :4 mixture of diastereoisomers 
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Conclusion 
5.5 
Structure to activity studies on the mycalamide skeleton of the class of natural 
products 5.1-5.4 have established the key features which were necessary or essential 
for the bioactivity observed across this class of natural products. These structural 
requirements have been summarized in structure 5.5. Examples of general structure 
5.5 have been synthesized and shown to give modest in vitro antitumour activity. The 
level of activity appears to be more sensitive to changes at R2 than R1 (structure 5.5) 
and a ( 1 'R)-configuration is favoured. 
The proposal that mycalamide analogues may exploit the potent activity of the 
parents by acting as peptidomimetics was supported by the comparable or better 
activity of the peptide-based compounds (R1 = NHR) over the R1 = OR series. The 
conformationally restrained cyclic oxazolidinones also show comparable or better 
activity compared with the linear analogues. Their level of activity appears to favour a 
(2R)-configuration and to be insensitive to the (!')-configuration. 
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Chapter Seven 
X-Ray Crystallography of an Unusual 
Crystal ofDMAP/Benzoic Acid 
During attempts at preparing a mycalamide analogue suitable for X-ray 
crystallographic analysis (see chapters five and six), crystals of (4-
dimethylaminopyridine)s(benzoic acid)3(H20)10 7.1 (figures 7.1-7.3) were obtained 
accidentally, which had an unique structure and sparked further investigation. 
The decahydrate 7.1 was obtained during the workup following the reaction of 
5.46 (8 mg, 0.03 mmol) with benzoyl chloride (6 JlL, 0.06 mmol), 4-
dimethylaminopyridine (DMAP, 6 mg, 0.045 mmol) and triethylamine (7 JlL, 0.06 
mmol) in dichloromethane (2 cm3) (scheme 7.1, see also scheme 5.16). After washing 
with aqueous NaHC03 the organic layer was dried and evaporated to give crude 5.58. 
Recrystallization from diethyl ether-petroleum ether at 5 oc gave crystals of7.1. 
OH H 
PhJy~yPh 
o o ... Me 
5.46 
Scheme 7.1: i, PhCOCl, DMAP, Et3N, CH2Ch, rt 2 d. 
The following discussion of the crystal structure of 7.1 is the result of 
consultation with Professor Ward Robinson, Dr. Gautam Desiraju et al . . 138 The crystal 
structure of7.1 was determined at 130 K and satisfactorily refined. There are eighteen 
residues in the asymmetric unit. Three out of the five DMAP residues are 
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protonated at the heterocyclic N atom and two of these form N-H··N hydrogen bonds 
with the two non-protonated DMAPs as shown in figure 7.1 [N(ll}""N(21); 
N(3I}"·N(41)]. The third protonated DMAP forms a hydrogen bond [N(5I)""·0(62)] 
with a benzoate anion which is also linked to bridging water molecules, via hydrogen 
bonds 0(61} .. 0(3) and 0(62}""0(4). The three dimeric aggregates in figure 7.1 form 
a herringbone slab arrangement as shown in figure 7.2. These slabs alternate with 
benzoate hydrate layers which are shown in figure 7.3. Notice that the benzoate 
anions in figure 7.2 form the points of attachment of the slabs to the benzoate hydrate 
layers via 0(3) and 0(4) which lie within the layers. The planes of the molecules in the 
slabs and layers are, therefore, nearly perpendicular. 
~0(4) 
~H(4A) 
Figure 7.1: DMAP building blocks for the herringbone slabs in the crystal structure of 
7.1. The hydrogen bonds between benzoate anions and water molecules constitute the 
link between slabs and layers. 
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Figure 7.2: Herringbone slab arrangement in the crystal structure of 7.1. [010] is 
vertical arid [00 1] is horizontal. 
The very high water content in this crystal occurs entirely within the benzoate 
layers which constitute the heart of this unique structure. Figure 7.3 shows that the 
benzoate anions are arranged with their hydrophobic portions facing each other 
forming a centrosymmetric dimer. This dimer is hydrophobic on the inside and 
hydrophilic on the outside. The outer hydrophilic surface is stabilized by a ring of 
water molecules and the hydrocarbon portions of the dimer are literally a drop of oil in 
the surrounding pool of water. Appropriately, the dimers are additionally stabilized by 
C-H"O hydrogen bonds to water molecules 0(3F) and 0(9A). In a sense, this 
structure is complementary to that of benzoic acid, wherein hydrogen-bonded 
centrosymmetric dimers are hydrophilic within and hydrophobic on the outside, being 
stabilized by herringbone contacts with other phenyl rings from neighbouring dimers. 
Alternatively, the structure in figure 7.3 may be likened to a two-dimensional 
equivalent of the polyhedral clathrate hydrate structures, in which a three-dimensional 
framework of water molecules surrounds the guest and the basic structural component 
is a regular pentagon formed by 0-H"O hydrogen bonds. The regular solid generated 
by assembling such pentagons is the dodecahedron, but because space cannot be filled 
periodically with these dodecahedra, hexagons are incorporated, resulting in tetradeca-
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, pentadeca- and hexadeca-hydra which alternate with the dodecahedra to generate the 
three-dimensional structure. In the two-dimensional benzoate hydrate layer seen in 
7.1, the polyhedra above reduce to quadrilaterals and other polygons formed by 0-
H"O hydrogen bonds. These include the parallelogram 0(71K)-0(1E)-0(71I)-0(1G), 
the quadrilateral 0(721)-0(7 A)-0(3A)-0(9E) and the distorted pentagon 0(1 G)-
0(71I)-0{72I)-0(9E)-0(5G). Different polygons are required for space filling in the 
three-dimensional clathrate hydrates. Interestingly, one or two benzoate 0 atoms are 
included in each of these polygons as in the three-dimensional polyhedral clathrate 
structure of tetra(butyl)ammonium benzoate hydrate, which seems to be the only 
reported crystal structure145' 146 even remotely resembling 7.1. 
Figure 7.3: Hydrated benzoate layer in the crystal structure of 7.1. The layers are 
parallel to [ 011] and symmetry-independent, although geometrically identical layers 
may be found at x 0 and at x = 0. 5. Symmetry-related atoms have the same 
numerical code. (001] is along the translation 0(71K)'"0(71L) and (010] is 
perpendicular to this direction. Notice that the centrosymmetric benzoate dimer is 
completely encircled by water molecules. 
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There are other unusual features in the crystal structure of 7.1: 1) The 
herringbone slabs consist of twice the number of cations as they do anions while the 
layers consist of anions only. There are, in effect, fairly large concentrations of charge 
in different regions of the structure, and anions and cations do not tend to make a 
maximum number of close contacts as would be expected in a salt. A possible reason 
for this is the presence of a large amount of water in the crystal which, with its high 
dielectric constant, may disperse the charge effectively; 2) The two hydrated layers 
which sandwich each herringbone slab are crystallographically independent though they 
are, geometrically speaking, virtually identical; 3) The presence of eighteen residues 
(five DMAPs, three benzoates and ten water molecules) in the asymmetric unit is 
unprecedented for a small-molecule structure. 
It is pertinent to mention that all subsequent attempts to crystallize 7.1 from 
solutions of DMAP and benzoic acid, proved futile. Rather, two simpler crystals, a 
DMAP benzoate monohydrate, mp 101-103 °C, and an anhydrous acid benzoate, 
(DMAP)(PhC02H)2, mp 128-129 °C, were obtained. The crystal structures of these 
substances were also determined, but their packing patterns proved to be 
straightforward. It is possible that the highly unusual crystal structure of 7.1 is a result 
of low concentrations of benzoate anion formed by hydrolysis ofPhCOCI by NaHC03 
in the workup. If so, it may be expected that polymorphic or related crystalline forms 
of other substances may also be obtained by generating the relevant material(s) in situ. 
It is well known that crystals of better quality are obtained when low concentrations of 
material are generated electrochemically. 147 That low concentrations are important in 
crystal growth is also shown by the efficacy of the gel diffusion method in obtaining 
crystals of organic donor-acceptor complexes. 148 The present example shows that 
entirely different and novel crystalline forms may be obtained when the crystallization 
conditions are such that low concentrations of material are generated chemically. 
Even with the recent advances in experimental and computational crystal 
engineering, it would be impossible to predict the details of this crystal structure, from 
such simple constituents as DMAP, benzoic acid and water. 
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X-ray Crystallographic Determination for 7.1 
Cs6HssN10016, M 1157.36, monoclinic space group P2t/c, a = 18.055(8), b = 
19.964(5), c 17.198(2) A, ~ 99.27(5t, V = 6118(3) A3, De= 1.26 g gm-3, Z = 4, 
crystal size 0.70 0.42 0.20 mm, !J(Cu-Ka) = 0.764 mm-1, F(OOO) = 2488, T = 130(2) 
K, Siemens P4 diffractometer, ro scans, 6494 reflections collected, 3148 onserved at 
2cr level, structure solution with SHELXS-86, refinement with SHELXL-93 on P for 
808 parameters, non-H atoms anisotropic, H-atoms in calculated positions. R 
0.0951, wR = 0.2164, Atomic coordinates, bond lengths and angles, and thermal 
parameters have been deposited at the Cambridge Crystallographic Data Centre. 
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Experimental 
cis-Hydroxyethylamine Isostere 
General procedure 
Mps were taken using a Reichert hot-stage microscope and are uncorrected. 
Optical rotations were measured on a JASCO J-20C recording spectropolarimeter and 
[a.]0 values are given in units of 10"1 deg cm2 g·1, with the concentration given in units 
of g cm"3. IR spectra were recorded on a Shimadzu FTIR-820 1PC spectrophotometer. 
1H and 13C NMR spectra were recorded on either a Varian CFT300 or XT300 
spectrometer. Samples were run in CDCb solution, with Me4Si as an internal 
standard, unless otherwise stated. Mass spectra were obtained using a Kratos 
MS80RF A spectrometer. Radial chromatography was performed on a Chromatatron 
(Harrison and Harrison) using Merck type 60 PF254 silica gel. Compounds 3.4, 3.8, 
L-Ala-OBzl, Cbz-L-Asn and L-Asn-OtBu were commercially available. 
Preparation 102•104 of (S)-4-phenyi-3-(N-phthalylamino )butanoic acid 3. 7 
r-3.4 X=OH 
L,.. 3.5 X= Cl 
Ph Phl <;? 
_ __,,..,.. P1h-N\CHN, _ __,,..,.. Pth-N~OH 
3.6 3.7 
To a solution of Pth-L-Phe 3.4 (100 mg, 0.34 mmol) in dry benzene (5 cm3) 
was added DMF (20 J.!L) and oxalyl chloride (0.16 cm3, 1.70 mmol) and the mixture 
was stirred at rt for 1 h. The solution was evaporated to give the acid chloride 3.5 
which was used without further purification; 1H NMR, 6 3.42 (1H, dd, J 14.2 & 10.8, 
CHAPh), 3.48 (1H, dd, 1 14.2 & 5.3, CHBPh), 5.21 (IH, dd, J 10.8 & 5.3, CHCH2), 
7.01-7.10 (5H, m, ArH), 7.62 (2H, m, PthH), 7.71 (2H, m, PthH); 1R /cm·1 1772, 
1750. The acid chloride 3.5 was redissolved in dry ether (5 cm3) and to it was added a 
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dried (Na2S04) solution of diazomethane (5 mmol) in ether (15 cm3). The mixture was 
left to stand at 5 oc for 18 h and evaporated. Recrystallization from benzene-hexane 
gave the o:-diazoketone 3.6 (102 mg, 93%); 1H NMR, o 3.54 (2H, m, CH2Ph), 5.09 
(IH, dd, J 10.3 & 6.4, CHCH2), 5.38 (1H, s, CHN2), 7.15 (5H, m, ArH), 7.71 (2H, m, 
PthH), 7.79 (2H, m, PthH); 13C NMR, o 33.92 (CH2Ph), 54.25 (CHN2), 58.33 
(CHCH2), 123.55, 126.88, 128.61, 128.85 & 134.32 (ArCH), 131.39 & 136.69 (ArC), 
167.59 (PthCO), 189.32 (PheCO); IR /cm·1 2098 (CHN2), 1708, 1651. 
To a stirred suspension of freshly prepared silver(!) oxide (61 mg, 0.26 mmol), 
Na2C03 (31 mg, 0.29 mmol) and Na2S20 3.5H20 (25 mg, 0.10 mmol) in water (2 cm3) 
was added dropwise, at 50-60 °C, a solution of the o:-diazoketone 3.6 (83 mg, 0.26 
mmol) in dioxane ( 4 cm3). The mixture was refluxed for 2 h, cooled, diluted with 
water and filtered. The solution was acidified with aqueous 10% HN03, extracted 
with ether (3 x 5 cm3), dried and evaporated to give the acid 3.7 (52 mg, 65%); 
(Found:~ 309.1008. C18H15N04 requires m!z 309.1001); 1HNMR, o 2.87 (lH, dd, J 
16.6 & 5.4, CH2Ph or CH2CO), 3.13 (1H, dd, J 13.7 & 6.4, CH2Ph or CH2CO), 3.24 
(2H, m, CH2Ph or CH2CO), 4.91 (1H, m, CHCH2), 7.17 (SH, m, ArH), 7.66 (2H, m, 
PthH), 7.73 (2H, m, PthH); 13C NMR, o 35.94 & 38.37 (CHzPh & CH2CO), 48.87 
(CHCH2), 123.20, 126.80, 128.50, 128.96 & 133.88 (ArCH), 131.47 & 136.99 (ArC), 
168.03 (PthCO), 175.95 (C02H); IR/cm·1 3032, 1773, 1708. 
Preparation 104 of (S)-3-(N-benzyloxycarbonylamino )-4-phenylbutanoic acid 3.11 
Ph Phl ~ --:JIIoJ~~oo Cbz-~\rCHN, _ _,..,..,. Cbz-N~OH 
H 0 H 
13.8 X OH 
~ 3.9 X= OC02Et 
3.10 3.11 
To a stirred solution ofCbz-L-Phe 3.8 (4.999 g, 16.70 mmol) in dry ether-THF 
(60 cm3 of a 1:1 mixture) was added triethylamine (2.33 mL, 16.70 mmol) and ethyl 
chloroformate (1.60 mL, 16.70 mmol) at -20 °C. After 15 min at -20 oc the mixed 
anhydride 3.9 was added to a dried (Na2S04) solution of diazomethane (33 mmol) in 
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ether (50 cm3). The mixture was stirred at -10 oc for 1 hand then left to stand at 5 °C 
for 18 h. The mixture was washed with ice-cooled saturated aqueous NaHC03 (10 
cm3), water (10 cm3), dried and evaporated to give the a-diazoketone104 3.10 as a 
yellow solid (5.01 g, 93%); [Found: (M-N2t 295.1206. C1sH17N03 requires mlz 
295.1208]; 1H NMR, B 3.05 (2H, d, J 6.8, CH2Ph), 4.48 (1H, m, CHCH2), 5.08 (2H, 
s, CbzCH2), 5.20 (1H, s, CHN2), 5.34 (1H, d, NH), 7.16-7.39 (10H, m, ArH); 13C 
NMR, B 38.30 (CHCH2), 54.53 (CHN2), 58.76 (C"1ICH2), 66.91 (CbzCH2), 126.97, 
127.93, 128.12, 128.44, 128.57 & 129.21 (ArCH), 135.94 & 136.05 (ArC), 155.66 
(CbzCO), 192.78 (PheCO); IR !cm·1 2124 (CHN2), 1730, 1635. 
To a stirred suspension of freshly prepared silver(I) oxide (3.59 g, 1 equiv), 
Na2C03 (0.74 g, 0.45 equiv) and Na2S203.SH20 (1.54 g, 0.4 equiv) in water (50 cm3) 
was added dropwise at 50-60 °C, a solution of the a-diazoketone 3.10 (5.01g, 15.53 
mmol) in dioxane (SO cm3). The mixture was stirred at 78-85 oc for 1.5 h, cooled, 
diluted with water and filtered. The solution was acidified with aqueous 10% HN03, 
extracted with ether (3 x 20 cm3), dried and evaporated to give the acid 3.11 (2.996 g, 
62%); (Found: M+ 313.1313. C18H19N04 requires mlz 313.1314); mp 119-121 oc 
(literature104 mp 118-119 °C); [a]0 20 -20° (c 0.023 in CH2Ch); 1H NMR, o 2.58 (2H, 
m, CH2CO), 2.88 (1H, dd, J 13.7 & 7.5, CHAPh), 2.97 (1H, dd, J 13.6 & 6.4, 
CHBPh), 4.25 (1H, m, CHCH2), 5.08 (2H, s, CbzCH2), 5.28 (1H, d, NH), 7.17-7.38 
(lOH, m, ArH); 13C NMR, B 37.19 (CH2CO), 40.07 (CH2Ph), 49.13 (CHCH2), 66.73 
(CbzCH2), 126.70, 128.01, 128.09, 128.46, 128.56 & 129.29 (ArCH), 137.27 (ArC), 
155.74 (CbzCO), 176.64 (C02H). 
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Preparation of N-benzyloxycarbonyl-L-phenylalaninal 3.16 
Method A107 
3.8 3.14 
155 
3.16 
To a solution of Cbz-L~Phe 3.8 (501 mg, 1.67 mmol) in dichloromethane (5 
cm3) was added triethylamine (0.233 cm3, 1.67 mmol) and BOP (739 mg, 1.67 mmol) 
and the mixture was stirred at rt for 5 min. O,N-Dimethylhydroxylamine hydrochloride 
(180 mg, 1.84 mmol) and triethylamine (0.256 cm3, 1.84 mmol) were added and 
stirring was continued at rt for a further 8 h. The mixture was washed with aqueous 
2M HCl (5 cm3), saturated aqueous NaHC03 (5 cm3) and saturated aqueous NaCl (5 
cm3), dried and evaporated. Purification of the crude product by flash chromatography 
eluting with ethyl acetate-dichloromethane (1:3) gave 3.14 (494 mg, 86%); 1H NMR, o 
2.91 (lH, dd, J 13.7 & 7.3, CHCHAPh), 3.08 (lH, dd, J 13.7 & 5.8, CHCH~h), 3.18 
(3H, s, NCH3), 3.68 (3H, s, OCH3), 5.02 (1H, m, CHCH2), 5.03 & 5.09 (2H, ABq, J 
12.2, CbzCH2), 5.41 (lH, d, J7.8, NH), 7.15 (2H, m, ArH), 7.24-7.37 (8H, m, ArH). 
To a suspension oflithium aluminium hydride (102 mg, 2.67 mmol) in dry THF 
(5 cm3) was added dropwise at ~50 oc over 5 min, a solution of 3.14 (763 mg, 2.23 
mmol) in THF (15 cm3). After stirring at -50 oc for 10 min, the mixture was allowed 
to warm to 0 oc over 20 min before recooling to -50 °C. Ethyl acetate (2 cm3) was 
slowly added to decompose any remaining lithium aluminium hydride and the mixture 
was stirred at 0 °C for 20 min. The mixture was filtered and evaporated. The residue 
was redissolved in ethyl acetate (10 cm3), washed with ice-cooled aqueous 1M HCl (5 
cm3), aqueous 10% NaHC03 (5 cm3) and water (5 cm3), dried and evaporated to give 
the aldehyde113 3.16 (484 mg, 77%); 1H NMR, o 3.14 (2H, d, J 6.4, CHCH2), 4.51 
(1H, m, CHCH2), 5.11 (2H, s, CbzCH2), 5.33 (1H, br d, J 6.3, NH), 7.14 (2H, m, 
ArH), 7.24~7.37 (8H, m, ArH), 9.64 (1H, s, CHO); 13C NMR, o 35.36 (CHC'fh), 
61.04 (CHCH2), 67.08 (CbzCH2), 127.18, 128.13, 128.26, 128.54, 128.81 & 128.29 
(ArCH), 135.38 (ArC), 198.80 (CHO). 
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Method B113 
3.8 3.15 
3.16 
l 
Ph Cbz-N~OH 
H 
3.17 
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To a solution of Cbz-L-Phe 3.8 (5.066 g, 16.90 mmol) and 3,5-
dimethylpyrazole (1.936 g, 20.30 mmol) in chloroform (250 cm3) at -10 °C was added 
dicylcohexylcarbodiimide (DCC, 3.492 g, 20.30 mmol) and the mixture was stirred for 
I h before warming to rt and stirring for a further 2 d. After removal of the 
dicyclohexylurea byproduct, the solvent was evaporated. The residue was redissolved 
in ethyl acetate (50 em\ washed with aqueous 2M HCl (10 cm3) and water (10 cm3), 
dried and evaporated to give a crude residue which was recrystallized from ethyl 
acetate-petroleum ether to give fine white needles of3.15 (5.443 g, 85%); mp 136-138 
oc (literature113 mp 142 °C); 1H NMR, 6 2.27 (3H, s, CH3}, 2.48 (3H, s, CH3), 3.09 
(lH, dd, J 13.8 & 7.1, CHCHAPh), 3.33 (IH, dd, J 13.7 & 4.9, CHCHBPh}, 5.05 & 
5.10 (2H, ABq, J 12.2, CbzCHz), 5.47 (lH, d, J8.8, NH), 5.58 (IH, m, CHCH2), 5.99 
(1H, s, CHCMe), 7.06 (2H, m, ArH), 7.22-7.33 (8H, m, ArH). 
Reduction of 3.15 (5.443 g, 14.40 mmol) was carried out as above to give an 
oily mixture (3.183 g, 5:3 by 1H NMR) of the aldehyde 3.16 (49%) and N-
benzyloxycarbonyl-L-phenylalaninol 3.17 (29%); 1H NMR, 6 2.86 (2H, d, J 7.3, 
CHCH2Ph}, 3.58 (lH, dd, J 11.2 & 4.9, CHAOH}, 3.68 (IH, dd, J 11.2 & 3.9, 
CHsOH), 3.94 (lH, m, CHCHz), 5.00 (1H, d, J1.3, NH), 5.07 (2H, s, CbzCH2), 7.18-
7.39 (10H, m, ArH). 
Experimental cis-Hydroxyethylamine Isostere 157 
To a stirred solution of Dess-Martin periodinane108 (774 mg, 1.82 mmol) in 
dichloromethane (5 cm3) was added a solution of the alcohol 3.17 (476 mg, 1.67 
mmol) in dichloromethane (5 cm3) and the mixture was stirred at rt for 1 h. Ether (25 
cm
3) and a solution ofNa2S203.5H20 (2 g, 8 mmol) in saturated aqueous NaHC03 (20 
cm
3) were added and the mixture was stirred at rt for 15 min. The organic layer was 
washed with saturated aqueous NaHC03 (5 cm3), water (5 cm3) and saturated aqueous 
NaCl (5 cm3), dried and evaporated to give further aldehyde 3.16 (468 mg, 98%). 
Preparation of (2S,3S)- and (2R,3S)-3-(N-benzyloxycarbonylamino)-2-hydroxy-4-
phenylbutanoic acid methyl esters106 3.19 and 3.20 
Ph~CN 
3.16 __. Cbz-N H H 
3.18 
PhJ ft 
_ _____,,...,. Cbz-N~OMe 
H OH 
3.19 
Phl ~ 
+ Cbz-N~OMe 
H OH 
3.20 
To a solution of3.16 (484 mg, 1.72 mmol) in ethyl acetate (10 cm3) was added 
a solution of potassium cyanide (143 mg, 1.72 mmol) in water (10 cm3) and the 
mixture was stirred vigorously at rt for 18 h. The organic layer was washed with 
water (5 cm3), dried and evaporated to give an epimeric mixture (1: 1 by 1H NMR) of 
the cyanohydrins 3.18 (408 mg, 76%); 1H NMR, epimer A 8 2.85 (1H, m, CHCHAPh), 
3.05 (1H, dd, J 14.2 & 6.3, CHCHBPh), 3.96 (1H, m, CHCH2), 4.49 (IH, d, J 3.9, 
CHOH), 5.01 (2H, s, CbzCH2), 5.18 (1H, d, J7.9, NH), 7.10-7.31 (lOH, m, ArH), 
epimer B 8 2.85 {2H, d, J 7.8, CHCH2), 4.17 (lH, m, CHCH2), 4.42 (1H, d, J 3.0, 
CHOH), 5.00 (2H, s, CbzCH2), 5.08 (1H, d, J 8.8, NH); IR /cm·1 3431 (OH), 2258, 
2253 (CN). 
The mixture of3.18 (1.781g, 5.74 mmol) was dissolved in dry and pre-cooled 
ether-methanol (80 cm3 of a 3:1 mixture), previously saturated with gaseous hydrogen 
chloride. The mixture was stirred at 5 oc for 24 h, ice-cooled water (15 cm3) was 
added (keeping the temperature below 10 °C) and stirring was continued at 5 °C for 2 
d. The mixture was concentrated and extracted with dichloromethane (3 x 10 cm3). 
The combined organic extracts were washed with water (5 cm3) and brine (5 cm3), 
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dried and evaporated to give a mixture of the methyl esters 3.19 and 3.20. Purification 
by flash chromatography, eluting with ethyl acetate-hexane (1:5 to 3:5) gave 3.20 (567 
mg, 29%)~ (Found: M+ 343.1415. C19H21N05 requires mlz 343.1419); mp 84-87 oc; 
[a]n20 -45° (c 0.032 in CH2Ch)~ RF 0.31 (3:7 EtOAc-pet. ether); 1H NMR106, o 2.92 
(2H, m, CHCH2), 3.65 (3H, s, OCH3), 4.09 (1H, d, J 1.5, CHOH), 4.33 (1H, m, 
CHCH2), 5.01 (2H, s, CbzCH2), 5.43 (IH, d, J 9.8, NH), 7.19-7.30 (lOH, m, ArH); 
13C NMR, o 37.96 (CHCH2), 52.54 (OMe), 54.70 (CHCH2), 66.49 (CbzCH2), 70.08 
(CHOH), 126.48, 127.68, 127.82, 128.24, 128.38 & 129.19 (ArCH), 136.24 & 137.21 
(ArC), 155.66 (CbzCO), 173.91 (CO). Further elution gave 3.19 (584 mg, 30%); 
(Found: M+ 343.1410. Ct9H2tN05 requires mlz 343.1419)~ mp 116-117 oc; [a]0 20 -5° 
(c 0.02 in MeOH); RF 0.21 (3:7 EtOAc-pet. ether); 1H NMR106, o 2.80 (2H, m, 
CHCH2), 3.56 (3H, s, OCH3), 4.34 (1H, d, J3.4, CHOH), 4.38 (1H, m, CHCH2), 5.05 
(2H, s, CbzCH2), 5.15 (1H, d, J 9.2, NH), 7.18-7.36 (IOH, m, ArH); 13C NMR, o 
35.37 (CHCHz), 52.30 (OMe), 54.54 (CHCHz), 66.51 (CbzCHz), 72.09 (CHOH), 
126.43, 127.78, 127.86, 128.16, 128.26 & 129.26 (ArCH), 136.19 & 136.83 (ArC), 
155.80 (CbzCO), 172.76 (CO). 
Preparation of (2S,3S)- and (2R,3S)-3-(N-benzyloxycarbonylamino )-2-hydroxy-4-
phenylbutanoic acids106 3.21 and 3.23 
Ph~ ~ 
Cbz-~~OH 
H OH 
3.21 
Phl ~ 
Cbz-N~OH 
I :: 
H OH 
3.23 
The methyl ester 3.19 Of 3.20 (1 equiv) and sodium hydroxide (1.4 equiv) was 
dissolved in methanol-water (0.5 to 5 cm3 of a 4:1 mixture) and the solution was 
stirred at rt for 2 h. The methanol was evaporated and the aqueous layer acidified 
(pH<3 by universal indicator paper) with aqueous 2M HCI, precipitating a white solid. 
The solid was extracted into ethyl acetate (3 x 10 em\ dried and evaporated to give 
the corresponding free acid 3.21 (88%) or 3.23 (88%). Acid 3.21; 1H NMR 106 
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(CDCh, d6-DMSO), o 2.81 (2H, m, CHCH2), 4.30 (2H, m, CHOH & CHCH2), 4.98 
(2H, s, CbzCH2), 6.07 (1H, d, J 9.2, NH), 7.12-7.35 (lOH, m, ArH). Acid 3.23; 1H 
NMR106 (CDCh, d6-DMSO), o 2.92 (2H, m, CHCH2), 4.01 (IH, d, J 1.9, CHOH), 
4.27 (1H, m, CHCH2), 5.02 (2H, s, CbzCH2), 6.25 (lH, d, J 9.8, NH), 7.20-7.36 
(10H, m, ArH). 
Preparation of (2S,3S)- and (2R,3S)-2-acetoxy-3-(N-benzyloxycarbonylamino)-4-
phenylbutanoic acids 3.22 and 3.24 
Ph~ ~ 
Cbz-~~OH 
H OAc 
Phl ~ 
Cbz-N~OH 
I :; 
H OAc 
3.22 3.24 
The acid 3.21 (609 mg, 1.85 mmol) or 3.23 (306 mg, 0.93 mmol) was 
dissolved in pyridine (3 cm3), acetic anhydride (3 equiv) was added and the mixture 
was stirred at rt for 18 h. Saturated aqueous NaCl (3 cm3) was added and the mixture 
was extracted with chloroform ( 4 x 10 em\ dried and evaporated to give the 
corresponding acetate 3.22 or 3.24 (quant) plus traces of pyridine. Acetate 3.22; 
[a]n20 -6° (c 0.009 in CH2Ch); 1H NMR, o 2.00 (3H, s, CH3), 2.72 (lH, m, 
CHCHAPh), 2.99 (IH, m, CHCHBPh), 4.43 (1H, m, CHCH2), 4.77 & 4.95 (2H, ABq, 
J 12.2, CbzCH2), 4.99 (lH, d, J 5.8, CHOAc), 5.54, (1H, d, J 8.8, NH), 7.06-7.26 
(10H, m, ArH); 13C NMR, o 21.54 (Me), 36.27 (CHCH2), 53.19 (CHCH2), 66.52 
(CbzCH2), 77.10 (CHOAc), 126.30, 127.67, 127.79, 128.28 & 129.19 (ArCH), 
136.30 & 137.64 (ArC), 156.38 (CbzCO), 172.01 & 174.48 (CO); 1R /cm·1 1750, 
1713, 1626. Acetate 3.24; [a]n20 -18° (c 0.018 in CH2Ch); 1H NMR, o 2.19 (3H, s, 
CH3), 2.84 (IH, dd, J 13.2 & 8.3, CHCHAPh), 2.96 (lH, dd, J 13.4 & 7.0, 
CHCHBPh), 4.59 (IH, m, CHCH2), 5.03 (1H, d, J 5.8, CHOAc), 5.00 & 5.09 (2H, 
ABq, J 12.7, CbzCH2), 5.32, (1H, d, J 9.1, NH), 7.18-7.32 (10H, m, ArH); IR lcm"1 
1750, 1713, 1628. 
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Preparation of (4S,5S)-4-benzyl-2-oxo-5-oxazolidinecarboxylic acid106 3.25 
Ph~ ~ 
Cbz-~~OMe 
H OH 
3.19 3.25 
The methyl ester 3.19 (31 mg, 0.09 mmol) and potassium carbonate (27 mg, 
0.18 mmol) were dissolved in methanol-water (3 cm3 of a 9:1 mixture) and stirred at rt 
for 18 h. The methanol was evaporated and the aqueous layer was acidified (pH<3) 
with aqueous 2M HCl, precipitating a white solid. The solid was extracted into ethyl 
acetate (3 x 5 cm3), dried and evaporated to give the acid 3.25 (14 mg, 72%); 1H 
NMR106 (CDCh, d6-DMSO), 8 2.64 (lH, dd, J 13.7 & 9.7, CHAPh), 2.98 (IH, dd, J 
13.7 & 3.9, CHsPh), 4.31 (1H, m, CHN), 5.05 (1H, d, J8.8, CHO), 7.19-7.34 (5H, m, 
ArH); 13C NMR (CDCh, d6-DMSO), 8 36.09 (CHzPh), 53.83 (CHN), 74.75 (CHO), 
125.58, 127.42 & 127.98 (ArCH), 135.44 (ArC), 156.48 (NCO), 172.98 (C02H). 
Preparation of compounds 3.32, 3.34, 3.36, 3.37, 3.39, 3.41 and 3.42 
General Coupling Method A (DCC/HOBT) 
To a solution of the carboxylic acid (1 equiv) in dichloromethane (5 cm3/mmol) 
was added at 0 °C, triethylamine (1 equiv), HOBT (1 equiv) and the amine (1 equiv; 
alternatively, 1 equiv of the amine.HCl or HBr salt and an extra 1 equiv of 
triethylamine), and the mixture was stirred for 10 min. DCC (1 equiv) was added, and 
stirring was continued at 0 oc for a further 10 min and then at rt for 18 h. The mixture 
was filtered and evaporated. The residue was redissolved in ethyl acetate ( 5 cm3), 
washed with aqueous 2M HCI (2.5 cm3), aqueous 10% NaHC03 (2.5 cm3) and water 
(2.5 cm3), dried and evaporated. The crude product was purified by flash 
chromatography or recrystallization to remove any remaining dicyclohexylurea. 
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General Coupling Method B (BOP) 
To a solution of the carboxylic acid (1 equiv), amine (1 equiv; alternatively, 1 
equiv of the amine.HCI or HBr salt and an extra 1 equiv of triethylamine) and BOP 
(1.1 equiv) in dichloromethane or DMF (0.5 to 5 cm3) was added triethylamine (2 
equiv) and the mixture was stirred at rt for 1 h. A further portion of triethylamine (1 
equiv) was added and stirring was continued at rt for 18 h. Saturated aqueous NaCl (3 
cm3) was added and the mixture extracted with ethyl acetate (3 x 5 em\ washed with 
aqueous 2M HCl (2.5 cm3), aqueous 1M NaHC03 (3 x 2.5 cm3) and water (2.5 cm3), 
dried and evaporated. The product was purified by flash chromatography. 
Benzyl 
3.32 
(2S)~2-[(3S)-4~phenyi-3-(N-phthalylamino)butanoylamino]propanoate 
Phl ~ Me 
Pth-N~~~OBzl 
H 0 
3.32 
Pth-L-PPhe 3.7 (55 mg, 0.18 mmol) was reacted with L-alanine benzyl ester 
hydrochloride according to general coupling method A. Purification by flash 
chromatography eluting with a gradient of ethyl acetate-dichloromethane (1: 100 to 
1:10) gave the amide 3.32 (38 mg, 45%); (Found: M" 470.1839. C2sH26N20 5 requires 
mlz 470.1841); Rp 0.38 (1 :20 Et0Ac-CH2Ch); 1H NMR, o 1.32 (3H, d, J 6.9, CH3), 
2.75 (IH, dd, J 14.6 & 5.4, CHCH2Ph or CH2CO), 3.14 (2H, m, CHCH2Ph or 
CH2CO), 3.26 (IH, dd, J 12.2 & 9.2, CHCH2Ph or CH2CO), 4.53 (1H, m, CliMe), 
4.99 (3H, m, CHCH2 & BzlCH2), 6.16 (lH, d, J7.3, NH), 7.13-7.33 (IOH, m, ArH), 
7.65 (2H, m, PthH), 7.72 (2H, m, PthH); 13C NMR, o 18.16 (Me), 38.29 & 38.53 
(CHCH2Ph & CH2CO), 48.01 & 49.73 (CHMe & CHCH2), 66.93 (BzlCH2), 123.11, 
126.74, 128.00, 128.34, 128.50, 128.54, 129.01 & 133.72 (ArCH), 131.69 & 137.23 
(ArC), 168.29 (PthCO), 169.30 & 172.50 (CO). 
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Benzyl (2S)-2-[ ( 3S)-4-phenyi-3-(N-benzyloxycarbonylamino )butanoylamino ]-
propanoate 3.34 
Phl 'if Me 
Cbz-N~N~OBzl 
H H g 
3.34 
Cbz-L-f)Phe 3.11 (1.451 g, 4.6 mmol) was reacted with £-alanine benzyl ester 
hydrochloride according to general coupling method A. Crystallization of the crude 
product from ethyl acetate-petroleum ether gave the amide 3.34 as fine white crystals 
(1.025 g, 47%); [Found: (M-PhCH2t 383.1606. C21H23N20s requires mlz 383.1607]; 
mp 144-145 °C; [a.]0 20 -19° (c 0.041 in CH2Ch); 1HNMR, 6 1.37 (3H, d, J7.4, CH3), 
2.33 (1H, dd, J 15.2 & 5.4, CHCHACO), 2.45 (1H, dd, J 14.8 & 5.2, CHCHBCO), 
2.80 (1H, dd, J 13.4 & 8.1, CHCHAPh), 2.99 (IH, dd, J 13.7 & 6.4, CHCHBPh), 4.14 
(IH, m, CHCH2), 4.61 (IH, m, CHMe), 5.07 (2H, s, CbzCH2), 5.16 & 5.22 (2H, ABq, 
J 12.2, BzlCH2), 5.75 (IH, d, J7.8, NHCHMe, 6.09 (IH, d, J 5.9, NHCbz), 7.19-7.40 
(ISH, m, ArH); 13CNMR, 5 18.10 (Me), 38.43 (CH2CO), 40.13 (CHCH2Ph), 48.07 
(CHMe), 50.11 (CHCH2), 66.48 (CbzCH2), 67.19 (BzlCH2), 126.57, 127.90, 127.97, 
128.17, 128.44, 128.46, 128.56, 128.62 & 129.29 (ArCH), 135.25 & 137.88 (ArC), 
155.86 (CbzCO), 170.41, 172.60 (CO); IR/cm"13427, 3030, 1713, 1670, 1499. 
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Benzyl (2S)-2-[(2S,3S)- and (2S)-2-[(2R,3S)-3-(N-benzyloxycarbonylamino)-2-
hydroxy-4-phenyl-butanoylamino]propanoate 3.36 and 3.37 
PhJ ~ Me 
Cbz-~~~~OBzl 
H OH H 0 
3.36 
Phl <;? Me 
Cbz-N~N~OBzl 
H OH H g 
3.37 
A mixture of the acids 3.23 and 3.21 (4:1 by 1H NMR) (45 mg, 0.14 mmol) 
was reacted with L-alanine benzyl ester hydrochloride according to general coupling 
method A. Purification by flash chromatography eluting with ethyl acetate-
dichloromethane (1:9 to 1:3) gave a mixture (42 mg, 61% yield, 4:1 by 1H NMR) of 
the amides 3.37 and 3.36; [Found: (M-PhCH2t 399.1556. C21H23N206 requires mlz 
399.1556]; 1HNMR, 3.37 (from the mixture) B 1.35 (3H, d, J7.3, CH3), 2.99 (2H, m, 
CHCH2Ph), 4.13 (2H, m, CHCH2 & CHOH), 4.57 (lH, m, CHM.e), 4.99 (2H, s, 
CbzCH2), 5.06 & 5.15 (2H, ABq, J 12.2, BzlCH2), 5.20 (1H, d, J 5.4, OH), 5.55 (1H, 
d, J 8.8, CbzNH), 7.17-7.36 (ISH, m, ArH), 3.36 (from the mixture) o 1.29 (3H, d, J 
7.4, CH3); 13C NMR, 3.36/3.37 B 17.69/17.88 (Me), 36.42 (CHCH2Ph), 47.74/47.80 
(CHMe), 55.37/55.55 (CHCH2), 66.69/66.74/66.94/67.02 (CbzCHz & BzlCH2), 
72.61172.43 (CHOH), 126.39, 127.67, 127.78, 127.94, 128.28, 128.32, 128.46 & 
129.18 (ArCH), 135.18, 136.16, 137.71 & 137.65 (ArC), 156.78 & 157.05 (CbzCO), 
172.16 & 172.39 (BzlCO). 
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Benzyl (2S)-2-[ ( 4S,5S)-4-benzyl-2-oxooxazolidin-5-ylcarbonylamino] propanoate 
3.39 
Ph~ ~ Me 
H-~~N~OBzl 
}-o A o 
0 
3.39 
The acid 3.25 (7 mg, 0.03 mmol) was reacted with L-alanine benzyl ester 
hydrochloride according to general coupling method A. Purification of the crude 
product by flash chromatography eluting with ethyl acetate-dichloromethane (1 :5) 
gave the amide 3.39 (10 mg, 83%); (Found: M+ 382.1527. C21H22N20s requires mlz 
382.1528); 1H NMR, o 1.50 (3H, d, J 7.4, CH3), 2.42 (1H, dd, J 13.2 & 7.7, 
CHCHAPh), 3.13 (lH, dd, J 13.2 & 3.0, CHCH8Ph), 4.42 (1H, m, NCHCH2), 4.70 
(1H, m, CHMe), 5.10 (1H, d, .18.3, CHO), 5.21 (2H, m, BzlCH2), 7.17 (2H, m, ArH), 
7.26-7.41 (8H, m, ArH). 
Benzyl (2S)-2-[(2S,3S)- and (2S)-2-[(2R,3S)-2-acetoxy-3-(N-
benzyloxycarbonylamino)-4-phenyl-butanoylamino]propanoate 3.41 and 3.43 
Ph~ Me 
Cbz-N N~OBzl 
H Ac H g 
Ph') c;? Me 
Cbz-N~N~OBzl 
H OAc H g 
3.41 3.43 
The acetate 3.22 or 3.24 (1 equiv; prepared from 3.21 and 3.23, respectively, 
as described above) was reacted with L-alanine benzyl ester hydrochloride ( 1.1 equiv) 
in dichloromethane according to general coupling method B. Purification by flash 
chromatography eluting with ethyl acetate-petroleum ether (3 :2) gave the 
corresponding amide 3.41 or 3.43. Amide 3.41 (218 mg, 44%); [Found: (M-PhCH2t 
441.1660. C23H2sN201 requires mlz 441.1661]; [ct]n20 -11° (c 0.060 in CH2Cb); 1H 
NMR, o 1.41 (3H, d, 17.0, CHCH3), 2.10 (3H, s, COCH3), 2.90 (lH, dd, J 13.7 & 
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8.8, CHCHAPh), 2.99 (lH, dd, J 14.2 & 63, CHCHsPh), 4.39 (lH, m, CHCH2), 4.59 
(lH, m, CHMe), 5.02 (2H, s, CbzCH2), 5.14 & 5.20 (2H, ABq, J 12.5, BzlCH2), 5.17 
(lH, m, CHOAc), 5.3S (IH, d, J 9.5, NHCbz), 6.95 (IH, d, J 7.S, NHCHMe), 7.22-
7.34 (ISH, m, ArH); 13C NMR, o 17.78 (CHCH3), 20.74 (COCH3), 36.78 (CHCH2), 
48.11 (CHMe), 53.74 (CHCH2), 66.67 (CbzCH2), 67.2S (BzlCH2), 74.11 (CHOAc), 
126.63, 127.74, 127.97, 128.13, 129.38, 128.46, 128.57 & 129.12 (ArCH), 13S.07 & 
136.94 (ArC), 1S5.99 (CbzCO), 167.31, 169.79 & 172.17 (CO); IR/cm·1 1713, 1686, 
1506, 1217. Amide 3.43 (501 mg, 51%); [Found: (M-PhCHzt 441.1661. C23H2sNz01 
requires mlz 441.1661]; mp 142-144 °C; [a]o20 -19° (c 0.012 in CH2Ch); 1H NMR, 0 
1.37 (3H, d, J 6.9, CHCH3), 2.05 (3H, s, COCH3), 2.84 (2H, d, J 7.3, CHCH2), 4.43 
(1H, m, CHCH2), 4.59 (1H, m, CHMe), 4.98 & 5.04 (2H, ABq, J 12.0, CbzCH2), 5.14 
& 5.21 (2H, ABq, J 12.0, BzlCH2), 5.21 (lH, d, J 3.9, CHOAc), 5.47 (1H, d, J 9.8, 
NHCbz), 6.68 {lH, d, J 7.3, NHCHMe), 7.17-7.38 (ISH, m, ArH); 13C NMR, o 17.96 
(CHCH3), 20.51 (COCH3), 37.75 (CHCH2), 48.01 (CHMe), 53.24 (CHCH2), 66.68 
(CbzCH2), 67.28 (BzlCH2), 73.35 (CHOAc), 126.65, 127.95, 128.36, 128.49, 128.58 
& 129.16 (ArCH), 135.07 & 136.89 (ArC), 155.52, (CbzCO), 167.52 & 168.98 (CO). 
Preparation of compounds 3.33, 3.35, 3.40, 3.42 and 3.44. 
General Method A for Tetrazole Formation (without stereochemical control) 
To a stirred suspension of the amide (1 equiv) in dry benzene (5 cm3/mmol) 
was added crystalline PCls (I equiv). A transparent solution formed and the mixture 
was stirred at rt for 45 min. An extra portion of PCls (0.2 equiv) was added and 
stirring was continued for a further 45 min. A benzene (3 cm3) solution of hydrazoic 
acid (10 equiv) was added and the mixture was stirred at rt for 2 d. The mixture was 
diluted with benzene (5 cm3) and washed with aqueous 1M NaHC03 (3 x 2.5 cm3), 
water (2.5 cm3) and saturated aqueous NaCl (2.5 cm3). The benzene solution was 
dried and evaporated to give a mixture of the tetrazole and the unreacted amide which 
was separated by flash chromatography. 
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General Method B for Tetrazole Formation (with stereochemical control) 
To a stirred solution of PCls (1.2 equiv) in dry chloroform (5 cm3/mmol) was 
added quinoline (2.4 equiv) at rt (a white precipitate formed). The mixture was stirred 
for 30 min before slowly adding a solution of the amide (1 equiv) in chloroform (5 
cm3 /mmol) at less than 20 °C. After stirring for 1 h a further portion of PC15 (0.2 
equiv.) was added and stirring was continued for 2.5 h. A benzene (3 cm3) solution of 
hydrazoic acid (30 equiv) was added and the mixture stirred at rt for 2d. The mixture 
was evaporated, redissolved in ethyl acetate (10 cm3) and washed with aqueous 2M 
HCI (2 x 2.5 cm3), water (2 x 2.5 cm3) and saturated aqueous NaCI (2.5 cm3). The 
solution was dried and evaporated to give a crude mixture of the tetrazole and the 
unreacted amide which was purified by flash chromatography. 
1-[(lS)-1-Benzyloxycarbonylethyl]-5-[(2S)-3-phenyi-2-(N-phthalylamino)propyi]-
IH-tetrazole 3.33 
PhuN - ,, 
Pth-N N"N 
Me'~~o 
OBzl 
3.33 
The amide 3.32 (24 mg, 0.05 mmol) was reacted according to general method 
A for tetrazole formation. Purification of the crude product (23 mg) by flash 
chromatography, eluting with ethyl acetate-dichloromethane (3 : 100 to 3: 1 0 ), gave two 
fractions. The first fraction contained 3.33 (13 mg, 51%); (Found: M+ 495.190. 
C2sHzsNs04 requires mlz 495.1906); RF 0.59 (1:20 EtOAc-CHzClz); 1H NMR, o 1.86 
(3H, d, J7.3, CH3), 3.15-3.31 (3H, m, CHCH2Ph & CH2CN4), 3.74 (1H, dd, J 15.6 & 
10.3, CHCH2Ph or CH2CN4), 5.08 (1H, m, CHCHz), 5.14 (1H, q, J7.4, CHMe), 5.18 
(2H, m, BzlCHz), 7.14-7.37 (IOH, m, ArH), 7.65-7.75 (4H, m, PthH); 13C NMR, o 
16.51 (Me), 25.42 (CHzCN4), 38.80 (CHCHzPh), 50.54 (CHCH2), 55.56 (CHMe), 
68.32 (BzlCHz), 123.31, 127.04, 128.43, 128.50, 128.67, 128.75, 128.85, 128.98, 
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131.33, 134.09 & 136.63 (ArC), 152.53 (CN4), 167.49 & 168.01 (CO); IR /cm"1 1774, 
1751,1712,1396,1372. Thesecondfractioncontained3.32(7mg, 30%). 
1-[ (JS)-1-Benzyloxycarbonylethyl]-5-[ ( 2S)-2-(N-benzyloxycarbonylamino )-3-
phenylpropyl]-JH-tetrazole 3.35 
Phu-N \\ 
... N 
Cbz-N N 
1 h{o H ~,~ 
Me" 
OBzl 
3.35 
The amide 3.34 (978 mg, 2.06 mmol) was reacted according to general method 
A for tetrazole formation. Purification on a 4 mm chromatatron plate, eluting with 
ethyl acetate-pentane (3:15 to 2:5), gave two fractions. The first fraction contained 
3.35 (484 mg, 47%); (Found: ~ 499.2223. C2sH29Ns04 requires mlz 499.2219); mp 
103-104 oc; [a.]0 20 -51° (c 0.007 in CH2Ch); 1H NMR, 8 1.88 (3H, d, J 7.3, CH3), 
2.87 (1H, dd, J 10.2 & 7.5, CHCHAPh), 2.98 (3H, m, CH2CN4 & CHCHsPh), 4.25 
(1H, m, CHCH2), 5.01 (IH, q, J7.3, CHMe), 5.04 (2H, s, CbzCH2), 5.08 & 5.14 (2H, 
ABq, J 12.0, BzlCH2), 5.48 (1H, d, J 7.8, NHCbz), 7.08 (2H, m, ArH), 7.19-7.38 
(13H, m, ArH); 13C NMR, 8 16.53 (Me), 26.74 (CH2CN4), 39.03 (CHCH2Ph), 50.79 
(CHCH2), 55.49 (CHMe), 66.75 (CbzCH2), 68.27 (BzlCH2), 126.97, 128.00, 128.18, 
128.26, 128.53, 128.73, 128.77, 128.82 & 129.06 (ArCH), 134.32 & 137.10 (ArC), 
152.76 (CN4), 157.59 (CbzCO), 167.59 (AlaCO); IR /cm·1 3431, 1751, 1713, 1510. 
The second fraction contained 3.34 (335 mg, 34%). 
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5-[ ( 4S,5S)-4-Benzyl-2-oxooxazolidin-5-yl]-1-[ (lS)-1-benzyloxycarbonylethyl)-lH-
tetrazole 3.40 
Ph)yt-N ,, 
H-N N"N 0 
\ 0 J.._ /~ 
or Me$'"'\ 
OBzl 
3.40 
The amide 3.39 (10 mg, 0.026 mmol) was reacted according to general method 
B for tetrazole formation to yield a crude mixture of 3.40 and 3.39. Purification by 
flash chromatography eluting with ethyl acetate-petroleum ether (1 :3 to 1: 1) gave a 
mixture of the tetrazole 3.40 and the amide 3.39 (6 mg, 5:3 by 1H NMR); (Found:~ 
407.1590. C21H21Ns04 requires mlz 407.1593); 1H NMR, o 3.40 (from the mixture) 
2.01 (3H, d, J 7.3, CH3), 2.36 (1H, m, CHCHAPh), 2.86 (1H, dd, J 13.7 & 3.4, 
CHCH8Ph), 4.49 (lH, m, CHCH2), 5.25 (2H, m, BzlCH2), 5.70 (1H, q, 17.3, CHMe), 
6.15 (1H, d, J7.9, CHO), 7.01 (2H, m, ArH), 7.26-7.37 (8H, m, ArH). 
5-[(1S,2S)- and 5-[(1R,2S)-1-Acetoxy-2-(N-benzyloxycarbonylamino )-3-
phenylpropyl]-1-[(lS)-1-benzyloxycarbonylethyl]-lH-tetrazole 3.42 and 3.44 
' I 
Ph~NN-
Cbz-N N"N 
H hfo OAc ~ 
Me.:~ OBzl 
3.42 
PhuN - ,, 
Cbz-N - N"N 
H :: ~0 OAc ~ Me.:~ 
Bzl 
3.44 
The amide 3.41 (184 mg, 0.346 mmol) was reacted according to general 
method B for tetrazole formation. Purification by flash chromatography, eluting with 
ethyl acetate-petroleum ether (2:3) gave two fractions. The first fraction contained an 
oily mixture (17:3 by 1H NMR) of the tetrazoles 3.42 and 3.44 (121 mg, 63% 
combined yield). Further flash chromatography of this fraction, eluting with ethyl 
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acetate-petroleum ether (2:3), gave pure 3.42 (25 mg, 13%) and mixtures of 3.42 and 
3.44; 3.42 (Found: ~ 557.2280. C3oH31Ns06 requires mlz 557.2274); [a.]0 20 -34° (c 
0.011 in CH2Cb); 1H NMR, o 1.84 (3H, d, .17.4, CHCH3), 1.84 (3H, s, COCH3), 2.82 
(1H, dd, .114.4 & 7.6, CHCHAPh), 2.93 (1H, dd, J 13.9 & 8.6, CHCHBPh), 4.58 (1H, 
m, CHCHz), 5.02 & 5.08 (2H, ABq, J 11.7, CbzCH2), 5.07 & 5.13 (2H, ABq, J 12.1, 
BzlCHz),.5.17 (1H, m, CHMe),5.79 (lH, d, .19.3, NH), 6.09 (1H, d, J 5.4, CHOAc), 
7.01 (2H, m, ArH), 7.21-7.34 (13H, m, ArH); 13C NMR, o 17.09 (CHMe), 20.13 
(COMe), 37.06 (CHCH2), 53.83 (CHCH2), 56.28 (CHMe), 64.43 (GIOAc), 66.81 
(CbzCH2), 68.27 (BzlCH2), 127.10, 127.86, 128.13, 128.22, 128.50, 128.67, 128.72 
& 128.80 (ArCH), 134.32 & 136.22 (ArC), 151.22 (CN4), 156.24 (CbzCO), 167.65 & 
169.60 (CO); IR /cm·1 1755, 1724, 1512; 3.44 (data given below). The second fraction 
contained the unreacted amide 3.41 (26 mg, 14%). 
The amide 3.43 (455 mg, 0.854 mmol) was also reacted according to general 
method B for tetrazole formation. Purification by flash chromatography gave two 
fractions. The first fraction contained a mixture (4:1 by 1H NMR) of the tetrazoles 
3.44 and 3.42 (302 mg, 63%), 15 mg of which was recrystallized from ethyl acetate-
petroleum ether to give fine white needles of 3.44 (5 mg); (Found: ~ 557.2273. 
C3oH31Ns06 requires mlz 557.2274); mp 96-98 oc; [a.]o20 -49° (c 0.010 in CH2Ch); 1H 
NMR, o 1.93 (3H, d, J 1.3, CHCH3), 1.97 (3H, s, COCH3), 2.91 (2H, m, CHCH2), 
4.42 (1H, m, CHCHz), 5.02 (2H, s, CbzCH2), 5.05 & 5.12 (2H, ABq, J 12.2, BzlCH2), 
5.36 (1H, m, CHMe), 5.92 (IH, d, J 5.4, CHOAc), 7.07 (2H, m, ArH), 7.20-7.32 
(13H, m, ArH); 13C NMR, o 16.52 (CHMe), 19.98 (COMe), 36.38 (CHCH2), 54.38 
(GICH2), 56.12 (CHMe), 64.95 (GIOAc), 66.68 (CbzCH2), 68.11 (BzlCH2), 126.72, 
127.82, 127.97, 128.13, 129.32, 128.49, 128.53, 128.58 & 128.89 (ArCH), 134.23, 
136.01 & 136.45 (ArC), 152.00 (CN4), 155.67 (CbzCO), 167.60 & 169.79 (CO). The 
second fraction contained the unreacted amide 3.43 (147 mg, 32%). 
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Preparation of compounds 3.49, 3.50, 3.53, 3.54 and 3.61-3.64 
General Method for removal of a Cbz protecting group 
To a stirred solution of the protected amine (1 equiv) in acetic acid (1 cm3) was 
added 50% HBr in acetic acid (1.9 cm3 /mmol). After 20 min at rt, pre-cooled ether · 
( 10 cm3) was added at -10 oc with vigorous stirring. To the resulting precipitate was 
added petroleum ether (5 cm3) and the mixture left to stand at 0 oc for 15 min. The 
residue was washed with petroleum ether (2 x 5 cm3) and dried in vacuo to give the 
corresponding amine hydrobromide. 
General Method for hydrogenolysis of a benzyl ester 
A stirred solution of the benzyl ester (1 equiv) and acetic acid (1 to 3 drops) in 
ethanol (2.5 to 5 cm3) was hydrogenated at rt for 18 h in the presence of 10% Pd/C 
(188 mg/mmol). The mixture was filtered through celite, evaporated, redissolved in 
sufficient aqueous 1M NaHC03 and washed with a small amount of ethyl acetate (2 
cm3). The aqueous phase was acidified with solid sodium bisulphite to pH 2.5 and the 
free acid extracted with ethyl acetate (3 x 10 cm3), dried and evaporated. 
5-[(28)-2-Amino-3-phenylpropyl]-1-[ (lS)-1-benzyloxycarbonylethyl]-lH-
tetrazole hydrobromide 3.45 
PhuN - ,, 
BrH.H2N ~~,.N 0 
Me~ 
Bzl 
3.45 
The tetrazole 3.35 (362 mg, 0.725 mmol) was reacted with 50% HBr in acetic 
acid, according to the general method, to give the amine hydrobromide 3.45 (271 mg, 
84%); (Found: MH+ 366.1931. C2oH24Ns02 requires mlz 366.1929); 1H NMR 
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(CD30D), o 1.89 (3H, d, J 7.4, CHCH3), 2.99-3.31 (4H, m, CHCH2Ph & CH2CN4), 
4.09 (lH, m, CHCH2), 5.14 (2H, s, BzlCH2), 5.61 (lH, q, J 7.3, CHMe), 7.26-7.38 
(IOH, m, ArH). 
(2 'S,l ''S) and (2 'S,l "R)-5-{2-[N-(N-Benzyloxycarbonyl-L-asparaginyl)amino]-3-
phenylpropyl}-1-[1-(1,1-dimethylethylaminocarbonyl)ethyl]-lH-tetrazole 3.49 
and 3.50 
Phu-N 
•• 
.. N 3.45 __ ,...,. Cbz-L-Asn-N N 
H ~L /p Me~''\ 
3.46 OBzl 
l 
N PhuN -
Cbz-L-Asn-N N" 
, kfo + 
Phu-N 
•• 
,N 
Cbz-L-Asn-N N 
H J--fo H ~,~ 
Me' OH 
3.47 
1 
PhuN - ,, 
Cbz-L-Asn-~ N~"N O + 
H ~~ 
Me HlBu 
3.49 
Me OH 
3.48 
Ph') ~;J-N 
I~\\ 
Cbz-L-Asn-N N"N 
H J--fo 
Me NHlBu 
3.50 
The amine hydrobromide 3.45 (13 mg, 0.03 mmol) was reacted with Cbz-L-
asparagine according to general coupling method A Purification by flash 
chromatography eluting with ethyl acetate-petroleum ether (2:3 to 1 :0) gave the amide 
3.46 (14 mg, 76%); (Found: Mit 614.2730. C32H36N106 requires mlz 614.2727); 
[a]0 20 -20° (c 0.010 in CH2Ch); 1H NMR (CDCh, d6-DMSO), o 1.89 (3H, d, J 7.4, 
CHCH3), 2.38 (2H, m, AsnCH2), 2.79-3.10 (4H, m, CHCH2Ph & CHzCN4), 4.29 (IH, 
m, AsnCH), 4.40 (lH, m, CHCH2Ph), 5.01 & 5.06 (2H, ABq, J 12.2, BzlCH2), 5.16 
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(2H, s, CbzCH2), 5.59 (IH, q, J 6.8, CHMe), 6.47 (IH, br s, NH), 7.04 (1H, d, J8.3, 
AsnNH), 7.16-7.38 (ISH, m, ArH), 7.96 (IH, d, J 8.3, NH); 13C NMR (CDCh, d6-
DMSO), o 14.96 (CI:IA4e), 25.47 (CH2CN4), 36.00 (AsnCH2), 38.36 (CHCH2Ph), 
48.26 (CHCH2Ph), 50.59 (AsnCH), 53.56 (CHMe), 64.69 (BzlCH2), 66.20 (CbzCH2), 
124.99, 126.45, 126.59, 126.91, 127.03, 127.10 & 127.77 (ArCH), 136.29 (ArC), 
152.20 (CN4), 169.01, 169.68 & 170.68 (CO). 
The benzyl ester 3.46 ( 13 mg, 0. 021 mmol) and potassium hydroxide ( 1.1 mg, 
0.0196 mmol) were dissolved in methanol-water (5 cm3 of a 4:1 mixture) and stirred at 
rt for 18 h. The mixture was acidified with aqueous 2M HCl and evaporated to give 
the acids 3.47 and 3.48 as a mixture of epimers (17:3 by 1H NMR), which was used 
without further purification~ 1H NMR (CDCh, d6-DMSO), a 3.47 (from the mixture) 
1.88 (3H, d, J 7.4, CHCH3), 2.46 (2H, m, AsnCH2), 2.91 (2H, m, CHCH2Ph or 
CH2CN4), 3.06 (2H, m, CHCH2Ph or CH2CN4), 4.33 (1H, m, AsnCH), 4.44 (IH, m, 
CHCH2Ph), 5.02 (2H, s, CbzCH2), 5.37 (IH, m, CHMe), 7.22-7.34 (10H, m, ArH), o 
3.48 (from the mixture) 1.81 (d, J 11.3, CHCH3). The mixture of acids was reacted 
with tert-butylamine (2 equiv) in dichloromethane according to general coupling 
method B to give a crude mixture of the amides 3.49 and 3.50. A mixture of 
unreacted acids 3.47 and 3.48 (6 mg, 43%) was extracted into the aqueous layer, by 
the NaHC03 wash during the workup, and later acidified with solid sodium bisulphite 
and reextracted with ethyl acetate (3 x 5 cm3). Purification of the crude products by 
flash chromatography, eluting with ethyl acetate-methanol (1 :0 to 9:1) gave a mixture 
(3:2 by 1H NMR) of the amides 3.49 and 3.50 (2 mg, 16%), which were not separated~ 
(Found: MH+ 579.3040. C29H39NsOs requires mlz 579.3043); 1H NMR (CDCh, d6-
DMSO), a 3.49 (from the mixture) 1.27 (9H, s, C(CHJ)3), 1.87 (3H, d, J 6.8, CHCH3), 
2.49 (2H, m, AsnCH2), 2.88-3.06 (4H, m, CHCH2Ph & CH2CN4), 4.32 (IH, m, 
AsnCH), 4.37-4.49 (IH, m, CHCH2Ph), 5.03 (2H, m, CbzCH2), 5.21 (IH, q, J 1.4, 
CHMe), 6.22 (lH, br s, NH), 6.84 (IH, d, J7.3, NH), 7.18-7.34 (IOH, m, ArH), 7.87 
(1H, d, J 7.8, NH), a 3.50 (from the mixture) 1.31 (s, C(CH3)3), 1.78 (d, J 6.4, 
CHCH3), 5.14 (q, J6.8, CHMe), 7.94 (d, J7.8, NH); 13C NMR (CDCh, d6-DMSO), o 
17.52 (CI:IA4e), 27.27 (CH2CN4), 28.03 (CMe3). 36.65 (AsnCH2), 39.25 (CHCH2Ph), 
48.46 (CHCH2Ph), 51.35 (AsnCH), 51.68 (CMe3), 57.32 (CHMe), 66.97 (CbzCH2), 
126.70, 126.81, 127.82, 128.04, 128.31, 128.47, 128.58, 128.92 & 128.97 (ArCH), 
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134.45 & 136.74 (ArC); reverse phase HPLC on a C1s analytical column [55 % 
methanol-45% water(0.1% TFA)] showed two peaks with retention times of24:13 
min and 25:41 min. 
(1 'S,2''S) and (1 'R,2''S)-1-[1-(1,1-dimethylethylaminocarbonyl)ethyl)-5-{3-
phenyi-2-[N-(N-quinolinyl-2-carbonyl-L-asparaginyl)amino]propyl}-1H-tetrazole 
3.53 and 3.54 
Phu-N II 
,N 
3.45 ---1J1o- QC-L-Asn-N N 0 ---~J~o-H )-- /~ Me~··-r 
OBzl 
3.51 
Phu-N I I 
,N 
• QC-L-Asn-~ Nkf0 + 
H # Me~ 
NHlBu 
3.53 
PhuN - ~~ 
,N 
QC-L-Asn-N N O 
H ~L /~ Me"~\ 
OH 
3.52 
Phu-N II 
,N 
QC-L-Asn-~ NL /p 
H Me' ~Hi:Bu 
3.54 
The amine hydrobromide 3.45 (218 mg, 0.49 mmol) was reacted with N-(2-
quinolinylcarbonyl)-L-asparagine119 (1.1 equiv) in dichloromethane (3 cm3) and DMF 
( 40 IJ.L) according to the general coupling method B. Purification by flash 
chromatography, eluting with ethyl acetate-petroleum ether (1: 1 to 1 :0) gave the 
amide 3.51 as an oil (186 mg, 60%); (Found: MH+ 635.2713. C3~3sNsOs requires mlz 
635.2730); [cx.]0 20 +12° (c 0.027 in MeOH); 1H NMR, o 1.88 (3H, d, J7.3, CHCH3), 
2.71 & 2.83-3.08 (6H, m, AsnCH2 & CHCH2Ph & CH2CN4), 4.52 (lH, m, 
CHCH2Ph), 4.96 (1H, m, AsnCH), 5.14 (2H, m, BzlCH2), 5.17 (IH, q, J7.3, CHMe), 
5.83 (1H, br s, NH), 6.26 (IH, br s, NH), 7.00-7.11 (5H, m, ArH), 7.23-7.34 (5H, m, 
ArH), 7.59 (1H, t, QCH), 7.73 (IH, t, QCH), 7.82 (1H, d, QCH), 8.12 (2H, m, QCH), 
8.22 (1H, d, QCH), 9.20 (1H, d, J 8.3, AsnNH); 13C NMR, o 16.39 (CHMe), 26.98 
(CH2CN4), 37.49 (AsnCH2), 39.87 (CHCl-hPh), 49.20 (CHCH2Ph), 50.28 (AsnCH), 
55.70 (CHMe), 68.32 (BzlCH2), 118.54, 126.76, 127.57, 128.32, 128.56, 128.68, 
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128.74, 129.19, 129.84 & 130.28 (ArCH), 134.50, 136.88 & 137.54 (ArC), 146.34 & 
148.21 (QC), 153.27 (CN4), 165.00, 168.00, 170.78 & 173.61 (CO). 
The benzyl ester 3.51 (60 mg, 0.095 mmol) was hydrogenated by the general 
method to give the acid 3.52 (41 mg, 79%); (Found: MH+ 545.2265. C27H29N80 5 
requires mlz 545.2260); 1H NMR, 8 1.91 (3H, d, J 7.3, CHCH3), 2.62-2.86 (2H, m, 
AsnCH2), 3.10 (4H, m, CH2Ph & CH2CN4), 4.60 (IH, m, CHCH2Ph), 4.92 (1H, m, 
AsnCH), 5.18 (lH, q, J 7.3, CHMe), 6.03 (1H, br s, NH), 6.28 (lH, br s, NH), 7.03 
(1H, d, J7.4, NH), 7.08-7.23 (SH, m, ArH), 7.65 (1H, t, QCH), 7.80 (1H, t, QCH), 
7.88 (lH, d, QCH), 8.17 (2H, m, QCH), 8.32 (lH, d, QCH), 9.17 (1H, d, J 8.3, 
AsnNH); 13C NMR (CDCh, d6-DMSO), 8 16.18 (CHMe), 26.62 (CH2CN4), 36.92 
(AsnCH2), 38.96 (CH2Ph), 49.05 (CHCH2Ph), 49.65 (AsnCH), 55.36 (CHMe), 
118.28, 126.19, 127.31, 127.77, 128.07, 128.79, 128.87, 129.43 & 129.83 (ArCH), 
136.77 & 137.06 (ArC), 146.05 & 148.55 (QC), 152.70 (CN4), 164.06, 170.07, 
170.22 & 172.81 (CO). 
The acid 3.52 (29 mg, 0.053 mmol) was reacted with tert-butylarnine (1.5 
equiv) in dichloromethane according to general coupling method B. Purification by 
flash chromatography eluting with ethyl acetate-methanol (1 :0 to 9: 1) gave an epimeric 
mixture (8 mg, 25%, 1:1 by 1H NMR) of the arnides 3.53 and 3.54. The epimers were 
separated by reverse phase HPLC on a C1s analytical column eluting with 55% 
rnethanol-45% water(0.1% TFA). The amide 3.53 eluted first; peak retention time 
18:48rnin; (Found: MNa+ 622.2875. C31H37N904Na requires mlz 622.2866); [a]0 20 
+22° (c 0.011 in MeOH); 1H NMR (CDCh, TFA), 8 1.31 (9H, s, C(CH3) 3), 1.92 (3H, 
d, J 7.3, CHCH3), 2.76-3.04 (4H, m, CH2CN4 & AsnCH2), 3.15 (2H, d, J 6.4, 
CH2Ph), 4.48 (1H, m, CHCH2Ph), 4.92 (1H, m, AsnCH), 5.09 (1H, q, J 7.3, CHMe), 
6.24 (2H, br s, AsnNH2), 6.44 (lH, br s, NH), 6.97-7.15 (3H, m, ArH), 7.13 (2H, m, 
ArH), 7.34 (1H, d, J 7.8, NH), 7.68 (1H, t, QCH), 7.82 (1H, t, QCH), 7.92 (1H, d, 
QCH), 8.19 (2H, m, QCH), 8.37 (1H, d, QCH), 9.23 (1H, d, J 8.3, AsnNH); 13C 
NMR (CDCh, CD30D), 8 17.85 (CHMe), 27.56 (CH2CN4), 28.14 (CMe3), 39.25 
(AsnCH2 & CH2Ph), 48.73 (CHCH2Ph), 49.88 (AsnCH), 51.66 (CMe3), 57.54 
(CHMe), 118.53, 126.58, 127.66, 128.25, 128.40, 128.98, 129.62 & 130.30 (ArCH), 
136.66 & 137.60 (ArC). The amide 3.54 eluted second; peak retention time 20:40min; 
(Found: MNa+ 622.2875. C31H37N904Na requires mlz 622.2866); [a.]0 20 +14° (c 0.017 
Experimental cis-Hydroxyethylamine Isostere 175 
in MeOH)~ 1H NMR (CDCh, CD30D, TFA), o 1.34 (9H, s, C(CH3)3), 1.74 (3H, d, J 
7.3, CHCH3), 2.73 (2H, m, AsnCH2), 2.91-3.13 (4H, m, CH2CN4 & CH2Ph), 4.50 
(1H, m, CHCHzPh), 4.90 (IH, m, AsnCH), 5.02 (1H, q, J 6.8, CHMe), 7.10-7.20 (SH, 
m, ArH), 7.33 {lH, d, J7.8, NH), 7.66 (1H, t, QCH), 7.81 (1H, t, QCH), 7.91 (IH, d, 
QCH), 8.12 (1H, d, QCH), 8.17 (lH, d, QCH), 8.34 (1H, d, QCH); 13C NMR (CDCh, 
CD30D, TFA), 8 17.56 (CHMe), 27.59 (C'HzCN4), 28.09 (CMe3), 37.41 (AsnCH2), 
38.84 (CHzPh), 49.29 (C'HCHzPh), 49.82 {AsnCH), 51.75 (CMe3), 57.22 (C'HMe), 
118.45, 126.74, 127.60, 128.21, 128.53, 128.89, 129.51 & 130.27 (ArCH), 136.65 & 
137.56 (ArC), 146.37 & 148.39 (QC), 165.69 & 166.86 (CO). Unreacted acid was 
extracted into the aqueous layer by the NaHC03 wash during the workup. The 
aqueous washings were acidified with solid sodium bisulphite, extracted with ethyl 
acetate (3 x 5 cm3), dried and evaporated to give 3.52 (18 mg, 62%). 
(1 'S,2'S,l ''S)- and (1 'R,2'S,l ''S)-5-(1-Acetoxy-2-amino-3-phenylpropyl)-1-(1-
benzyloxycarbonylethyl)-lH-tetrazole hydrobromide 3.55 and 3.56 
Ph;_;N N-
'' 
BrH.H2N N"N O 
OAc )..._ /) Me'"~·\ 
OBzl 
3.55 
,, Phu-N
,.N 
BrH.H2N = N O 
OAc ~L /; Me~··\ 
OBzl 
3.56 
The tetrazole 3.42 (25 mg, 0.045 mmol) was reacted with 50% HBr in acetic 
acid, according to the general method, to give the amine hydrobromide 3.55 (17 mg, 
84%); 1H NMR (CD30D), o 1.89 (3H, d, J 7.4, CHCH3), 2.04 (3H, s, COCH3), 3.03 
(2H, m, CHCH2), 4.30 (1H, m, CHCH2), 5.16 (2H, s, BzlCH2), 5.65 (IH, q, J 7.3, 
CHMe), 6.28 (lH, d, J 4.4, CHOAc), 7.17-7.38 (IOH, m, ArH). By an identical 
procedure, a mixture (3:2 by 1H NMR) of the tetrazoles 3.42 and 3.44 (45 mg, 0.080 
mmol) was reacted with 50% HBr in acetic acid to give a mixture (3 :2 by 1H NMR) of 
the amine hydrobromides 3.55 and 3.56 (31 mg, 89%); (Found: MH+ 424.1991. 
C22H26Ns04 requires mlz 424.1984); 1H NMR (CD30D), o 3.56 (from the mixture) 
1.93 (3H, d, J7.3, CHCH3), 2.16 (3H, s, COCH3), 2.95 (2H, m, CHCH2), 4.08 {lH, 
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m, CHCH2), 5.07 & 5.13 {2H, ABq, J 12.2, BzlCH2), 5.71 {1H, q, J 7.3, CHMe), 5.89 
{lH, d, J 4.4, CHOAc), 7.17-7.38 {lOH, m, ArH). 
(1 'S,2 'S,1''S)-, (1 'R,2 'S,1 ''S)-, (1 'S,2 'S,1 ''R)-, and (1 'R,2 'S,1 ''R)-5-{1-Acetoxy-3-
phenyi-2-[N-(N-q uinolinyl-2-carbonyl-L-asparaginyl)amino] propyl}-1-[ 1-(1,1-
dimethylethylaminocarbonyl)ethyl]-lH-tetrazole 3.61, 3.62, 3.63 and 3.64 
N- ,, ,, Ph)y(N
,.N 
3.55/3.56 _...,. QC-L-Asn-~ N O + 
H OAc ~~ 
PhuN-
,.N 
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A mixture {31 mg, 0.071 mmol, 3:2 by 1H NMR) of 3.55 and 3.56 was reacted 
with QC-L-Asn (1.3 equiv) and BOP {1.3 equiv) in dichloromethane {5 cm3)-DMF 
{0.05 cm3) for 2 d, according to the general coupling method B. The crude product 
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(36 mg) contained a mixture of 3.57 and 3.58 (3 :2 by 1H NMR) and was used without 
further purification; 1H NMR, o 3.57 (from the mixture) 1.93 (3H, s, COCH3), 1.92 
(3H, d, J 1.3, CHCH3), 2.68-3.18 (4H, m, CHCH2Ph & AsnCH2), 4.59 (lH, m, 
CHCH2Ph), 4.86 (1H, m, AsnCH), 5.11 (2H, m, BzlCH2), 5.80 (1H, m, CHMe), 6.36 
(1H, d, J 5.4, CHOAc), 6.60 (1H, d, J7.8, NH), 7.02-7.36 (IOH, m, ArH), 7.57-8.27 
(6H, m, QCH), 9.07 (lH, d, J 8.3, AsnNH); o 3.58 (from the mixture) 1.83 (3H, s, 
COCH3), 1.98 (3H, d,J7.3, CHCH3), 2.68-3.18 (4H, m, CHCH2Ph& AsnCH2), 4.59 
(IH, m, CHCH2Ph), 4.86 (1H, m, AsnCH), 5.11 (2H, m, BzlCH2), 5.80 (1H, m, 
CHMe), 6.12 (1H, d, J 6.3, CHOAc), 6.79 (1H, d, J 7.8, NH), 7.02-7.36 (lOH, m, 
ArH), 7.57-8.27 (6H, m, QCH), 9.17 (1H, d, J 7.8, AsnNH). The crude mixture of 
benzyl esters 3.57 and 3.58 (36 mg) was hydrogenated by the general method to give a 
mixture of the acids 3.59 and 3.60 (15 mg, 3:2 by 1H NMR); 1H NMR, o 1.84-2.00 
(6H, m, COCH3 & CHCH3), 2.66-3.22 (4H, m, CH2Ph & AsnCH2), 4.70-4.98 
(CHCH2Ph & AsnCH), 5.50, 5.67 (lH, q, J1.3, CHMe), 6.31 (lH, d, J 4.4, CHOAc), 
6.82-8.30 (11H, m, ArH), 9.12 & 9.23 (lH, d, J 8.3, AsnNH). The mixture of acids 
3.59 and 3.60 (15 mg, 0.025 mmol) was reacted with tert-butylamine (5 equiv), BOP 
(1.9 equiv) and triethylamine (1.5 equiv) in DMF (0.5 cm3) according to general 
coupling method B to give a crude mixture of 3.61, 3.62, 3.63 and 3.64 (1: 1.5:1.2:1.5 
by 1H NMR). Purification by flash chromatography eluting with ethyl acetate-
methanol (1:0 to 9: 1) gave fractions containing varying mixtures of the four 
diastereoisomers 3.61-3.64 (4 mg, 24%); (Found: MH+ 658.3104. C33H4oN906 
requires mlz 658.3101); 1H NMR, o 3.61 (from the mixtures) 1.29 (9H, s, C(CH3) 3), 
2.16 (3H, s, COCH3), 1.97 (3H, d, J 1.3, CHCH3), 2.40-2.66, 2.75-2.99, 3.12-3.23 
(4H, m, CH2Ph & AsnCH2), 4.57-4.68 (lH, m, CHCH2Ph), 4.82-4.92 (1H, m, 
AsnCH), 5.42 (1H, q, J7.3, CHMe), 6.32 (1H, d, J 5.4, CHOAc), 7.01-7.38 (5H, m, 
ArH), 7.65, 7.80, 7.90, 8.08-8.23 & 8.32 (6H, m, QCH), 9.09 (1H, d, J7.3, AsnNH); 
1H NMR, o 3.62 (from the mixtures) 1.33 (9H, s, C(CH3)3), 2.10 (3H, s, COCH3), 
2.06 (3H, d, J 7.8, CHCH3), 2.40-2.66, 2.75-2.99, 3.12-3.23 (4H, m, CH2Ph & 
AsnCH2), 4.57-4.68 (IH, m, CHCH2Ph), 4.82-4.92 (1H, m, AsnCH), 5.58 (IH, q, J 
7.3, CHMe), 6.24 (IH, d, J 5.4, CHOAc), 7.01-7.38 (5H, m, ArH), 7.65, 7.80, 7.90, 
8.08-8.23 & 8.32 (6H, m, QCH), 9.19 (1H, d, J7.8, AsnNH); 1H NMR, o 3.63 (from 
the mixtures) 1.35 (9H, s, C(CH3)3), 2.05 (3H, s, COCH3), 1.82 (3H, d, J 6.8, 
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CHCH3), 2.40-2.66, 2.75-2.99, 3.12-3.23 (4H, m, CH2Ph & AsnCH2), 4.57-4.68 (1H, 
m, CHCH2Ph), 4.82-4.92 (1H, m, AsnCH), 5.27 (1H, q, J7.3, CHMe), 6.22 (1H, d, J 
4.4, CHOAc), 7.01-7.38 (5H, m, ArH), 7.65, 7.80, 7.90, 8.08-8.23 & 8.32 (6H, m, 
QCH), 9.27 (1H, d, J7.3, AsnNH); 1H NMR, o 3.64 (from the mixtures) 1.32 (9H, s, 
C(CH3)3), 2.13 (3H, s, COCH3), 1.85 (3H, d, J 6.9, CHCH3), 2.40-2.66, 2.75-2.99, 
3.12-3.23 (4H, m, CH2Ph & AsnCH2), 4.57-4.68 (1H, m, CHCH2Ph), 4.82-4.92 (1H, 
m, AsnCH), 5.34 (1H, q, J 6.8, CHMe), 6.18 (1H, d, J 5.9, CHOAc), 7.01-7.38 (SH, 
m, ArH), 7.65, 7.80, 7.90, 8.08-8.23 & 8.32 (6H, m, QCH), 8.96 (1H, d, J 8.3, 
AsnNH); reverse phase HPLC on aCts analytical column [55% methanol-45% water 
(0.1% TFA)] showed four peaks with retention times of20:46 min, 24:31 min, 28:46 
min and 30:46 min. A mixture of the unreacted acids was extracted into the aqueous 
layer, by the NaHC03 wash, during the workup. The aqueous washings were acidified 
with solid sodium bisulphite, extracted with ethyl acetate (3 x 5 cm3), dried and 
evaporated to give a mixture of the unreacted acids 3.59 and 3.60 (1 0 mg, 1: 1 by 1H 
NMR, 67%). 
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(J 'S,2 'S,l ''S)- and ( 1 'R,2 'S,l ''S)-5-[2-(N-Benzyloxycarbonylamino )-1-hydroxy-3-
phenylpropyl]-1-(1-methoxycarbonylethyi)-JH-tetrazole 3.65 and 3.66 
Ph)y(N N- ,,
Cbz"~ N"N 0 
H OAc §~ Me~ 
Bzl 
3.42 
+ 
Phu-N ,, 
,.N 
Cbz"N = N 0 
H 0Ac ~ I - kf Me~ 
OBzl 
3.44 
N ,, Ph)y(N N-
Cbz-~ N"' O + 
H OH ,:.~ 
PhuN-
,N 
Cbz-N = N O ~ OH §'L /~ 
Me'~ 
Me 
3.65 
Ph)y(N N- ,,
,N 
Cbz-~ N 0 H OH )-_ /; Me'"~·\ 
OH 
3.67 
Me~··\ 
3.66 
PhuN - ,, 
OMe 
.,N 
+ Cbz-N - N 
1 = hfo H OH 'b" Me~ 
OH 
3.68 
A mixture (24 mg, 0.040 mmol, 4:1 by 1H NMR) of the tetrazoles 3.44 and 
3.42 was dissolved in methanol-water (0.4 cm3 of a 9:1 mixture) with potassium 
carbonate (1.2 mg, 0.009 mmol) and stirred at rt for 30 min. The mixture was 
acidified with aqueous 2M HCI and evaporated. Purification by flash chromatography, 
eluting with ethyl acetate-petroleum ether (3 :2), gave two fractions. The first fraction 
contained a mixture (7:3 by 1H NMR) of the methyl esters 3.66 and 3.65 (7 mg, 40%, 
see separation and data below). The second fraction contained a mixture (3: I by 1H 
NMR) of the free acids 3.68 and 3.67 (5 mg, 29%); 1H NMR (d6-DMSO), o 3.68 
(from the mixture) 1.75 (3H, d, J 7.0, CHCHs), 2.65-2.85 (2H, m, CHCH2), 4.17 (lH, 
m, CHCH2), 4.80 & 4.90 (2H, ABq, J 12.5, CbzCH2), 5.03 (IH, d, J 4.5, CHOH), 
5.37 (IH, m, CHMe), 7.01 (IH, d, J9.0, NH), 7.12-7.25 (IOH, m, ArH), o 3.67 (from 
the mixture) 1.66 (3H, d, J 7.5, CHCHs), 4.98 (lH, d, J 6.0, CHOH); 13C NMR (d6-
DMSO), o 16.24, 16.35 (CHCH3), 35.14, 36.02 (CHCH2), 55.00, 55.87 (CHMe), 
57.70, 58.06 (CHCH2), 64.37, 64.43 (CbzCH2), 65.14 (CHOH), 125.10, 125.23, 
126.42, 126.47, 126.69, 127.18, 127.30, 127.39, 128.38 & 128.48 (ArCH), 137.88 & 
137.95 (ArC), 154.39 & 155.22 (CN4 & CbzCO), 170.96 & 171.35 (CO); mlz (FAB), 
426 (MH\ 8), 448 (MNa+, 4). 
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In a similar hydrolysis procedure, a mixture (121 mg, 0.22 mmol, 17:3 by 1H 
NMR) of the tetrazoles 3.42 and 3.44 was dissolved in methanol-water (5 cm3 of a 8:2 
mixture), with potassium hydroxide (2.2 mg, 0.04 mmol), and stirred at rt for 18 h. 
The mixture was acidified with aqueous 2M HCl and evaporated. Purification on a 
1mm chromatatron plate, eluting with a gradient of petroleum ether-ethyl acetate-
methanol (3:2:0 to 0:7:3), gave two fractions. The first fraction contained a mixture 
(7:3 by 1H NMR) of the methyl esters 3.65 and 3.66 (19 mg, 20%). The second 
fraction contained a mixture (1:1 by 1H NMR) of the free acids 3.67 and 3.68 (55 mg, 
59%). 
The methyl esters 3.65 and 3.66 were separated by reverse phase HPLC on a 
C18 analytical column, elutingwith40% methanol-60% water(0.1% TFA). The methyl 
ester 3.66 eluted first; peak retention time 39:46 min; (Found: M+ 439.1858. 
C22H25N50s requires mlz 439.1855); 1H NMR, o 1.88 (3H, d, J 7.4, CHCH3), 3.15 
(2H, m, CHCH2), 3.72 (3H, s, OCH3), 4.29 (1H, m, CHCH2), 4.97 & 5.04 (2H, ABq, 
J 12.4, CbzCH2), 5.10 (1H, d, J3.9, CHOH), 5.45 (1H, d, J7.8, NH), 5.69 (IH, q, J 
7.3, CHMe), 7.17-7.31 (lOH, m, ArH); 13C NMR, o 17.05 (CHCH3), 35.98 (CHCH2), 
53.16 (OMe), 56.88 (CliMe & CHCH2), 67.13 (CbzCH2), 68.04 (CHOH), 126.80, 
127.77, 128.17, 128.47, 128.64 & 129.16 (ArCH), 135.83 & 137.30 (ArC), 154.72 
(CN4), 157.31 (CbzCO), 169.19 (CO). The methyl ester 3.65 eluted second; peak 
retention time 41:31 min; [Found: (M-CH.tOt 407.1594. C21H21Ns04 requires mlz 
407.1593]; 1H NMR, o 1.92 (3H, d, J 1.4, CHCH3), 3.09-3.18 (2H, m, CHCH2), 3.70 
(3H, s, OCH3), 4.25 (1H, m, CHCH2), 4.97 & 5.04 (2H, ABq, J 12.2, CbzCH2), 5.09 
(IH, d, J 4.4, CHOH), 5.30 (IH, d, J8.3, NH), 5.63 (1H, q, J7.3, CHMe), 7.13-7.30 
(IOH, m, ArH); 13C NMR, o 16.37 (CHCH3), 36.52 (CHCH2), 53.35 (OMe), 56.62 
(CliMe & CHCH2), 67.02 (CbzCH2), 67.10 (CHOH), 126.73, 127.71, 128.44, 
128.58, 129.04 & 129.14 (ArCH), 135.83 & 136.94 (ArC), 154.08 (CN4), 157.28 
(CbzCO), 169.20 (CO). 
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5-[(2S)-2-(N-Benzyloxycarbonylamino )-3-phenylpropanoyl]-1-[(lS)-1-
methoxycarbonylethyl]-lH-tetrazole 3. 70 
Ph~N N-
' \ Cbz-~ N~··,N 0 
H 0 ~ Me~ 
Me 
3.70 
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A mixture of3.65 and 3.66 (2.7 mg, 0.007 mmol, 1:1 by 1HNMR) and ness-
Martin periodinane108 (14 mg, 0.035 mmol) was dissolved in dichloromethane (3 cm3) 
and stirred at rt for 18 h. To the cloudy solution was added a solution of Na2S20 3 
(0.049 mmol) in saturated aqueous NaHC03 (2 em\ and the mixture was stirred at rt 
for 10 min. The mixture was washed with saturated aqueous NaHC03 (2 cm3), water 
(2 em\ dried and evaporated to give 3.70 as a colourless oil; (Found: ~ 437.1701. 
C22H23Ns0s requires mlz 437.1699); 1H NMR, o 1.98 (3H, d, J 7.3, CHCH3), 3.21 
(lH, dd, J 13.9 & 7.6, CHCHAPh), 3.45 (1H, dd, J 14.2 & 4.0, CHCHsPh), 3.75 (3H, 
s, OMe), 5.04 (2H, s, CbzCH2), 5.33 (1H, d, J 6.8, NH), 5.59 (IH, m, CHCH2), 5.79 
(1H, q, J7.3, CHMe), 7.10 (2H, m, ArH), 7.24-7.37 (8H, m, ArH); 13C NMR, o 16.19 
(CHMe), 37.39 (CHCH2), 53.39 (OMe), 58.31 (CHMe), 59.83 (CHCH2), 67.26 
(CbzCH2), 127.43, 128.03, 128.29, 128.54, 128.80 & 129.36 (ArCH), 164.79 (CO). 
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(1 'S,1 "S,2 ''S)-, (1 'S,1 "R,2 "S)-, (1 'R,1 ''S,2 "S)-, and (1 'R,1 ''R,2 ''S)-1-[1-(1,1-
dimethylethylaminocarbonyl)ethyl]-5-{1-hydroxy-3-phenyi-2-[N-(N-quinolinyl-2-
carbonyi-L-asparaginyl)amino]propyl}-1H-tetrazole 2.20, 2.19, 3. 71 and 3. 72 
Ph),ylt N N- ,,
3 N 
QCL-Asn-~ 2 N~" 6 0 
H OH ~ Me~ 
2•20 1 HiBu 
Ph~N N- ,, 
,N 
QC..L-Asn-N N O R OH L/~ 
Me'\ 
3•71 NHiBu 
PhuN -
N QC-L-Asn-~ § N" O 
H OH 1Fl_ /~ Me~··\ 
2•19 NHiBu 
PhuN - ,, 
QC..L-Asn-N - N"N 
R OH >-to 
Me 
3.72 HiBu 
A mixture of the acetates 3.61-3.64 (4.0 mg, 0.006 mmol) and potassium 
carbonate (1.7 mg, 0.012 mmol) were dissolved in methanol-water (0.5 cm3 of a 9:1 
mixture), stirred at rt for 18 h and evaporated. The residue was dissolved in ethyl 
acetate, washed with water, dried and evaporated to give a mixture of the hydroxy 
compounds 2.20, 2.19, 3.71 and 3.72 (3.5 mg, 1:2.8:1.3:2.8 by mass, 95%); (Found: 
Mir 616.2995. C31H3sN90s requires mlz 616.2995). The four diastereoisomers were 
separated by reverse phase HPLC on a C1s analytical column, eluting with 1: 1 
methanol-water(0.1% TFA); peak retention times 2.20 14:19 min (0.39 mg), 3.71 
16:53 min (0.51 mg), 2.19 20:11 min (1.11 mg), 3.72 26:14 min (1.11 mg); 1H NMR 
data is shown in table E.l. 
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Table E.1: 1H NMR (solvent CDCh, 2 drops CD30D) spectroscopic data for 2.19, 
2.20, 3. 71, 3. 72 
Resonance 2.20 [6 m ( J)] 2.19 3.71 3.72 
C(Me)3 1.30 s 1.31 s 1.29 s 1.32 s 
7-H3 1.93 d (7.3) 1.95 d (7.3) 1.80 d (6.8) 1.79 d (6.9) 
AsnCH2 2.44 & 2.70 dd 2.68 m 2.52 & 2.66 dd 2.75 m 
CH2Ph 2.89 & 3.09 dd 2.83 & 3.15 dd 2.97 & 3.12 dd 2.93 & 3.19 dd 
2-H 4.65 m 4.62m 4.61 m 4.58m 
AsnCH 4.77 m 4.81 m 4.83 m 4.84m 
3-H 5.12 d (5.3) 5.09 d (5.9) 5.04 d (5.9) 5.00 d (5.4) 
6-H 5.52 q (6.8) 5.55 q (7.3) 5.42 q (7.3) 5.49 q (6.8) 
ArH 7.09-7.15, m 6.87 t 1H, 7.00 7.09-7.13, m 7.01 t 1H, 7.10 t 
t 2H, 7.15 d 2H 2H, 7.17 d 2H 
QCH 7.67 t, 7.81 t, 7.68 t, 7.82 t, 7.68 t, 7.81 t, 7.67 t, 7.82 t, 
7.93 d, 7.94 d, 7.93 d, 7.93 d, 
8.17 m 2H, 8.15 m 2H, 8.17 m 2H, 8.14m 2H, 
8.37 d 8.38 d 8.38 d 8.36 d 
General procedure 
Experimental 
Mycalamide Analogues 
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Mps were taken using a Reichert hot-stage microscope and are uncorrected. 
Optical rotations were measured on a JASCO J-20C recording spectropolarimeter and 
[a]n values are given in units of 10-1 deg cm2 g-1, with the concentration given in units 
of g cm-3. IR spectra were recorded on a Shimadzu FTIR-8201PC spectrophotometer. 
1H and 13C NMR spectra were recorded on either a Varian CFT300 or XT300 
spectrometer. Samples were run in CDCh solution, with Me4Si as an internal 
standard, unless otherwise stated. Mass spectra were obtained using a Kratos 
MS80RF A spectrometer. Radial chromatography was performed on a Chromatatron 
(Harrison and Harrison) using Merck type 60 PF254 silica gel. Compounds 5.15, 
5.20, 5.23, 5.28 and 5.40 were commercially available. 
Preparation of methyl benzimidate 5.12 
Ph 
H~OMe 
5.12 
A solution of benzonitrile (15.0 cm3, 0.15 mmol) in dry methanol (20.0 cm3, 
0.49 mmol) was saturated with dry hydrogen chloride gas at 4 °C and the solution was 
stirred for 18 hat 4 °C. Aqueous 5% Na2C03 solution (200 cm3) was added and the 
mixture was extracted with dichloromethane (3 x 200 cm3). The combined organic 
extracts were dried and evaporated to give134 5.12 (21.950 g, quant) as a pale yellow 
liquid which was not purified further; 1H NMR (CDCh), o 3.92 (3H, s, OMe), 5.26 
(IH, s, NH), 7.36-7.44 (5H, m, ArH). 
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Preparation of (S)-2-acetoxy-3-phenylpropanoic acid 5.16 
OAc 
Ph~OH 
0 
5.16 
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To a solution of (S)-3-phenyllactic acid 5.15 (106 mg, 0.64 mmol) in dry 
pyridine (1 cm3) was added acetic anhydride (0.12 cm3, 1.27mmol) and the mixture 
was stirred at rt for 18 h. Water (2 cm3) was added and the solution was extracted 
with chloroform (3 x 5 cm3), dried and evaporated to give 5.16 (quant) as a yellow oil 
which was not purified further. 1H NMR data as previously reported. 149 1H NMR 
(CDCh), o 2.09 (3H, s, Me), 3.14 (1H, dd, J 14.2 & 9.3, CHAPh), 3.28 (1H, dd, J 14.2 
& 3.9, CH8Ph), 5.27 (1H, dd, J9.3 & 3.9, CHO), 7.29 (5H, m, ArH). 
Preparation of compounds based on 5.5 
5.5 
The general methods A and B detailed below gave essentially pure ( 1 ')-epimeric 
mixtures of analogues that were unstable to silica. However, for purposes of 
biological testing, rapid silica-based radial chromatography of the mixtures, where 
specified, gave samples of the separate isomers in low yield. 
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General Method A for the preparation of compounds based on 5.5 
5.16 R1 = OAc 
5.23 Rt NH-Cbz 
5.28 Rt NH-L-Ala-Cbz 
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Compound 5.16, 5.23 or 5.28 (typically 0.60 mmol), 1-hydroxybenzotriazole 
(1 equiv) and 1.5 equivalents of 5.12, (or the hydrochloride salt of 5.20 and 1.5 
equivalents of triethylamine) were dissolved in dichloromethane (2.5 cm3) at 0 °C and 
the mixture was stirred for 10 min. Dicyclohexylcarbodiimide (DCC, 1 equiv) was 
added and the mixture stirred for a further 10 min at 0 oc and finally at rt for 18 h. 
The reaction mixture was diluted with dichloromethane (5 cm3), filtered and 
evaporated to give a residue containing the methyl N-acylimidate intermediate, which 
was reacted without further purification. The residue was redissolved in dry isopropyl 
alcohol (5 cm3), sodium borohydride (15 equiv) was added and the suspension was 
stirred at 0 oc for 2 h. Brine (5 cm3) was added and the mixture extracted with ethyl 
acetate (3 x 5 cm3). The combined organic extracts were washed with water (5 em\ 
dried and evaporated to give 5.18/5.19, 5.2115.22, 5.24/5.25 or 5.29/5.30 as mixtures. 
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(1 ~,2S)~ and (1 'R,2S)-2-Hydroxy-N-(1-methoxybenzyl)-3-phenylpropanamide 
5.18 and 5.19 
5.18 5.19 
The acid 5.16, prepared from 5.15 (96 mg, 0.58 mmol) as previously described, 
was reacted with 5.12 according to the general method A to give a mixture of 5.18 and 
5.19 (54 mg, 33%, 1:1 by 1H NMR). Purification on a 1 mm silica chromatatron plate 
eluting with diethyl ether-dichloromethane (1 :9 to 1 :0) gave 5.18 (6 mg). Further 
elution gave a second fraction (7 mg) containing a mixture of 5.18 and 5.19 (3 :2 by 1R 
NMR). The final fraction gave 5.19 (9 mg) (see below for data). 
Compounds 5.18 and 5.19 were also prepared by hydrolyzing separate samples 
of5.35 (3.7 mg, 0.011 mmol) and 5.36 (4.7 mg, 0.014 mmol) in methanol-water (2.5 
cm3 of a 9:1 mixture) with potassium carbonate (0.2 equiv) at rt for 2 h. The mixtures 
were evaporated and redissolved in dichloromethane (0.5 cm3). The organic solutions 
were washed with water (0.5 cm3), dried and evaporated to give white crystalline 
solids 5.18 (3.5 mg) and 5.19 (3.6 mg). 5.18 [Found: (M - Met, 270.1125. 
C1JI16N03 requires mlz 270.1130]~ mp 104-105 oc; [a]n23 -92 (c 0.038 in CH2Ch); IR 
/cm·1 3406, 1684, 1504, 1497, 1092; 1H NMR, 6 2.61 (1H, d, J 4.9, OR), 2.96 (1H, 
dd, J 14.0 & 8.5, CH2Ph), 3.27 (1R, dd, J 14.0 & 4.2, CHzPh), 3.37 (3R, s, OMe), 
4.32 (1H, m, CHCH2), 6.10 (1H, d, J 9.3, NCH), 7.00 (1H, d, J 9.8, NH), 7.30-7.38 
(lOR, m, ArR); 13C NMR, 6 40.82 (CR2Ph), 55.88 (OMe), 72.85 (CHOH), 81.16 
(NCH), 125.79, 127.10, 128.56, 128.58, 128.78 & 129.55 (ArCH), 136.48 & 139.93 
(ArCR), 172.82 (CONH); mlz (EI) 270 (M+- Me, 15%), 253 (M+- MeOH, 22), 121 
(99), 106 (100). 5.19 [Found: (M - Met, 270.1128. C16R16N03 requires mlz 
270.1130]; mp 66-68 °C; (a]0 23 -17 (c 0.036 in CH2Ch); IR /cm·1 3406, 1684, 1504, 
1497, 1090; 1H NMR, 6 2.96 (1H, dd, J 13.8 & 8.1, CH2Ph), 3.27 (1R, dd, J 13.9 & 
4.1, CH2Ph), 3.47 (3H, s, OMe), 4.45 (lR, dd, J 8.3 & 3.9, CHCH2), 6.12 (1R, d, J 
9.3, NCH), 7.01 (lH, d, J9.3, NH), 7.31 (lOR, m, ArH); 13C NMR, 6 40.59 (CR2Ph), 
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56.09 (OMe), 72.66 (CHOH), 81.07 (NCH), 125.82, 127.09, 128.49, 128.54, 128.78 
& 129.61 (ArCH), 136.34 & 138.76 (ArCR), 172.85 (CONH); mlz (EI) 270 (M+- Me, 
7), 253 (~ -MeOH, 17), 121 (77), 106(100). 
(1 'S,2S)- and (1 'R,2S)-2-Hydroxy-N-(1-methoxyethyl)-3-phenylpropanamide 5.21 
and 5.22. 
5.21 5.22 
The acid 5.16, prepared from 5.15 (100 mg, 0.60 mmol) as previously described, 
was reacted with 5.20 according to the general method A to give a mixture of 5.21 and 
5.22 (55 mg, 42%, 1:1 by 1H NMR). Purification on a preparative silica column 
eluting with methanol-water (92:5) gave three fractions. The first fraction (11 mg) 
contained a mixture of5.22 and 5.21 (1:1 by 1H NMR). The second fraction (6 mg) 
contained a mixture of 5.22 and 5.21 (3:2 by 1H NMR); 1H NMR, o 5.21 (from the 
mixture) 1.30 (3H, d, J 5.8, CHMe), 2.94 (IH, m, CH2Ph), 3.28 (1H, m, CH2Ph), 3.24 
(3H, s, OMe), 4.36 (IH, m, CHCH2), 5.26 (1H, m, NCH), 7.00 (1H, d, NH), 7.28 
(5H, m, ArH). The final fraction gave 5.22 as an oil (1 mg); [Found: (M - Me)\ 
208.0966. C11H14N03 requires mlz 208.0973]; 1H NMR, o 1.26 (3H, d, J 5.8, CHMe), 
2.90 (lH, dd, J 9.6 & 8.3, CH2Ph), 3.24 (1H, m, CH2Ph), 3.30 (3H, s, OMe), 4.41 
(1H, dd, J 8.3 & 3.4, CHCH2), 5.25 (1H, dd, J 9.7 & 5.8, NCH), 7.03 (1H, d, J 9.8, 
NH), 7.25 (5H, m, ArH); mlz (EI) 208 (~-Me, 2), 205 (~- H20, 6), 191 (~­
MeOH, 80), 91 (100). 
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(1 'S,2S)- and (1 'R,2S)-2-(N-Benzyloxycarbonylamino)-N-(1-methoxybenzyl)-3-
phenylpropanamide 5.24 and 5.25 
Phf H 
Cbz-~~NYPh 
H 0 O ... Me 
5.24 5.25 
The acid 5.23 (203 mg, 0.68 mmol) was reacted with 5.12 according to the 
general method A to give a crude mixture of 5.24 and 5.25. Purification on a 2 mm 
silica chromatatron plate eluting with ethyl acetate gave two fractions. The first 
fraction (118 mg) contained a mixture of 5.24, 5.25 and dicyclohexylurea ( 1: 1: 1 by 1H 
NMR). The second fraction gave N~Cbz-L-phenylalaninamide150 5.26 (73 mg, 3 7%) as 
a white solid which was used to prepare 5.51 and 5.52 by general method B~ 1H NMR, 
o 5.26 3.10 (2H, m, CHCH2), 4.45 (lH, m, CHCH2), 5.08 (2H, s, CbzCH2), 5.45 (1H, 
br d, NHCbz), 5.53 (IH, br s, NH), 5.88 (1H, br s, NH), 7.20-7.35 (10H, m, ArH). 
Fraction one was further purified on a 1 mm chromatatron plate eluting with ethyl 
acetate-pentane (1 :20 to 1:3) to give two fractions. The first fraction (37 mg) 
contained a mixture of 5.24 and 5.25 (7:3 by 1H NMR); [Found: (M- Met, 403.1667. 
C2Jl23N20 4 requires mlz 403.1658]; mp 151-157 °C; 1H NMR (CDCh, ds-pyridine), o 
5.24 (from the mixture) 3.15 (2H, d, J 6.8, CHCH2), 3.32 (3H, s, OMe), 4.60 (1H, m, 
CHCH2), 5.04 (2H, s, CbzCH2), 6.09 (1H, d, J 9.3, NCHO), 7.14-7.31 (ISH, m, 
ArH); 13C NMR (CDCh, ds-pyridine), o 5.24 (from the mixture) 38.33 (CHCH2), 
55.67 (OMe), 56.21 (CHCH2), 66.70 (CbzCH2), 81.37 (NCHO), 125.68, 126.73, 
127.74, 127.90, 128.11, 128.18, 128.26, 128.38 & 129.19 (ArCH), 136.09 & 138.76 
(ArCR), 155.85 (CbzCO), 171.48 (CONH); mlz (EI) 403 (M+- Me, 32), 386 (~­
MeOH, 100). The second fraction (22 mg) was rechromatagraphed on a 1 mm 
chromatatron plate eluting with ethyl acetate-petroleum ether (1 :4) to give three 
further fractions. The first fraction (2 mg) contained a mixture of 5.24 and 5.25 ( 1: 1 
by 1H NMR). The second fraction (3 mg) contained a mixture of 5.25 and 5.24 (17:3 
by 1H NMR). The final fraction (2 mg) contained 5.25~ (Found: M+, 418.1884. 
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C2sH26N204 requires mlz 418.1893); mp 151-153 oc; 1H NMR (CDCh, d5-pyridine), o 
3.08 (2H, d, J 6.8, CHCH2), 3.40 (3H, s, OMe), 4.53 (lH, m, CHCH2), 5.07 (2H, s, 
CbzCH2), 6.07 (1H, d, 19.7, NCHO), 7.10-7.31 (ISH, m, ArH), 7.45 (lH, d, J9.3, 
NH); 13C NMR (CDCb, ds-pyridine), o 38.56 (CHCH2), 55.79 (OMe), 56.44 
(CHCH2), 66.81 (CbzCH2), 81.29 (NCHO), 125.73, 126.77, 127.82, 127.99, 128.14, 
128.25, 128.36, 128.49, 129.20 & 129.27 (ArCH), 136.15 & 138.73 (ArCR), 155.85 
(CbzCO), 171.37 (CONH); mlz (EI) 418 {M', 5), 403 (M+- Me), 386 {M'- MeOH, 
100). 
(1 'S,2S)- and (1 'R,2S)-2-[N-(N-Benzyloxycarbonyi-L-alaninyl)amino]-N-(1-
methoxybenzyl)-3-phenylpropanamide 5.29 and 5.30 
Ph)yH 
N Ph Cbz-L-Aia-~ '( 
H o o ... Me 
5.29 
Ph~H ! N Ph Cbz-L-Aia-~ Y 
H o o ... Me 
5.30 
The acid 5.28 (50 mg, 0.13 mmol) was reacted with 5.12 according to the 
general method A to give a mixture of 5.29 and 5.30 (36 mg, 54%, 1: 1 by 1H NMR) 
which was loaded onto a 1 mm chromatatron plate and eluted with ethyl acetate-
petroleum ether (1:3 to 3:1) to give three fractions. The first fraction (9 mg) contained 
5.30; [Found: (M- MeOHt, 457.1993. C27H27N30 4 requires mlz 457.2001]; 1H NMR, 
5 1.20 (3H, d, J 6.8, CHMe), 3.11 (2H, d, J 6.8, CHCH2), 3.30 (3H, s, OMe), 4.24 
(1H, m, CHMe), 4.76 (lH, m, CHCH2), 4.92 (2H, m, CbzCH2), 5.50 (IH, d, J 6.3, 
AlaNH), 6.02 (lH, d, J 9.3, NCHO), 7.06-7.30 (ISH, m, ArH); 13C NMR, o 18.07 
(CHMe), 37.71 (CHCH2), 50.96 (CHMe), 54.25 (CHCH2), 55.83 (OMe), 67.11 
(CbzCH2), 81.61 (NCHO), 125.85, 125.91, 126.91, 126.99, 128.07, 128.31, 128.49, 
128.61 & 129.26 (ArCH), 136.08 & 138.54 (ArCR), 171.05 & 172.28 (CO); rn/z (EI) 
457 (~- MeOH, 2), 352 (4), 91 (100). The second fraction (11 mg) gave a mixture 
of 5.29 and 5.30 (1: 1 by 1H NMR); for comparison with the 5.30 data above, 1H 
NMR, 8 5.29 (from the mixture) 1.24 (3H, d, J 7.3, CHMe), 3.04 (2H, d, J 3.6, 
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CHCH2), 3.31 (3H, s, OMe), 4.36 (lH, m, CliMe), 4.83 (lH, m, CHCH2), 5.00 (2H, 
m, CbzCH2), 5.73 (lH, d, J7.3, AlaNH), 5.96 (lH, d, J9.3, NCHO), 7.06-7.30 (ISH, 
m, ArH). Crystallisation of the second fraction from CDCh gave 5.29; [Found: (M -
MeOHt, 457.2005. C21H21N304 requires mlz 457.2002]; 1H NMR (CDCh, d6-
DMSO), o 1.23 (3H, d, J 7.3, CHMe), 3.01 (lH, m, CHCH2), 3.15 (1H, m, CHCH2), 
3.39 (3H, s, OMe), 4.12 (lH, m, CliMe), 4.71 (1H, m, CHCH2), 5.05 (2H, m, 
CbzCH2), 6.04 (IH, d, J9.3, NCHO), 6.86 (IH, d, J7.3, AlaNH), 7.17-7.34 (ISH, m, 
ArH), 7.72 (IH, d, J9.3, PheNH), 8.23 (1H, d, J9.3, CONH); 13C NMR (CDCh, d6-
DMSO), 5 17.16 (CHMe), 36.63 (CHCH2), 49.87 (CHMe), 53.32 (CHCH2), 54.47 
(OMe), 65.30 (CbzCH2), 80.17 (NCHO), 125.08, 125.42, 127.01, 127.14, 127.35 & 
128.36 (ArCH), 136.06 & 138.19 (ArCR), 170.60, 171.58 (CO). The final fraction 
gave more 5.29 (10 mg). 
Preparation136 of (S)-3-phenyllactamide 5.27 
5.27 
Concentrated sulphuric acid (52 J.IL, 0.98 mmol) was added with stirring to 
(S)-3-phenyllactic acid 5.15 (155 mg, 0.94 mmol), dissolved in dry acetone (0.7 cm3) 
at -10 °C. An ice cold solution of sodium carbonate (200 mg, 1.88 mmol) in water 
(2.2 cm3) was added slowly and the reaction mixture evaporated to dryness under 
reduced pressure. Liquid ammonia ( 5 cm3) was added to the residue and the solution 
was stirred at rt for 18 h. The mixture was evaporated and partitioned between 
chloroform and water. The aqueous layer was extracted with chloroform (3 x 5 cm3) 
and ethyl acetate (3 x 5 cm3). The combined organic extracts were dried and 
evaporated to give 5.27 as a white solid (97 mg, 63%), (Found: MH+, 166.0867. 
C9H12N02 requires mlz 166.0868); mp 111-112 oc (literature151 mp 109-112 °C); 
[a]n23 -71 (c 0.050 in CH2Ch); 1H NMR, o 2.74 (1H, d, J 3.9, OH), 2.91 (1H, dd, J 
13.7 & 8.8, CH2), 3.24 (lH, dd, J 14.0 & 4.2, CH2), 4.32 (1H, m, CH), 5.64 (IH, br s, 
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NH), 6.44 (1H, br s, NH), 7.25-7.37 (5H, m, ArH); 13C NMR, o 40.78 (CH2), 72.77 
(CH), 127.10, 128.81 & 129.51 (ArCH), 136.71 (ArCR), 175.47 (CO); mlz (EI) 166 
(MH+, 1), 147 (M"- H20, 82), 91 (100). 
Preparation137 of methyl 1-chlorobenzyl ether 5.34 
ClyPh 
OMe 
5.34 
A mixture of freshly distilled benzaldehyde (5.0 cm3, 49.30 mmol), dry 
methanol (2.0 cm3, 49.30 mmol) and anhydrous sodium sulphate (4.8 g) in ethyl 
chloride (6 em\ at -60 °C, was saturated with dry gaseous hydrogen chloride and left 
to stand at that temperature for 1 h. The excess hydrogen chloride gas was removed 
by flushing the solution with dry nitrogen gas for 15 min and the mixture was stored at 
-10 oc over anhydrous CaS04. Analysis by 1H NMR, by comparing the integrals of 
the aldehyde CHO resonance with the characteristic new CHCI resonance, indicated 
that the solution contained a mixture of the a.-chloro ether 5.34 and benzaldehyde 
(17:3), with some ethyl chloride present; 1H NMR, o 3.69 (3H, s, OMe), 6.47 (lH, s, 
CHCl), 7.32-7.41 (3H, m, ArH), 7.50 (2H, m, ArH). 
General Method137 for the preparation of the a.-chloro ethers 5.37-5.39 
ClyR 
OMe 
5.37 R Et 
5.38 R=Me 
5.39 R = iPr 
Dry gaseous hydrogen chloride was bubbled through a solution of the aldehyde 
(propanal, ethanal or 2-methylpropanal, typically 0.179 mol) and dry methanol (7.25 
cm
3
, 0.179 mol) at -30 °C for 1 h. The excess HCI gas was removed by flushing the 
solution with dry nitrogen gas for 15 min to give mixtures of 5.37-5.39 and the 
corresponding aldehydes, which could be stored at -10 °C over anhydrous CaS04. 
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The products were analyzed by 1H NMR, by comparing the integrals of the aldehyde 
CHO resonance with the characteristic new CHCl resonance of the a-chloro ether. 
1-chloropropyl methyl ether 5.37 
Reaction with propanal gave a mixture of 5.37 and propanal (17:3 by 1H 
NMR); 1HNMR, o 5.37 (from the mixture) 1.04 (3H, t, J7.6, CH2CH3), 2.02 (2H, m, 
CH2CH3), 3.53 (3H, s, OMe), 5,46 (1H, t, J 5.4, CHCl). 
1-chloroethyl methyl ether 5.38. 
Reaction with ethanal gave a mixture of 5.38 and ethanal (17:3 by 1H NMR); 
1H NMR data as previously reported 152; 1H NMR, o 5.38 (from the mixture) 1. 78 (3H, 
d, J 5.4, CHCH3), 3.51 (3H, s, OMe), 5.63 (lH, q, J 5.3, CHCl). 
1-chloro-2-methylpropyl methyl ether 5.39 
Reaction with 2-methylpropanal gave a mixture of 5.39 and 2-methylpropanal 
(9: 1 by 1H NMR); 1H NMR, o 5.39 (from the mixture) 1.02 (3H, d, J 1.4 Hz, 
CHCH3), 1.05 (3H, d, J 1.5 Hz, CHCH3), 2.14 (1H, m, CHMe2), 3.52 (3H, s, OMe), 
5.36 (IH, d, J3.9 Hz, CHCI). 
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General Method B for the preparation of analogues based on 5.5 
5.33 R1 = (S)-OAc 
5.42 R1 = (R)-OAc 
CIYR2 
OMe 
5.34 R2 =Ph 
5.37 R2 Et 
5.38 R2 =Me 
5.39 ~ iPr 
5.26 R1 = (S)-NH-Cbz 
5.59 R1 = (S)-OCOPhBr 
5.62 R1 (S)-Ocamphanyl 
R1 H 
Ph~NYR2 
o o'Me 
+ 
R1 H Ph~NYR2 
o o ... Me 
194 
Triethylamine (25 equiv) and either 5.34, 5.37, 5.38 or 5.39 (25 equiv, see 
preparation above) were added to 5.33, 5.42, 5.26, 5.59 or 5.62 (typically 0.3 mmol), 
dissolved in dry dichloromethane (2.5 cm3) at 0 °C. The mixture was allowed to warm 
to rt and then stirring was continued at 5 oc for 18 h. The reaction mixture was 
washed with water, dried and evaporated to give 5.35/5.36, 5.43/5.44, 5.47 /5.48, 
5.51/5.52, 5.60/5.61 or 5.63/5.64 as (1 ')-epimeric mixtures. 
(1 'S,2S)- and (1 'R,2S)-2-Acetoxy-N-(1-methoxybenzyl)-3-phenylpropanamide 
5.35 and 5.36 
OAc H OAc H 
: I 
Ph~NyPh 
0 O,Me 
: I 
Ph~NYPh 
o o ... Me 
5.35 5.36 
The amide 5.27 (87 mg, 0.53 mmol) was acetylated with acetic anhydride (0.15 
cm
3
, 1.59 mmol) in pyridine (3 cm3) to give 5.33153 as a yellow oil (quant), which was 
not purified further; 1H NMR, o 2.07 (3H, s, Ac), 3.19 (2H, m, CH2), 5.39 (1H, m, 
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CH), 6.09 (1H, br s, NH), 6.17 (IH, br s, NH), 7.18-7.35 (SH, m, ArH). The amide 
5.33 (0.53 mmol) was reacted with 5.34 according to the general method B to give a 
crude mixture (296 mg) of 5.35 and 5.36 and benzaldehyde. Purification on a 2 mm 
silica chromatatron plate eluting with ethyl acetate-petroleum ether (I: 1) gave a 
mixture of5.35 and 5.36 (144 mg, 83%, 1:1 by 1H NMR). Further purification on a 1 
mm silica chromatatron plate eluting with ethyl acetate-petroleum ether (1 :20 to 1:1) 
gave three fractions. The first fraction (21 mg) contained a mixture of 5.36 and 5.35 
(9: 1 by 1H NMR). Recrystallization from ethyl acetate-petroleum ether gave 5.36 (6 
mg); [Found: (M- Mef, 312.1233. C18H18N04 requires mlz 312.1236]; mp 122-125 
oc; [a.]0 23 +89 (c 0.053 in CH2Ch); IR /cm·1 3419, 1747, 1693, 1506, 1454, 1373, 
1220; 1H NMR, 8 2.07 (3H, s, Ac), 3.21 (2H, dd, J 5.6 & 2.2, CH2Ph), 3.41 (3H, s, 
OMe), 5.49 (lH, m, CHCH2), 6.11 (lH, d, J 9.8, NCH), 6.46 (IH, d, J 9.7, NH), 
7.12-7.30 (10H, m, ArH); 13C NMR, 8 20.85 (Ac), 37.49 (CH2Ph), 56.12 (OMe) 
74.17 (CHCH2), 80.82 (NCH), 125.71, 126.94, 128.31, 128.35, 128.40 & 129.66 
(ArCH), 135.87 & 138.57 (ArCR), 149.71 (AcCO), 169.32 (CONH); mlz (EI) 312 
~-Me, 8), 296 (M+- OMe, 15), 237 (50), 106 (100). The second fraction (56 mg) 
contained a mixture of 5.35 and 5.36 (7:3 by 1H NMR). The final fraction (28 mg) 
contained a mixture of 5.35 and 5.36 (9: 1 by 1H NMR). Recrystallization from ethyl 
acetate-petroleum ether gave 5.35 (5 mg); [Found: (M - Mef, 312.1234. CtsHlsN04 
requires mlz 312. 1236]; mp 110-112 oc; [a]0 23 -25 (c 0.053 in CH2Ch); IR/cm·1 3419, 
1747, 1693, 1506, 1454, 1373, 1220; 1H NMR, 8 2.04 (3H, s, Ac), 3.22 (2H, m, 
CH2Ph), 3.33 (3H, s, OMe), 5.36 (1H, m, CHCH2), 6.10 (1H, d, J 9.2, NCH), 6.77 
(IH, d, NH), 7.17-7.33 (10H, m, ArH); 13C NMR, 8 20.72 (Ac), 37.48 (CH2Ph), 
55.88 (OMe), 74.50 (CHCH2), 80.97 (NCH), 123.62, 125.61, 126.91, 128.28, 128.36, 
129.54 (ArCH), 135.86, 138.87 (ArCR), 149.64 (AcCO), 169.32 (CONH); mlz (EI) 
312 (M+- Me, 1%), 296 (M+- OMe, 8), 252 (84), 121 (100). 
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Preparation of (R)-3-phenyllactamide 5.41 
5.41 
Prepared from (R)-3-phenyllactic acid 5.40 (174 mg, 1.04 mmol), as for 5.27, 
to give 5.41 as fine white crystals (133 mg, 77%); mp 111-112 °C (literature151 mp 
109-112 °C); [a.]0 23 +63 (c 0.050 in CH2Ch); NMR data identical to enantiomer 5.27. 
(1 '.R,2R)- and (1 ~,2R)-2-Acetoxy-N-(1-methoxybenzyl)-3-phenylpropanamide 
5.43 and 5.44 
5.43 5.44 
The amide 5.41 (40 mg, 0.24 mmol) was acetylated with acetic anhydride (69 
flL, 0. 73 mmol) in pyridine (3 cm3) to give 5.42 as a yellow oil ( quant ), which was not 
purified further; 1H NMR identical to enantiomer 5.33. The amide 5.42 (0.24 mmol) 
was reacted with 5.34 according to the general method B to give a mixture (3 3 mg, 
41%) of5.43 and 5.44 (1:1 by 1H NMR). Purification on a 1 nun silica chromatatron 
plate eluting with ethyl acetate-petroleum ether (2:25 to 1 :3) gave four fractions. The 
first fraction (2 mg) contained a mixture of 5.44 and 5.43 (9: 1 by 1H NMR). The 
second fraction (5 mg) contained a mixture of 5.44 and 5.43 (7:3 by 1H NMR). 
Recrystallization from ethyl acetate-petroleum ether gave 5.44 (3 mg); [Found: (M+ -
Me), 312.1233. Ct8H18N04 requires mlz 312.1236]; mp 129-131 °C; [a.]0 23 -37 (c 
0.023 in CHzCh); NMR data identical to enantiomer 5.36; mlz (EI) 312 (M+ - Me, 
0.2), 296 ~- OMe, 2), 252 (47), 121 (100). The third fraction (5 mg) contained a 
mixture of 5.43 and 5.44 (8:2 by 1H NMR). Recrystallization from ethyl acetate-
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petroleum ether gave 5.43 (1 mg); [Found: (M - Me f, 312.1234. C1sH1sN04 requires 
mlz 312.1236t mp 111-113 °C; [a]0 23 +24 (c 0.007 in CH2Cb); NMR data identical to 
enantiomer 5.35; mlz (EI) 312 (M+- Me, 0.1), 296 (~- OMe, 2), 252 (43), 121 
(100). The final fraction (2 mg) contained 5.43. 
(1 'R,2R)~ and (1 S,2R)-2-Hydroxy-N-(1-methoxybenzyl)-3-phenylpropanamide 
5.45 and 5.46 
5.45 5.46 
The acetates 5.43 (1.3 mg, 0.004 mmol) and 5.44 (2.3 mg, 0.007 mmol) were 
hydrolyzed (as described for 5.35 and 5.36 in the preparation of 5.18 and 5.19) to give 
5.45 (0.7 mg, 60%) and 5.46 (1.7 mg, 84%), respectively. 5.45 [Found: (M- Mef, 
270.1128. C16H16N03 requires mlz 270.1130]; mp 99-101 oc; [a]0 23 +76 (c 0.004 in 
CH2Cb); NMR data identical to enantiomer 5.18; mlz (EI) 270 (M+ - Me, 29), 253 (M+ 
- MeOH, 33), 162 (39), 121 (100). 5.46 [Found: (M- Mef, 270.1134. C16H16N03 
requires mlz 270.1130]; mp 62-64 oc; [a]0 23 +21 (c 0.009 in CH2Ch); NMR data 
identical to enantiomer 5.19; mlz (EI) 270 (~-Me, 47), 253 ~- MeOH, 43), 162 
(49), 121 (100). 
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(1 S,2S)- and (1 'R,2S)-2-Acetoxy-N-(1-methoxypropyl)-3-phenylpropanamide 
5.47 and 5.48 
5.47 5.48 
The amide 5.33 (0.25 mmol), prepared as described in the preparation of 5.35 
and 5.36, was reacted with 5.37 according to the general method B to give a mixture 
of 5.47 and 5.48 (49 mg, 70%). Purification on a 1 mm silica chromatatron plate 
eluting with ethyl acetate-petroleum ether (1 :5 to 1 :3) gave a mixture (12 mg) of 5.47 
and 5.48 (1:1 by 1H NMR) which were unable to be separated; 1H NMR, 5.47/5.48 o 
0.78/0.83 (3H, t, CH2CH3), 1.42/1.57 (2H, m, CH2Me), 2.09/2.11 (3H, s, Ac), 
3.14/3.24 (3H, s, OMe), 3.15-3.22 (2H, m, CH2Ph), 4.99 (1H, m, NCH), 5.35/5.40 
(lH, m, CHCO), 6.10 (lH, br m, NH), 7.17-7.31 (5H, m, ArH); 13C NMR, 5.47/5.48 
8 8.78 (CH2Me), 20.67/20.85 (Ac), 28.28/28.53 (C'H2Me), 37.46/37.56 (CH2Ph), 
55.76/55.90 (OMe), 74.29/74.44 (C'HCO), 82.27 (NCH), 126.97, 128.36, 128.39, 
129.58 & 129.62 (ArCH), 135.57 & 135.66 (ArCR), 169.26 & 169.42 (CO). 
(1 S,2S)- and (1 'R,2S)- 2-Hydroxy-N-(1-methoxypropyl)-3-phenylpropanamide 
5.49 and 5.50 
5.49 5.50 
The mixture of 5.47 and 5.48 prepared by the general method B above (12 mg of 
a 1:1 mixture by 1H NMR) was hydrolyzed in methanol and water (2.5 cm3 of a 9:1 
mixture) with potassium carbonate (0.2 equiv) at rt for 2 h. The mixture was 
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evaporated and redissolved in dichloromethane (2 cm3). The organic solution was 
washed with water (2 cm3), dried and evaporated to give an oil (11 mg, 92%) which 
was chromatographed on a 1 mm silica chromatatron plate eluting with ethyl acetate-
petroleum ether (3: 1 0) to give two fractions. The first fraction gave 5.49 as an oil (1 
mg); [Found: (M- Mef, 222.1125. C12Ht6N03 requires mlz 222.1130]; [ct]n23 + 104 (c 
0.002 in CH2Ch); IR /cm"1 3400, 2972, 1680, 1301, 1085; 1H NMR (CDCh, d5-
pyridine), o 0.91 (3H, t, J 7.3, CH2CH3), 1.57 (1H, m, CH2Me), 1.65 (1H, m, 
CH2Me), 2.95 (1H, dd, J 13.7 & 8.3, CH2Ph), 3.22 (3H, s, OMe), 3.28 (lH, m, 
CH2Ph), 4.38 (1H, dd, J 8.3 & 3.9, CHCO), 5.03 (lH, m, NCH), 6.98 (1H, d, J 9.3, 
NH), 7.21-7.30 (5H, m, ArH); 13C NMR (CDCh, ds-pyridine), o 8.96 (CH2Me), 28.55 
(CH2Me), 41.05 (CH2Ph), 55.56 (OMe), 72.70 (CHCO), 81.82 (NCH), 126.66, 
128.45 & 129.65 {ArCH), 137.52 (ArCR); mlz (EI) 222 (M+ - Me, 2), 208 ~ -
C2H5, 13), 205 (~-MeOH, 64), 91 (63), 73 (100). The second fraction gave 5.50 as 
an oil (1 mg); [Found: (M - Mef, 222.1085. C12Ht6N03 requires mlz 222.1130]; 
[a]n23 +423 (c 0.002 in CH2Ch); IR /cm-1 3400, 2972, 1680, 1301, 1085; 1H NMR 
(CDCh, ds-pyridine), 6 0.84 (3H, t, J 7.3, CH2CH3), 1.48 (1H, m, CH2Me), 1.65 (1H, 
m, CH2Me), 2.91 (1H, dd, J 13.7 & 8.3, CH2Ph), 3.28 (lH, dd, J 13.7 & 3.4, CH2Ph), 
3.31 (3H, s, OMe), 4.46 (1H, dd, J8.3 & 3.4, CHCO), 5.03 (lH, m, NCH), 6.95 (1H, 
br s, NH), 7.18-7.33 (5H, m, ArH); 13C NMR (CDCb, ds-pyridine), o 8.78 (CHMe), 
28.20 (CH2Me), 40.93 (CH2Ph), 55.54 (OMe), 72.30 (CHCO), 81.70 (NCH), 126.22, 
128.07 & 129.58 (ArCH), 137.88 (ArCR), 174.25 (CONH); mlz {EI) 222 (~-Me, 
1), 208 (M+- C2Hs, 4), 205 (M+- MeOH, 27), 91 (36), 73 (100). 
Experimental Mycalamide Analogues 200 
(1 'S,2S)- and (1 'R,2S)-2-(N-Benzyloxycarbonylamino)-N-(1-methoxyethyl)-3-
phenylpropanamide 5.51 and 5.52 
5.51 5.52 
The amide 5.26 ( 61 mg, 0. 21 mmol) was reacted with 5.38 according to the 
general method B to give a mixture of 5.51 and 5.52 (38 mg, 52%, 1:1 by 1H NMR). 
Purification on a 1 mm silica chromatatron plate eluting with ethyl acetate-petroleum 
ether (1 :5 to 1 : 1) gave three fractions. The first fraction (18 mg) gave 5.52 as a solid; 
[Found: (M- OMet, 324.1474. C1~20N203 requires mlz 324.1474]; mp 136-138 oc; 
[a]n23 -10 (c 0.007 in CH2C}z); IR /em·• 3416, 3034, 1757, 1713, 1690, 1497; 1H 
NMR (CDCh, ds-pyridine), 5 1.12 (3H, d, J 5.8, CHMe), 3.08 (2H, d, J7.4, CHCH2), 
3.24 (3H, s, OMe), 4.47 (1H, m, CHCH2), 5.08 (2H, s, CbzCH2), 5.18 (lH, m, 
NCHO), 6.24 (1H, d, J1.4, CbzNH), 7.11-7.36 (lOH, m, ArH); 13C NMR (CDCh, d5-
pyridine), 6 20.87 (CHMe), 38.44 (CHCH2), 55.14 (OMe), 56.28 (CHCH2), 66.53 
(CbzCH2), 77.51 (NCHO), 126.63, 127.62, 127.79, 128.18, 128.28 & 129.05 (ArC), 
171.12 (CO); mlz (EI) 324 (M"- OMe, 2), 282 (M"- C3H1NO, 1), 91 (100). The 
second fraction (10 mg) contained a mixture of 5.52 and 5.51 (3:2 by 1H NMR). The 
final fraction gave 5.51 (19 mg) (<10% 5.52 by 1H NMR); [Found: (M - OMe)+, 
324.1474. C19H2oN20 3 requires mlz 324.1474]; mp 158-160 oc; [a]n23 +3 (c 0.020 in 
CH2Ch); IR /cm·1 3416, 3034, 1757, 1713, 1690, 1499; 1H NMR (CDCh, d5-
pyridine), 5 1.23 (3H, d, J 6.8, CHMe), 3.06 (2H, d, J 6.8, CHCH2), 3.12 (3H, s, 
OMe), 4.55 (1H, m, CHCH2), 5.06 (2H, s, CbzCH2), 5.20 (1H, m, NCHO), 6.24 (1H, 
d, J 7.8, CbzNH), 7.16-7.30 (IOH, m, ArH), 7.39 (IH, d, J 8.7, CONH); 13C NMR 
(CDCh, ds-pyridine), 5 20.99 (CHMe), 38.22 (CHCH2), 55.08 (OMe), 56.20 
(CHCH2), 66.55 (CbzCH2), 77.75 (NCO), 126.59, 127.62, 127.79, 128.17, 128.24 & 
129.05 (ArCH), 155.84 (CbzCO), 166.12 (CONH); mlz (EI) 324 (M+- OMe, 4), 282 
(~- C3H1NO, 1), 91 (100). 
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Reaction of the a-hydroxy primary amides 5.27 and 5.41 with the a.-chloro 
ethers 5.37 and 5.34 
5.53 
Amide 5.27 (9 mg, 0.06 mmol) was reacted directed with 3 equivalents of 5.37 
and 5 equivalents of triethylamine in dichloromethane (1 cm3) at rt for 18 h. The 
mixture was washed with water (2 cm3), dried and evaporated to give a crude residue, 
which was purified by silica-based flash chromatography. Elution with ethyl acetate-
dichloromethane (1 :20 to 1:0) gave four fractions. The first fraction contained an 
mixture of four epimers, identified by 1H NMR as having structure 5.53 (5 mg, 24%); 
1H NMR, () 0.75-0.93 (6H, 8 t, CH2Me), 1.36-1.70 (4H, m, CH2Me), 2.87-3.23 (2H, 
m, CH2Ph), 2.97, 3.04, 3.08, 3.12, 3.22, 3.24, 3.29 & 3.33 (6H total, 8 s, OMe), 4.10 
& 4.14 (Y:!H total, 2 t, J 5.3, OCHO), 4.24-4.37 (1 Y:!H, m, OCHO & CHCH2), 4.96-
5.01 (1H, m, NCH), 6.42, 6.52, 6.72 & 6.85 (1H total, 4 d, J9.3-9.6, NH), 7.19-7.32 
(5H, m, ArH). The second fraction contained 5.49 (2 mg, 18%). The third fraction 
contained a mixture of5.50 and 5.49 (3:1 by 1HNMR, 3 mg, 25%). The final fraction 
gave starting amide 5.27 (2 mg, 22%), which was formed by acid-catalyzed 
decomposition on silica. 
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Me,....o,,,,(Ph 
0 H 
Ph~~YPh 
o o'Me 
5.57 
202 
In a similar reaction, amide 5.41 was reacted with ether 5.34 according to the 
general method B to give an epimeric mixture of 5.54-5.57. The mixture was purified 
twice on a 1 mm silica chromatatron plate, eluting with ethyl acetate-dichloromethane 
(0 : 1 to 1 : 1) to give fractions containing varying mixtures of epimers A-D (181 mg, 
79%), corresponding in no particular order to 5.54-5.57, as the configurations were 
unable to be assigned. The most pure fractions of epimers A-D are described as 
follows. A pure fraction of epimer A eluted first ( 4 mg), 1H NMR (CDCb, d5-
pyridine), a 3.02 (1H, m, CH2Ph), 3.01 (3H, s, OCHOMe), 3.31 (3H, s, NCHOMe), 
3.34 (1H, dd, J 14.1 & 3.4, CH2Ph), 4.44 (1H, dd, J8.3 & 3.5, CHCH2), 5.02 (1H, s, 
OCHO), 6.12 (1H, d, J9.8, NCH), 7.10-7.46 (ISH, m, ArH)~ 13C NMR (CDCh, d5-
pyridine), a 38.77 (CH2Ph), 53.63 & 55.30 (OMe), 79.24 (CHCH2), 80.82 (NCH), 
104.76 (OCHO}, 125.55, 126.17, 126.31, 127.95, 128.00, 128.07, 128.62, 129.51 
(ArCH), 136.80, 136.97, 139.06 (ArCR}, 171.71 (CO). A fraction containing a 
mixture of epimer B, epimer A and epimer C eluted second (4:2: 1 by 1H NMR, 18 
mg}, 1H NMR (CDCh, d5-pyridine), 8 epimer B (from the mixture) 2.93 (3H, s, 
OCHOMe), 3.07 (IH, dd, J 13.7 & 7.4, CH2Ph), 3.25 (3H, s, NCHOMe), 3.21 (lH, 
dd, CH2Ph), 4.48 (IH, dd, J1.5 & 4.1, CHCH2), 5.25 (IH, s, OCHO), 6.04 (IH, d, J 
9.8, NCH), 7.08-7.33 (ISH, m, ArH). A fraction containing a mixture of epimer C, 
epimer D and epimer B eluted third (11 :6:1 by 1H NMR, 47 mg), 1H NMR (CDCh), a 
epimer C (from the mixture) 3.01 (IH, m, CH2Ph}, 3.22 (3H, s, OCHOMe), 3.27 (lH, 
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m, CH2Ph), 3.44 (3H, s, NCHOMe), 4.54 (lH, dd, J7.8 & 4.0, CHCH2), 5.18 (lH, s, 
OCHO), 6.11 (lH, d, J9.8, NCR), 6.90 (lH, d, NH), 7.16-7.39 (ISH, m, ArH). A 
pure fraction of epimer D eluted last (13 mg), 1H NMR, 8 3.05 (2H, m, CH2Ph), 3.08 
(3H, s, OCHOMe), 3.32 (3H, s, NCHOMe), 4.56 (lH, dd, J6.3 & 4.4, CHCH2), 5.44 
(lH, s, OCHO), 6.01 (lH, d, J 9.8, NCH), 6.89 (IH, d, J 9.7, NH), 7.05 (2H, m, 
ArH), 7.20-7.40 (13H, m, ArH); 13C NMR, o 39.19 (CH2Ph), 53.40 & 55.89 (OMe), 
76.33 (CHCH2), 80.76 (NCR), 103.21 (OCHO), 125.64, 126.56, 126.61, 128.22, 
128.35, 128.52, 129.10 & 129.91 (ArCH), 136.59, 137.08 & 138.67 (ArCR), 171.94 
(CO). 
Derivatization of Analogue 5.46 
OBn H 
Ph~NYPh 
0 O,Me 
5.58 
Compound 5.46 (8 mg, 0.03 mmol) was dissolved in dichloromethane (2 cm3), 
and triethylamine (7 JlL, 0. 06 mmol), benzoyl chloride ( 6 JlL, 0. 06 mmol) and 4-
dimethylaminopyridine (6 mg, 0.045 mmol) were added, and the mixture was stirred at 
rt for 18 h. The solution was washed with saturated aqueous NaHC03 (1 cm3), dried 
and evaporated to give crude benzoate 5.58, 1H NMR, o 3.36 (2H, m, CH2Ph), 3.42 
(3H, s, OMe), 5.75 (lH, t, J 5.9, CHCH2), 6.14 (1H, d, J 9.3, NCR), 6.50 (lH, d, J 
9.3, NH), 7.26 (lOH, m, ArH), 7.45 (lH, m, ArH), 7.58 (2H, m, ArH), 7.97 (2H, m, 
ArH). Attempts at recrystallization of crude 5.58, from diethyl ether-petroleum ether, 
gave crystals of benzoic acid/4-dimethylaminopyridine, suitable for X-ray 
crystallography (see chapter seven for discussion). 
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(1 'S,2S)- and (1 'R,2S)-2-(4-Bromobenzoyloxy)-N-(1-methoxy-2-methylpropyl)-3-
phenylpropanamide 5.60 and 5.61 
5.60 5.61 
To a solution of amide 5.27 (55 mg, 0.33 mmol) and 4-dimethylaminopyridine 
(61 mg, 0.50 mmol) in dichloromethane (2.5 cm3) was added triethylamine (92 JlL, 
0.66 mmol) and 4-bromobenzoyl chloride (81 mg, 0.57 mmol). After stirring the 
mixture at rt for 3 h the solvent was evaporated and benzene ( 5 cm3) was added. The 
organic layer was washed with 2M aqueous HCl (3 cm3), saturated aqueous NaHC03 
(3 cm3), water (3 cm3) and dried. Evaporation under reduced pressure gave 5.59 (117 
mg) which was used without further purification; 1H NMR (CDCh), o 3.31 (2H, m, 
CH2Ph), 5.60 (1H, m, CHO), 5.77 (1H, br s, NH), 6.00 (1H, br s, NH), 7.23-7.29 (SH, 
m, ArH), 7.59 (2H, m, ArH), 7.82 (2H, m, ArH). The amide 5.59 was reacted with 
5.39 according to the general method B to give a crude mixture of5.60 and 5.61 (150 
mg). Purification on a 1 mm silica chromatatron plate eluting with ethyl acetate-
petroleum ether (3: 50) gave a mixture of 5.60 and 5.61 (17 mg, 12% yield from 5.27, 
1: 1 by 1H NMR). The mixture was further purified on a 1 mm silica chromatatron 
plate eluting with ethyl acetate-petroleum ether (1 :50) to give four fractions. The first 
fraction (1 mg) gave 5.60 (<5% 5.61 by 1H NMR) as an oil; [Found: (M- MeOHt, 
403.0609 & 401.0635. C2oH2oN03Br requires mlz 403.0606 & 401.0627]; 1H NMR, o 
5.60 (from the mixture) 0.75 (3H, d, J 6.9, CHMe), 0.81 (3H, d, J 6.4, CHMe), 1.68 
(lH, m, CHMe2), 3.16 (3H, s, OMe), 3.34 (2H, m, CH2Ph), 4.83 (1H, dd, J 5.8 & 9.7, 
NCH), 5.60 (lH, t, J 5.9, CHCH2), 5.93 (lH, d, J9.3, NH), 7.22-7.28 (5H, m, ArH), 
7.62 (2H, m, ArH), 7.86 (2H, m, ArH); mlz (EI) 403 [M\81Br) - MeOH, 3], 401 
[M"'(79_sr) - MeOH, 4], 333 (9), 185 (95), 183 (100). The second fraction (7 mg) 
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contained a mixture of 5.60 and 5.61 (2: I by 1H NMR). The third fraction (6 mg) 
contained a mixture of 5.61 to 5.60 (2: I by 1H NMR). The final fraction (3 mg) 
contained a mixture of 5.61 to 5.60 (17:3 by 1H NMR); [Found: (M - MeOHt, 
403.0608 & 401.0633. C2oH20N03Br requires m!z 403.0606 & 401.0627]; 1H NMR, o 
5.61 (from the mixture) 0.76 (3H, d, J 6.9, CHMe), 0.79 (3H, d, J 6.4, CHMe), 1.68 
(IH, m, CHMe2), 3.22 (3H, s, OMe), 3.33 (2H, m, CH2Ph), 4.83 (IH, dd, J5.8 & 9.7, 
NCH), 5.64 (IH, t, J 5.9, CHCH2), 5.97 (lH, d, J9.3, NH), 7.22-7.27 (5H, m, ArH), 
7.62 (2H, m, ArH), 7.84 (2H, m, ArH); m!z (EI) 403 [~(81Br) - MeOH, 3], 401 
[~(~r)-MeOH, 3], 333 (8), 185 (87), 183 (85). 
(1 'S,2S)- and (1 'R,2S)-2-[(1S,4R)-Camphanyloxy]-N-(1-methoxybenzyl)-3-
phenylpropanamide 5.63 and 5.64 
jcamphanyl) 
<} H 
Ph = J\1 Ph ~y 
0 O,Me 
5.63 5.64 
A solution of(JS,4R)-camphanic acid (66 mg, 0.33 mmol) in thionyl chloride (5 
cm3) was refluxed for 2 h. Evaporation of the solvent under reduced pressure gave an 
oiL The oil was dissolved in dichloromethane (1 cm3) and the solution added to a 
stirred solution of 5.27 (24 mg, O.IS mmol), 4-dimethylaminopyridine (18 mg, 0.15 
mmol) and diisopropylethylamine (28 ~L, 0.16 mmol) in dichloromethane (1 cm3). 
After stirring for 18 h at rt the reaction mixture was washed with water (2 cm3) and 
dried. Evaporation under reduced pressure gave 5.62 (65 mg) which was used without 
further purification; 1H NMR (CDCh), o 0.71 (3H, s, camphanyl-Me), 0.96 (3H, s, 
camphanyl-Me), 0.98 (3H, s, camphanyl-Me), 5.57 (lH, m, CHCH2Ph), 6.11 (lH, br 
s, NH), 6.61 (lH, br s, NH). The amide 5.62, (65 mg, 0.19 mmol) was reacted with 
5.34 according to the general method B to give a mixture of 5.63 and 5.64 ( 44 mg, 
51%). Purification on a 1 mm silica chromatatron plate eluting with ethyl acetate-
petroleum ether (2:3) gave a mixture of 5.63 to 5.64 (26 mg) (1: 1 by 1H NMR). 
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Further purification on a 1 mm chromatatron plate eluting with ethyl acetate-petroleum 
ether (1:4 to 3:7) gave three fractions. The first fraction (14 mg) contained a mixture 
of 5.64 and 5.63 (3:2 by 1H NMR); [Found: (M - OMef, 434.1942. C27H31N06 
requires mlz 434.1968]; 1H NMR (CDCh, d5-pyridine), 8 5.64 (from the mixture) 0.71 
(3H, s, camphanyl-Me), 0.97 (3H, s, camphanyl-Me), 1.07 (3H, s, camphanyl-Me), 
1.65 (IH, m, CHzCHz), 1.90 (2H, m, CHzCHz), 2.33 (lH, m, CHzCHz), 3.16 (1H, dd, 
J 14.6 & 8.3, CH2Ph), 3.33 (lH, dd, J 14.6 & 4.6, CHzPh), 3.39 (3H, s, OMe), 5.52 
(lH, dd, J8.3 & 4.6, CHCH2), 6.10 (1H, d, J9.3, NCH), 7.19-7.37 (IOH, m, ArH); 
m/z (EI) 434 (~- OMe, 11), 329 (5), 273 (82), 131 (100). The second fraction {9 
mg) contained a mixture of 5.63 and 5.64 {7:3 by 1H NMR). Recrystallization from 
ethyl acetate-petroleum ether gave crystals of 5.63 suitable for X-ray crystallography. 
The final fraction (2 mg) gave 5.63 (<10% 5.64 by 1H NMR); [Found: (M- OMef, 
434.1974. Cz1H31N06 requires mlz 434.1968]; 1H NMR (CDCh, ds-pyridine), 8 0.76 
(3H, s, camphanyl-Me), 1.00 (3H, s, camphanyl-Me), 1.08 (3H, s, camphanyl-Me), 
1.60 (1H, m, CHzCHz), 1.76 (1H, m, CHzCH2), 1.87 (1H, m, CHzCHz), 2.26 (1H, m, 
CH2CH2), 3.17 (1H, dd, J 14.4 & 8.5, CH2Ph), 3.30 (lH, dd, J 14.2 & 5.4, CH2Ph), 
3.42 (3H, s, OMe), 5.41 (1H, dd, J 8.4 & 5.4, CHCHz), 6.11 (lH, d, J 9.3, NCH), 
7.17-7.32 (lOH, m, ArH), 7.99 (lH, d, J 9.3, NH); mlz (EI) 434 (M+ - OMe, 6), 330 
(7), 273 (70), 131 (1 00). 
A mixture (5 mg, 72%) of 5.64 and 5.63 (9: 1 by 1H NMR) was also prepared 
from a mixture (5mg, 0.015 mmol) of5.19 and 5.18 (9:1 by 1H NMR) by an identical 
procedure to the above preparation of camphanyl ester 5.62 from amide 5.27. 
X-ray Crystallographic Determination for Compound 5.63 
Cz1H:nN06, M = 465.53, crystal dimensions 0.7 x 0.2 x 0.08, Triclinic, a 
6.2953(13), b = 12.667(3), c = 15.522(3) A, a = 88.73(3), ~ = 86.45(3), y = 
85.19(3t, V = 1230.9(4) A3, spacegroup P1, Z = 2, F(OOO) 496, Deale 1.256 Mg/m3, 
f..!.(Cu-Ka) = 6.71 cm"1, absorption coefficient 0.722 mm·1, e range for data collection 
2.85 to 60.10, index ranges 0 :s; h :s; 7, -14 :s; k :s; 14, -17 :s; 1 :s; 17, minimum and 
maximum transmissions 0.8829 and 1.0000, data/restraints/parameters 4053 I 3 I 621, 
goodness of fit on F2 was 1.121, final R indices [I>2s(I)] R1 = 0.0282, wR2 0.0739, 
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R indices (all data) Rt = 0.0408, wR2 = 0.1017, largest difference peak and hold 0.146 
and -0.142eA-3. 
The unit cell parameters were obtained by least-squares refinement of the 
setting angles of 25 reflections with 106.4° s 29 s 114.7° from a Rigaku 
diffractometer. A unique data set was measured at 293(2)K within 29max 120.2° limit 
(co-29). Of the 4056 reflections obtained, 3665 were unique (R.mt 0.024) and were 
used in the full-matrix least-squares refinement154 after being corrected for absorption 
by using the psi-scan method. The intensities of 3 standard reflections, measured every 
150 reflections throughout the data collection, showed only 1.27% decay. The 
structure was solved by direct methods. 155 Hydrogen atoms were fixed in idealized 
positions. All non-hydrogen atoms were refined with anisotropic atomic displacement 
parameters. Neutral scattering factors and anomalous dispersion corrections for non-
hydrogen atoms were taken from Ibers and Hamilton. 156 The functions minimised 
were Lw(F/ - Fc2), with w = [cr2(Fo2) + 0.045P2 + 0.044Pf1 where P = [max(Fo)2 + 
2F c 2]/3. Full tables of atomic coordinates, bond lengths and angles, and thermal 
parameters have been deposited at the Cambridge Crystallographic Data Center. 
Preparation of cis-(2R,5S)- and trans-(2S,5S)-5-benzyl-2-ethyloxazolidin-4-one 
5.65 and 5.66 
5.65 5.66 
An excess of 5.37 (5 equiv) was added to the amide 5.27 (124 mg, 0.73 mmol) 
in dichloromethane ( 5 cm3) and the mixture was stirred at rt for 18 h. The solution 
was washed with 10% aqueous NaHC03 (5 cm3), water (5 cm3}, dried and evaporated 
under reduced pressure to give a crude mixture of 5.66 and 5.65 (208 mg, 13:7 by 1H 
NMR). Purification of the crude mixture on a 1 mm silica chromatatron plate eluting 
with ethyl acetate-dichloromethane (0: 1 to 3: 10) gave three fractions. The first 
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fraction (6 mg) contained 5.66 as an oil; (Found: M\ 205.1103. C12H1sNOz requires 
m/z 205.1103); 1HNMR, o 0.90 (3H, t, J1.5, Me), 1.60 (2H, m, CH2Me), 3.05 (2H, 
m, CH2Ph), 4.57 (1H, m, CHCH2), 4.85 (1H, m, NCR), 6.46 (1H, br s, NH), 7.29 
(SH, m, ArH); 13C NMR, o 7.17 (Me), 29.50 (CH2Me), 37.83 (CH2Ph), 77.91 
(CHCH2), 87.67 (NCR), 126.74, 128.33 & 129.80 (ArCH), 136.50 (ArCR), 175.99 
(CO); mlz (EI) 205 (M+, 54), 176 (~- C2Hs, 49), 131 ~- C31IgNO, 87), 91 (100). 
The second fraction (6 mg) contained a mixture of 5.66 to 5.65 (4:1 by 1H NMR). 
The final fraction (13 mg) gave 5.65 as an oil; (Found: ~. 205.1106. C12H1sNOz 
requires mlz 205.1103); 1H NMR, o 0.87 (3H, t, J 7.6, Me), 1.46 (2H, m, CH2Me), 
3.07 (2H, m, CH2Ph), 4.49 (1H, m, CHCH2), 5.10 (lH, m, NCR), 6.88 (1H, br s, 
NH), 7.28 (5H, m, ArH); 13C NMR, o 7.31 (Me), 29.05 (CH2Me), 37.89 (CH2Ph), 
78.20 (CHCH2), 87.17 (NCR), 126.65, 128.22 & 129.72 (ArCH), 136.87 (ArCR), 
174.09 (CO); mlz (EI) 205 ~. 40), 176 (M+- C2Hs, 78), 131 (M+- C3HsNO, 73), 91 
(100). 
Preparation of cis-(2R,5S)- and trans-(2S,5S)-5-benzyl-2-phenyloxazolidin-4-one 
5.67 and 5.68 
5.67 5.68 
An excess of 5.34 (25 equiv) was added to the amide 5.27 (93 mg, 0.56 mmol) 
in dichloromethane (5 cm3) and the mixture was left to stand at -10 oc for 18 h. The 
solution was washed with 10% aqueous NaHC03 (5 cm3), water (5 cm3), dried and 
evaporated under reduced pressure to give a crude mixture of5.67 and 5.68 (141 mg). 
Purification on a 1 mm silica chromatatron plate eluting with ethyl acetate-petroleum 
ether (2:3) gave a mixture (76 mg, 54%) of 5.68 and 5.67 (2: 1 by 1H NMR). Further 
purification on a 1 mm silica chromatatron plate eluting with ethyl acetate-petroleum 
ether (1 :9 to 1 :0) gave two fractions. The first fraction gave 5.68 as an oil (19 mg); 
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(Found: M\ 253.1102. C16H1sN02 requires mlz 253.1103); [a.]n23 -17 (c 0.007 in 
CH2Ch); IR /cm"1 3429, 1756, 1728, 1278, 1247, 1126; 1H NMR, 8 3.13 (2H, m, 
CH2Ph), 4.77 (lH, m, CHCH2), 5.72 (1H, d, J2.4, NCR), 7.24-7.37 (lOH, m, ArH), 
7.86 (lH, br s, NH); 13C NMR, 8 37.57 (CH2Ph), 78.19 (CHCR2), 87.81 (NCR), 
126.22, 126.79, 128.31, 128.69, 129.66 & 129.73 (ArCH), 136.09 & 138.28 (ArCR), 
166.36 (CO); mlz (EI) 253 (M", 76), 106 (100). The second fraction gave 5.67 as an 
oil (11 mg); (Found: M", 253.1105. C16R15N02 requires mlz 253.1103); [a.]n23 -121 (c 
0.007 in CH2Ch); IR /cm-1 3430, 1730, 1498, 1462, 1313, 1081; 1H NMR, 8 3.11 (2R, 
m, CH2Ph), 4.59 (IR, m, CHCR2), 5.96 (1R, d, J2.1, NCR), 7.03-7.07 (2H, m, ArR), 
7.18-7.36 (8R, m, ArH), 7.75 (IR, br s, NH); 13C NMR, 8 37.42 (CH2Ph), 78.51 
(CHCH2), 87.12 (NCH), 126.61, 126.99, 128.29, 128.51, 129.81 & 129.92 (ArCH), 
136.45 & 137.50 (ArCR), 174.47 (CO); mlz (EI) 253 (M+, 25), 147 (90), 106 (100). 
Preparation of cis-(2S,5R)- and trans-(2R,5R)-5-benzyl-2-phenyloxazolidin-4-ones 
5.69 and 5. 70 
5.69 5.70 
An excess of 5.34 (25 equiv) was added to the amide 5.41 (40 mg, 0.24 mmol) 
in dichloromethane (2 cm3) and the mixture was stirred at rt for 18 h. Workup as 
above gave a crude mixture of5.70 and 5.69 (141 mg, 3:2 by 1R NMR), which was 
purified by flash chromatography, eluting with ethyl acetate-dichloromethane (1 :20 to 
1: 5) to give two fractions. The first fraction (16 mg) contained a mixture of 5. 70 and 
5.69 (7:3 by 1R NMR). The second fraction gave 5.69 as an oil (16 mg); (Found: M+, 
253.1105. C16R1sN02 requires mlz 253.1103); 1H NMR data identical to enantiomer 
5.67. Fraction 1 was further purified on a 1 mm silica chromatatron plate eluting with 
ethyl acetate-petroleum ether (1:3 to 1:1) to give 5.70 (2 mg) as an oil; (Found: M+, 
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253.1102. C16H1sN02 requires mlz 253.1103); 1H NMR data identical to enantiomer 
5.68. Further elution gave more 5.69 (3 mg). 
Preparation of (2S)-2-hydroxyl-3-phenyl-N-(2,3,4,6-tetra-O-acetyl-J3-D-
glucopyranosyl)propanamide 5. 76 
OAc 
HO AcO~OAc ~ HN._t....O.......t.-:: 
Ph__/\\' OAc 
0 
5.76 
To a stirred mixture of D-glucose 5.71 (5.020 g, 27.80 mmol) and acetic 
anhydride (21.8 cm3, 231 mmol) was added cone. sulphuric acid (3 drops). The solid 
dissolved over 10 min and the temperature of the mixture rose to approximately 100 
°C. The solution was then heated on a steam bath for 2 h. The remaining acetic acid 
and acetic anhydride were removed by vacuum distillation (water pump) to give a 
viscous light yellow syrup of pentaacetate 5. 72. A solution of 40% HBr in acetic acid 
(10 cm3) was added to the syrup at 0 oc and the solution was stirred at rt for 3 h. 
Evaporation under reduced pressure and crystallisation from diisopropyl ether gave 
2,3,4,6-tetra-0-acetyl-a-D-glucopyranosyl bromide141 5.73 (4.690 g, 94%); mp 87-88 
oc (literature mp 87-88 °C); 1H NMR, o 2.04 (3H, s, Ac), 2.06 (3H, s, Ac), 2.10 (3H, 
s, Ac), 2.11 (3H, s, Ac), 4.13 (1H, m), 4.33 (2H, m), 4.86 (1H, dd, J 10.0 & 4.1), 5.18 
(1H, t, J 10.0), 5.55 (1H, t, J 9.8), 6.62 (1H, d, J 3.9, CHBr); 13C NMR, o 20.06, 
20.11, 20.14, 60.49, 66.65, 69.69, 70.04, 71.77, 86.44, 168.93, 169.20, 169.27, 
169.89. 
A mixture of5.73 (1.842 g, 4.50 mmol) and sodium azide (0.817 g, 12.60 mmol) 
in formamide (15 cm3) was stirred at 80-85 oc for 3 h. After cooling, the mixture was 
poured into water (50 cm3) and extracted with chloroform (3 x 15 cm3). The organic 
extracts were washed with water (10 cm3), dried and evaporated to yield a dark oil, 
which crystallized after 18 h at -1 0 oc. Recrystallization from ethyl acetate-petroleum 
ether gave 2,3,4,6-tetra-O-acetyl-f3-D-glucopyranosyl azide 5.74 (355 mg); mp 126-
127 oc (literature142 mp 124-125 °C). The mother liquor was evaporated to yield less 
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pure 5.74 (854 mg, 72% combined yield); 1H NMR, 8 2.02 (3H, s, Ac), 2.04 (3H, s, 
Ac), 2.09 (3H, s, Ac), 2.11 (3H, s, Ac), 3.80 (1H, m, glucH5), 4.17 (1H, m, glucH6a), 
4.28 (1H, m, glucH6b), 4.65 (IH, d, J 8.8, glucH1), 4.96 & 5.11 & 5.23 (3H, 3 t, 
glucH2 & H3 & H4); Be NMR, 8 20.48, 20.64, 61.57, 67.78, 70.54, 72.52, 73.94, 
87.83, 169.16, 169.27, 170.07, 170.58. 
A solution of 5.74 (198 mg, 0.53 mmol) in ethyl acetate (20 cm3) was 
catalytically hydrogenated over Pt02 (19 mg, 0.085 mmol) at atmospheric pressure for 
3. 5 h. The mixture was filtered and evaporated to yield a white solid residue of 
2,3,4,6-tetra-0-acetyl-[J-D-glucosylamine 5.75 (156 mg, 85%); mp 125-126 oc 
(literature143 mp 126 °C); 1H NMR, 8 1.94 (3H, s, Ac), 1.96 (3H, s, Ac), 1.97 (3H, s, 
Ac), 2.00 (3H, s, Ac), 2.90 (2H, br s, NH2), 3.65 (1H, m, glucH5), 4.06 (1H, m, 
glucH6a), 4.16 (2H, m, glucHl & H6b), 4.76 & 4.97 & 5.18 (3H, t, glucH2 & H3 & 
H4); Be NMR, o 20.22, 20.36 & 20.40 (Ac), 61.97, 68.42, 71.73, 72.31, 72.84, 84.44 
(CNH2), 169.25, 169.81 & 170.39 (CO). 
A mixture of the acid 5.15 (50 mg, 0.30 mmol), glucosylamine 5.75 (104 mg, 
0.30 mmol), 1-hydroxybenzotriazole (42 mg, 0.30 mmol) and 
dicyclohexylcarbodiimide (61 mg, 0.30 mmol) in dichloromethane (10 cm3) was stirred 
at rt for 5 d. The mixture was filtered and evaporated to yield crude amide 5.76 (218 
mg). The amide was loaded onto a 1 mm chromatatron plate and eluted with ethyl 
acetate-petroleum ether (1:1) to give 5.76 (87 mg, 59%), which was recrystallized 
from ethyl acetate-petroleum ether to give fine white crystals of5.76 (15 mg); (Found: 
MH+, 496.1810. C23H3oNOu requires mlz 496.1819); mp 172.5-174.5 oC; [a,]0 23 +46 
(c 0.007 in CH2Ch); 1H NMR, 8 1.94 (3H, s, Ac), 2.02 (3H, s, Ac), 2.03 (3H, s, Ac), 
2.07 (3H, s, Ac), 2.78 (1H, dd, J 13.6 & 8.5, CH2Ph), 2.86 (1H, d, J 4.8, OH), 3.18 
(1H, dd, J 13.7 & 2.9, CH2Ph), 3.82 (IH, m, glucH5), 4.11 (1H, m, glucH6a), 4.31 
(1H, m, glucH6b), 4.33 (1H, m, CHCH2Ph), 4.94 (1H, t, J9.5, glucH2), 5.06 (1H, t, J 
9.5, glucH4), 5.21 (IH, t, J9.3, glucH1), 5.30 (1H, t, J9.5, glucH3), 7.23-7.34 (4H, 
m, ArH), 7.46 (1H, m, ArH); 13C NMR, 8 20.50 & 20.63 (Ac), 40.32 (CH2Ph), 61.52 
(glucC6), 67.97 (glucC4), 70.36 (glucC2), 72.59 (glucC3), 72.71 (CHCH2Ph), 73.56 
(glucC5), 77.82 (glucC1), 126.97, 128.62 & 129.52 (ArCH), 136.40 (ArCR), 169.47, 
170.48 & 173.57 (CO); IR /cm·1 3052, 1756, 1225, 1043; mlz (FAB) 496 (Mit, 53), 
169 (100). 
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Preparation of (2S)-N-(f3-D-glucopyranosyl)-2-hydroxyl-3-phenylpropanamide 
5.77 
OH 
HO HO~OH ~ HN_t.....O........t--::OH 
Ph~ 
0 
5.77 
The amide 5.76 (37 mg, 0.075 mmol) and potassium carbonate (2 mg, 0.015 
mmol) were dissolved in methanol-water ( 4 cm3 of a 9: 1 mixture) and the solution was 
stirred at rt for 1 h. The methanol was removed under reduced pressure and the 
aqueous layer was washed with dichloromethane (3 x 5 cm3) and evaporated to give 
5.77 (24 mg, 96%); (Found: MK+, 366.0960. C1JI21N07K requires mlz 366.0955); 1H 
NMR (D20), o 1.77 (1H, s, OH), 2.84 (1H, dd, J 14.2 & 7.8, CH2Ph), 3.02 (1H, dd, J 
14.1 & 4.9, CH2Ph), 3.25-3.77 (6H, m, glucH2-H6), 4.36 (lH, dd, J 7.8 & 4.9, 
CHCH2Ph), 4.81 (lH, d, J 9.3, glucH1), 7.16-7.26 (5H, m, ArH); mlz (FAB) 366 
(MK+, 8), 307 (10), 154 (100). 
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